

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York State

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	114,868.6	474.4	473.1-475.7	57,391.0	517.8	515.8-519.7	57,477.6	446.6	444.9-448.3	33,634.8	134.5	133.9-135.2	16,814.8	156.8	155.7-157.9	16,820.0	119.4	118.6-120.2
Oral cavity and pharynx	2,772.8	11.3	11.1-11.5	1,888.6	16.7	16.4-17.1	884.2	6.7	6.5-6.9	541.2	2.1	2.1-2.2	374.0	3.3	3.2-3.5	167.2	1.2	1.1-1.3
Lip	87.8	0.4	0.3-0.4	58.6	0.5	0.5-0.6	29.2	0.2	0.2-0.3	4.6	0.0	0.0-0.0	2.0	0.0	0.0-0.0	2.6	0.0	0.0-0.0
Tongue	878.2	3.5	3.4-3.6	604.2	5.2	5.0-5.4	274.0	2.1	2.0-2.2	138.2	0.5	0.5-0.6	90.8	0.8	0.7-0.9	47.4	0.3	0.3-0.4
Salivary gland	318.6	1.4	1.3-1.4	171.2	1.6	1.5-1.8	147.4	1.2	1.1-1.3	50.2	0.2	0.2-0.2	30.0	0.3	0.2-0.3	20.2	0.1	0.1-0.2
Floor of mouth	114.4	0.5	0.4-0.5	74.6	0.6	0.6-0.7	39.8	0.3	0.3-0.3	4.8	0.0	0.0-0.0	3.0	0.0	0.0-0.0	1.8	0.0	0.0-0.0
Gum & other mouth	402.6	1.6	1.6-1.7	216.8	2.0	1.9-2.1	185.8	1.4	1.3-1.5	80.2	0.3	0.3-0.3	49.4	0.4	0.4-0.5	30.8	0.2	0.2-0.2
Nasopharynx	165.0	0.7	0.7-0.8	115.4	1.1	1.0-1.2	49.6	0.4	0.4-0.5	52.8	0.2	0.2-0.3	38.4	0.3	0.3-0.4	14.4	0.1	0.1-0.1
Tonsil	476.4	1.9	1.8-2.0	390.4	3.3	3.2-3.5	86.0	0.6	0.6-0.7	46.8	0.2	0.2-0.2	39.4	0.3	0.3-0.4	7.4	0.1	0.0-0.1
Oropharynx	150.4	0.6	0.6-0.6	120.0	1.0	0.9-1.1	30.4	0.2	0.2-0.3	71.0	0.3	0.2-0.3	52.6	0.5	0.4-0.5	18.4	0.1	0.1-0.2
Hypopharynx	146.4	0.6	0.5-0.6	113.4	1.0	0.9-1.1	33.0	0.2	0.2-0.3	26.4	0.1	0.1-0.1	20.2	0.2	0.1-0.2	6.2	0.0	0.0-0.1
Other buccal cavity and pharynx	33.0	0.1	0.1-0.1	24.0	0.2	0.2-0.2	9.0	0.1	0.0-0.1	66.2	0.3	0.2-0.3	48.2	0.4	0.4-0.5	18.0	0.1	0.1-0.2
Digestive system	20,085.2	82.1	81.6-82.6	10,992.0	100.1	99.2-101.0	9,093.2	67.5	66.9-68.2	9,262.4	37.0	36.6-37.3	5,139.4	47.1	46.5-47.7	4,123.0	28.9	28.5-29.3
Esophagus	1,080.0	4.3	4.2-4.4	817.0	7.3	7.0-7.5	263.0	1.9	1.8-2.0	828.8	3.3	3.2-3.4	644.6	5.8	5.6-6.0	184.2	1.3	1.2-1.4
Stomach	2,009.2	8.3	8.1-8.5	1,191.4	11.0	10.7-11.2	817.8	6.2	6.0-6.4	787.4	3.2	3.1-3.3	468.8	4.4	4.2-4.6	318.6	2.3	2.2-2.4
Small intestine	664.0	2.8	2.7-2.9	355.4	3.2	3.1-3.4	308.6	2.4	2.3-2.5	100.2	0.4	0.4-0.4	56.0	0.5	0.5-0.6	44.2	0.3	0.3-0.4
Colorectal	8,792.8	36.6	36.3-37.0	4,552.8	42.2	41.7-42.8	4,240.0	32.1	31.6-32.5	2,888.6	11.6	11.4-11.8	1,461.0	13.7	13.4-14.0	1,427.6	10.0	9.7-10.2
Colon excluding rectum	6,212.6	25.8	25.5-26.0	3,061.0	28.5	28.0-29.0	3,151.6	23.5	23.1-23.9	2,287.6	9.2	9.0-9.3	1,119.8	10.5	10.3-10.8	1,167.8	8.1	7.9-8.3
Cecum	1,181.2	4.8	4.7-4.9	517.4	4.8	4.6-5.0	663.8	4.7	4.6-4.9									
Appendix	402.6	1.9	1.8-2.0	171.2	1.7	1.6-1.8	231.4	2.1	1.9-2.2									
Ascending colon	1,192.2	4.8	4.7-5.0	540.6	5.0	4.8-5.2	651.6	4.7	4.5-4.8									
Hepatic flexure	284.6	1.2	1.1-1.2	147.8	1.4	1.3-1.5	136.8	1.0	0.9-1.1									
Transverse colon	575.4	2.4	2.3-2.4	288.2	2.7	2.6-2.8	287.2	2.1	2.0-2.2									
Splenic flexure	171.8	0.7	0.7-0.8	90.8	0.8	0.8-0.9	81.0	0.6	0.5-0.7									
Descending colon	388.8	1.6	1.6-1.7	221.2	2.1	1.9-2.2	167.6	1.3	1.2-1.4									
Sigmoid colon	1,586.2	6.7	6.5-6.8	883.2	8.1	7.9-8.4	703.0	5.5	5.3-5.7									
Large intestine, NOS	429.8	1.7	1.6-1.8	200.6	1.9	1.8-2.0	229.2	1.6	1.5-1.7									
Rectum & rectosigmoid	2,580.2	10.9	10.7-11.1	1,491.8	13.7	13.4-14.0	1,088.4	8.5	8.3-8.8	601.0	2.4	2.4-2.5	341.2	3.2	3.0-3.3	259.8	1.9	1.8-2.0
Rectosigmoid junction	588.8	2.5	2.4-2.6	326.6	3.0	2.8-3.1	262.2	2.1	2.0-2.2									
Rectum	1,991.4	8.4	8.2-8.6	1,165.2	10.7	10.5-11.0	826.2	6.5	6.3-6.7									
Anus, anal canal & anorectum	533.8	2.2	2.1-2.3	204.8	1.9	1.8-2.0	329.0	2.5	2.4-2.6	79.2	0.3	0.3-0.4	35.2	0.3	0.3-0.4	44.0	0.3	0.3-0.4
Liver and intrahepatic bile duct	2,204.0	8.7	8.5-8.8	1,547.2	13.4	13.1-13.7	656.8	4.7	4.6-4.9	1,413.8	5.6	5.4-5.7	941.0	8.3	8.1-8.6	472.8	3.3	3.2-3.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York State

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	1,750.4	6.8	6.7-7.0	1,314.8	11.2	11.0-11.5	435.6	3.1	3.0-3.3	976.0	3.8	3.7-3.9	721.0	6.3	6.1-6.5	255.0	1.8	1.7-1.9
Intrahepatic bile duct	453.6	1.8	1.8-1.9	232.4	2.1	2.0-2.2	221.2	1.6	1.5-1.7	437.8	1.8	1.7-1.8	220.0	2.0	1.9-2.1	217.8	1.6	1.5-1.7
Gallbladder	348.0	1.4	1.3-1.5	113.2	1.0	1.0-1.1	234.8	1.7	1.6-1.8	167.4	0.7	0.6-0.7	53.6	0.5	0.4-0.6	113.8	0.8	0.7-0.9
Other biliary	459.0	1.9	1.8-1.9	245.6	2.3	2.1-2.4	213.4	1.5	1.5-1.6	130.0	0.5	0.5-0.6	63.0	0.6	0.5-0.7	67.0	0.5	0.4-0.5
Pancreas	3,603.2	14.4	14.2-14.6	1,809.4	16.4	16.1-16.8	1,793.8	12.8	12.5-13.1	2,716.6	10.8	10.6-11.0	1,350.4	12.3	12.0-12.6	1,366.2	9.5	9.3-9.7
Retroperitoneum	106.4	0.5	0.4-0.5	55.0	0.5	0.5-0.6	51.4	0.4	0.4-0.5	17.2	0.1	0.1-0.1	10.6	0.1	0.1-0.1	6.6	0.0	0.0-0.1
Peritoneum, omentum & mesentery	94.4	0.4	0.3-0.4	8.6	0.1	0.1-0.1	85.8	0.6	0.6-0.7	51.2	0.2	0.2-0.2	10.6	0.1	0.1-0.1	40.6	0.3	0.3-0.3
Other digestive organs	190.4	0.8	0.7-0.8	91.6	0.8	0.8-0.9	98.8	0.7	0.7-0.8	82.0	0.3	0.3-0.4	44.6	0.4	0.4-0.5	37.4	0.3	0.2-0.3
Respiratory system	14,880.8	59.2	58.8-59.6	7,419.8	67.0	66.3-67.7	7,461.0	53.5	52.9-54.0	7,702.6	30.5	30.2-30.8	4,004.8	36.7	36.2-37.2	3,697.8	25.9	25.5-26.3
Nasal cavity, middle ear & sinuses	180.2	0.8	0.7-0.8	105.6	1.0	0.9-1.1	74.6	0.6	0.5-0.6	25.8	0.1	0.1-0.1	14.6	0.1	0.1-0.2	11.2	0.1	0.1-0.1
Larynx	705.8	2.8	2.7-2.9	557.0	4.9	4.7-5.1	148.8	1.1	1.0-1.2	198.4	0.8	0.7-0.8	157.6	1.4	1.3-1.5	40.8	0.3	0.2-0.3
Lung and bronchus	13,946.4	55.4	55.0-55.8	6,724.0	60.8	60.1-61.4	7,222.4	51.7	51.1-52.2	7,448.2	29.5	29.2-29.8	3,813.4	35.0	34.5-35.5	3,634.8	25.5	25.1-25.8
Pleura	5.4	0.0	0.0-0.0	3.0	0.0	0.0-0.0	2.4	0.0	0.0-0.0	14.2	0.1	0.0-0.1	10.6	0.1	0.1-0.1	3.6	0.0	0.0-0.0
Trachea, mediastinum, other respiratory	43.0	0.2	0.2-0.2	30.2	0.3	0.3-0.4	12.8	0.1	0.1-0.1	16.0	0.1	0.1-0.1	8.6	0.1	0.1-0.1	7.4	0.1	0.0-0.1
Bones & joints	235.0	1.2	1.1-1.2	138.4	1.4	1.3-1.5	96.6	0.9	0.8-1.0	89.4	0.4	0.4-0.5	53.0	0.5	0.5-0.6	36.4	0.3	0.3-0.4
Soft tissue (including heart)	800.2	3.6	3.5-3.7	437.0	4.2	4.0-4.4	363.2	3.1	2.9-3.2	290.2	1.2	1.2-1.3	147.8	1.4	1.3-1.5	142.4	1.1	1.0-1.2
Skin*	4,665.8	19.6	19.4-19.9	2,696.2	25.2	24.8-25.6	1,969.6	15.7	15.4-16.0	587.8	2.3	2.3-2.4	379.6	3.6	3.5-3.8	208.2	1.4	1.3-1.5
Melanoma of the skin	4,216.0	17.7	17.5-18.0	2,430.0	22.6	22.2-23.0	1,786.0	14.3	14.0-14.6	387.8	1.6	1.5-1.6	243.2	2.3	2.2-2.4	144.6	1.0	0.9-1.1
Breast	16,844.8	72.4	71.9-72.9	156.6	1.4	1.3-1.5	16,688.2	134.0	133.1-135.0	2,510.6	10.3	10.1-10.4	24.6	0.2	0.2-0.3	2,486.0	18.2	17.9-18.6
Breast (in situ)#	5,034.6	22.3	22.1-22.6	20.2	0.2	0.2-0.2	5,014.4	42.2	41.7-42.7									
Female genital system							7,120.8	55.2	54.7-55.8							2,106.0	15.2	14.9-15.5
Cervix uteri							808.6	7.4	7.1-7.6							233.2	1.9	1.8-2.0
Corpus uterus and NOS							4,168.8	31.2	30.7-31.6							842.6	6.0	5.8-6.2
Ovary							1,409.6	11.2	10.9-11.5							866.0	6.2	6.0-6.4
Vagina							83.0	0.6	0.6-0.7							23.4	0.2	0.1-0.2
Vulva							348.0	2.6	2.5-2.7							85.6	0.6	0.5-0.6
Other female genital organs							302.8	2.3	2.2-2.4							55.2	0.4	0.3-0.4
Male genital system				16,158.2	137.6	136.7-138.6							1,752.2	17.0	16.7-17.4			
Prostate				15,455.6	130.3	129.4-131.2							1,706.4	16.6	16.2-16.9			
Testis				579.2	6.2	6.0-6.4							22.0	0.2	0.2-0.3			
Penis				95.2	0.9	0.8-1.0							20.0	0.2	0.2-0.2			
Other male genital organs				28.2	0.3	0.2-0.3							3.8	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York State

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	9,643.4	39.2	38.9-39.6	6,772.2	62.3	61.6-63.0	2,871.2	21.3	20.9-21.6	1,659.8	6.6	6.4-6.7	1,118.2	10.7	10.4-11.0	541.6	3.7	3.5-3.8
Urinary bladder (including in situ)	5,362.4	21.4	21.2-21.7	4,001.0	37.1	36.6-37.7	1,361.4	9.6	9.4-9.9	958.2	3.8	3.6-3.9	672.2	6.5	6.3-6.8	286.0	1.9	1.8-2.0
Kidney and renal pelvis	4,044.2	16.8	16.6-17.1	2,618.2	23.7	23.3-24.2	1,426.0	11.0	10.8-11.3	655.8	2.6	2.5-2.7	420.8	3.9	3.7-4.1	235.0	1.6	1.5-1.7
Ureter	140.0	0.6	0.5-0.6	86.2	0.8	0.7-0.9	53.8	0.4	0.3-0.4	22.0	0.1	0.1-0.1	9.6	0.1	0.1-0.1	12.4	0.1	0.1-0.1
Other urinary organs	96.8	0.4	0.4-0.4	66.8	0.6	0.6-0.7	30.0	0.2	0.2-0.3	23.8	0.1	0.1-0.1	15.6	0.1	0.1-0.2	8.2	0.1	0.0-0.1
Eye & orbit	204.0	0.9	0.8-0.9	102.8	1.0	0.9-1.1	101.2	0.8	0.8-0.9	15.6	0.1	0.1-0.1	7.6	0.1	0.0-0.1	8.0	0.1	0.0-0.1
Brain / other central nervous system (all behaviors)	4,968.2	21.8	21.5-22.1	1,943.6	18.7	18.3-19.1	3,024.6	24.5	24.1-24.9	1,072.8	4.5	4.4-4.6	586.2	5.5	5.3-5.7	486.6	3.7	3.6-3.9
Malignant brain / other central nervous system	1,419.0	6.4	6.3-6.6	791.8	7.7	7.4-7.9	627.2	5.4	5.2-5.6	900.4	3.8	3.7-3.9	510.0	4.7	4.5-4.9	390.4	3.0	2.9-3.2
Malignant brain	1,334.0	6.0	5.9-6.2	749.0	7.2	7.0-7.5	585.0	5.0	4.8-5.2									
Malignant other central nervous system	85.0	0.4	0.4-0.5	42.8	0.4	0.4-0.5	42.2	0.4	0.3-0.5									
Benign brain / other central nervous system#	3,549.2	15.4	15.2-15.6	1,151.8	11.0	10.7-11.3	2,397.4	19.2	18.8-19.5	172.4	0.7	0.7-0.8	76.2	0.7	0.7-0.8	96.2	0.7	0.6-0.8
Benign brain	309.4	1.5	1.4-1.6	156.6	1.6	1.5-1.7	152.8	1.5	1.3-1.6									
Benign other central nervous system	3,239.8	13.9	13.6-14.1	995.2	9.4	9.1-9.7	2,244.6	17.7	17.4-18.1									
Endocrine system	4,064.2	19.4	19.2-19.7	1,146.0	11.2	10.9-11.5	2,918.2	27.3	26.9-27.8	187.6	0.8	0.7-0.8	80.2	0.8	0.7-0.9	107.4	0.8	0.7-0.9
Thyroid	3,820.0	18.3	18.1-18.6	1,021.4	10.0	9.7-10.2	2,798.6	26.3	25.9-26.8	124.8	0.5	0.5-0.5	52.6	0.5	0.4-0.6	72.2	0.5	0.4-0.6
Other endocrine (including thymus)	244.2	1.1	1.0-1.2	124.6	1.2	1.1-1.3	119.6	1.0	1.0-1.1	62.8	0.3	0.3-0.3	27.6	0.3	0.2-0.3	35.2	0.3	0.3-0.3
Lymphomas	5,626.4	24.0	23.7-24.3	3,017.0	28.5	28.0-29.0	2,609.4	20.5	20.1-20.9	1,233.8	5.0	4.9-5.1	688.0	6.6	6.3-6.8	545.8	3.8	3.7-4.0
Hodgkin lymphoma	620.2	3.0	2.9-3.1	335.4	3.4	3.2-3.6	284.8	2.7	2.6-2.9	62.2	0.3	0.2-0.3	37.6	0.4	0.3-0.4	24.6	0.2	0.2-0.2
Non-Hodgkin lymphomas	5,006.2	21.0	20.7-21.3	2,681.6	25.1	24.7-25.5	2,324.6	17.8	17.4-18.1	1,171.6	4.7	4.6-4.8	650.4	6.2	6.0-6.4	521.2	3.6	3.5-3.8
Myeloma	1,984.6	8.0	7.9-8.2	1,078.6	9.8	9.5-10.1	906.0	6.7	6.5-6.9	672.4	2.7	2.6-2.7	352.8	3.3	3.1-3.4	319.6	2.2	2.1-2.3
Leukemias	3,697.8	15.7	15.5-15.9	2,150.4	20.4	20.0-20.8	1,547.4	12.0	11.7-12.3	1,343.4	5.5	5.4-5.6	759.8	7.4	7.1-7.6	583.6	4.2	4.0-4.3
Lymphocytic leukemias	1,901.2	8.0	7.9-8.2	1,154.6	10.8	10.5-11.1	746.6	5.8	5.6-6.0	347.6	1.4	1.3-1.5	204.0	2.0	1.9-2.1	143.6	1.0	0.9-1.1
Acute lymphocytic leukemia	311.8	1.7	1.6-1.8	174.8	1.9	1.8-2.0	137.0	1.4	1.3-1.6	78.2	0.4	0.3-0.4	43.4	0.4	0.4-0.5	34.8	0.3	0.3-0.4
Chronic lymphocytic leukemia	1,475.2	5.9	5.7-6.0	895.0	8.1	7.8-8.3	580.2	4.1	4.0-4.3	245.2	1.0	0.9-1.0	147.0	1.4	1.3-1.6	98.2	0.6	0.6-0.7
Other lymphocytic leukemias	114.2	0.5	0.4-0.5	84.8	0.8	0.7-0.9	29.4	0.2	0.2-0.3	24.2	0.1	0.1-0.1	13.6	0.1	0.1-0.2	10.6	0.1	0.1-0.1
Myeloid and monocytic leukemias	1,596.2	6.8	6.7-7.0	891.0	8.6	8.3-8.8	705.2	5.5	5.3-5.7	755.2	3.1	3.0-3.2	424.8	4.1	3.9-4.3	330.4	2.4	2.3-2.5
Acute myeloid leukemia	1,053.4	4.5	4.4-4.6	582.6	5.6	5.4-5.8	470.8	3.7	3.5-3.8	647.8	2.7	2.6-2.8	365.0	3.5	3.4-3.7	282.8	2.1	2.0-2.2
Acute monocytic leukemia	41.0	0.2	0.2-0.2	25.2	0.2	0.2-0.3	15.8	0.1	0.1-0.2	3.8	0.0	0.0-0.0	1.8	0.0	0.0-0.0	2.0	0.0	0.0-0.0
Chronic myeloid leukemia	471.6	2.0	1.9-2.1	266.8	2.6	2.4-2.7	204.8	1.6	1.5-1.7	59.6	0.2	0.2-0.3	32.2	0.3	0.3-0.4	27.4	0.2	0.2-0.2
Other myeloid/monocytic leukemias	30.2	0.1	0.1-0.1	16.4	0.2	0.1-0.2	13.8	0.1	0.1-0.1	44.0	0.2	0.2-0.2	25.8	0.2	0.2-0.3	18.2	0.1	0.1-0.2
Other leukemias	200.4	0.8	0.8-0.9	104.8	1.0	0.9-1.1	95.6	0.7	0.7-0.8	240.6	1.0	0.9-1.0	131.0	1.3	1.2-1.4	109.6	0.8	0.7-0.8
Other acute leukemias	52.2	0.2	0.2-0.3	27.6	0.3	0.2-0.3	24.6	0.2	0.1-0.2	81.6	0.3	0.3-0.4	44.4	0.4	0.4-0.5	37.2	0.3	0.2-0.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York State

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	148.2	0.6	0.6-0.7	77.2	0.7	0.7-0.8	71.0	0.5	0.5-0.6	159.0	0.6	0.6-0.7	86.6	0.8	0.8-0.9	72.4	0.5	0.5-0.6
Mesothelioma	177.6	0.7	0.7-0.8	122.8	1.2	1.1-1.3	54.8	0.4	0.4-0.5									
Kaposi sarcoma	129.6	0.6	0.5-0.6	115.2	1.1	1.0-1.2	14.4	0.1	0.1-0.1									
Myelodysplastic syndromes	1,067.8	4.3	4.2-4.4	611.0	6.0	5.8-6.2	456.8	3.2	3.0-3.3									
Chronic myeloproliferative disorders [^]	1,147.0	4.8	4.7-5.0	541.2	5.1	4.9-5.3	605.8	4.6	4.4-4.8									
Ill defined and unspecified sites	2,143.6	8.6	8.4-8.8	1,055.2	9.9	9.7-10.2	1,088.4	7.6	7.4-7.8	2,779.4	11.0	10.9-11.2	1,422.8	13.3	13.0-13.7	1,356.6	9.4	9.1-9.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	41,441.6	431.7	429.8-433.6	19,931.0	469.5	466.6-472.5	21,510.6	409.9	407.4-412.4	11,816.6	120.7	119.7-121.7	5,754.6	141.4	139.7-143.0	6,062.0	107.2	106.0-108.5
Oral cavity and pharynx	931.6	9.6	9.4-9.9	608.0	14.2	13.6-14.7	323.6	6.0	5.7-6.4	198.2	2.0	1.9-2.2	136.4	3.2	3.0-3.5	61.8	1.1	1.0-1.2
Lip	20.6	0.2	0.2-0.3	13.8	0.3	0.3-0.4	6.8	0.1	0.1-0.2	1.6	0.0	0.0-0.0	0.6	0.0	0.0-0.0	1.0	0.0	0.0-0.0
Tongue	255.8	2.6	2.5-2.8	167.2	3.8	3.6-4.1	88.6	1.6	1.5-1.8	44.2	0.5	0.4-0.5	27.8	0.7	0.6-0.8	16.4	0.3	0.2-0.4
Salivary gland	118.0	1.3	1.2-1.4	60.4	1.5	1.3-1.6	57.6	1.1	1.0-1.3	18.2	0.2	0.2-0.2	10.6	0.3	0.2-0.4	7.6	0.1	0.1-0.2
Floor of mouth	30.6	0.3	0.3-0.4	20.0	0.5	0.4-0.6	10.6	0.2	0.1-0.3	1.2	0.0	0.0-0.0	1.0	0.0	0.0-0.1	0.2	0.0	0.0-0.0
Gum & other mouth	151.2	1.6	1.5-1.7	76.6	1.8	1.6-2.0	74.6	1.3	1.2-1.5	26.0	0.3	0.2-0.3	15.4	0.4	0.3-0.4	10.6	0.2	0.1-0.2
Nasopharynx	101.0	1.1	1.0-1.2	70.8	1.7	1.5-1.9	30.2	0.6	0.5-0.7	32.4	0.3	0.3-0.4	23.8	0.6	0.5-0.7	8.6	0.2	0.1-0.2
Tonsil	136.6	1.4	1.3-1.5	109.4	2.5	2.3-2.7	27.2	0.5	0.4-0.6	12.0	0.1	0.1-0.2	10.8	0.3	0.2-0.3	1.2	0.0	0.0-0.1
Oropharynx	53.0	0.5	0.5-0.6	39.8	0.9	0.8-1.1	13.2	0.2	0.2-0.3	28.4	0.3	0.2-0.3	20.2	0.5	0.4-0.6	8.2	0.1	0.1-0.2
Hypopharynx	54.6	0.6	0.5-0.6	42.2	1.0	0.9-1.1	12.4	0.2	0.2-0.3	9.8	0.1	0.1-0.1	7.6	0.2	0.1-0.2	2.2	0.0	0.0-0.1
Other buccal cavity and pharynx	10.2	0.1	0.1-0.1	7.8	0.2	0.1-0.2	2.4	0.0	0.0-0.1	24.4	0.2	0.2-0.3	18.6	0.4	0.4-0.5	5.8	0.1	0.1-0.1
Digestive system	8,008.8	82.7	81.9-83.5	4,325.2	102.5	101.1-103.9	3,683.6	67.4	66.4-68.4	3,609.6	36.7	36.2-37.3	1,959.2	47.3	46.3-48.2	1,650.4	28.8	28.2-29.4
Esophagus	316.0	3.2	3.0-3.3	225.8	5.3	5.0-5.6	90.2	1.6	1.4-1.7	213.0	2.1	2.0-2.3	157.2	3.7	3.4-4.0	55.8	1.0	0.9-1.1
Stomach	960.8	10.0	9.7-10.3	549.8	13.2	12.7-13.7	411.0	7.6	7.3-8.0	416.6	4.3	4.1-4.5	250.4	6.1	5.8-6.5	166.2	3.0	2.8-3.2
Small intestine	239.8	2.5	2.4-2.7	121.2	2.9	2.7-3.1	118.6	2.2	2.1-2.4	31.4	0.3	0.3-0.4	16.4	0.4	0.3-0.5	15.0	0.3	0.2-0.3
Colorectal	3,423.8	35.8	35.2-36.3	1,772.0	42.4	41.5-43.3	1,651.8	30.7	30.0-31.4	1,120.2	11.5	11.2-11.8	560.4	13.8	13.3-14.3	559.8	9.8	9.4-10.1
Colon excluding rectum	2,410.2	25.1	24.6-25.5	1,197.6	28.8	28.0-29.5	1,212.6	22.3	21.7-22.9	907.8	9.3	9.0-9.5	440.2	10.8	10.4-11.3	467.6	8.1	7.8-8.5
Cecum	425.2	4.4	4.2-4.6	185.4	4.5	4.2-4.8	239.8	4.3	4.0-4.5									
Appendix	131.8	1.5	1.3-1.6	56.6	1.4	1.2-1.6	75.2	1.5	1.4-1.7									
Ascending colon	450.4	4.6	4.5-4.8	209.4	5.1	4.8-5.4	241.0	4.3	4.1-4.5									
Hepatic flexure	113.2	1.2	1.1-1.3	59.6	1.5	1.3-1.6	53.6	1.0	0.8-1.1									
Transverse colon	216.0	2.2	2.1-2.4	107.6	2.6	2.4-2.8	108.4	2.0	1.8-2.1									
Splenic flexure	71.4	0.8	0.7-0.8	40.4	1.0	0.9-1.1	31.0	0.6	0.5-0.7									
Descending colon	182.0	1.9	1.8-2.0	100.4	2.4	2.2-2.6	81.6	1.5	1.4-1.7									
Sigmoid colon	640.2	6.7	6.5-7.0	353.6	8.3	7.9-8.7	286.6	5.5	5.2-5.8									
Large intestine, NOS	180.0	1.8	1.7-2.0	84.6	2.1	1.9-2.3	95.4	1.7	1.5-1.8									
Rectum & rectosigmoid	1,013.6	10.7	10.4-11.0	574.4	13.6	13.1-14.1	439.2	8.4	8.0-8.8	212.4	2.2	2.1-2.3	120.2	2.9	2.7-3.2	92.2	1.6	1.5-1.8
Rectosigmoid junction	242.6	2.6	2.4-2.7	133.8	3.2	2.9-3.4	108.8	2.1	1.9-2.3									
Rectum	771.0	8.1	7.9-8.4	440.6	10.5	10.0-10.9	330.4	6.3	6.0-6.6									
Anus, anal canal & anorectum	216.6	2.2	2.1-2.4	98.4	2.3	2.1-2.5	118.2	2.2	2.0-2.4	32.2	0.3	0.3-0.4	16.6	0.4	0.3-0.5	15.6	0.3	0.2-0.3
Liver and intrahepatic bile duct	1,032.2	10.3	10.1-10.6	718.4	16.3	15.8-16.9	313.8	5.6	5.3-5.9	628.2	6.3	6.1-6.5	413.8	9.7	9.2-10.1	214.4	3.7	3.5-4.0

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	840.2	8.4	8.1-8.6	620.6	14.0	13.5-14.5	219.6	3.9	3.7-4.1	450.6	4.5	4.3-4.7	328.6	7.6	7.2-8.0	122.0	2.1	1.9-2.3
Intrahepatic bile duct	192.0	2.0	1.8-2.1	97.8	2.3	2.1-2.5	94.2	1.7	1.5-1.8	177.6	1.8	1.7-1.9	85.2	2.0	1.8-2.2	92.4	1.6	1.5-1.8
Gallbladder	178.0	1.8	1.7-1.9	58.0	1.4	1.2-1.6	120.0	2.2	2.0-2.3	90.4	0.9	0.8-1.0	27.8	0.7	0.6-0.8	62.6	1.1	1.0-1.2
Other biliary	193.4	2.0	1.9-2.1	98.4	2.4	2.2-2.6	95.0	1.7	1.6-1.9	49.8	0.5	0.4-0.6	23.0	0.6	0.5-0.7	26.8	0.5	0.4-0.6
Pancreas	1,312.0	13.4	13.0-13.7	629.2	15.0	14.5-15.5	682.8	12.1	11.6-12.5	974.0	9.9	9.6-10.1	467.8	11.3	10.8-11.8	506.2	8.8	8.4-9.1
Retroperitoneum	45.0	0.5	0.4-0.6	22.6	0.5	0.4-0.7	22.4	0.4	0.4-0.5	8.2	0.1	0.1-0.1	5.2	0.1	0.1-0.2	3.0	0.1	0.0-0.1
Peritoneum, omentum & mesentery	29.0	0.3	0.3-0.4	3.4	0.1	0.0-0.1	25.6	0.5	0.4-0.6	17.6	0.2	0.1-0.2	3.6	0.1	0.1-0.1	14.0	0.3	0.2-0.3
Other digestive organs	62.2	0.6	0.6-0.7	28.0	0.7	0.6-0.8	34.2	0.6	0.5-0.7	28.0	0.3	0.2-0.3	17.0	0.4	0.3-0.5	11.0	0.2	0.1-0.3
Respiratory system	4,641.4	47.3	46.7-47.9	2,389.2	57.3	56.2-58.3	2,252.2	40.2	39.4-40.9	2,292.4	23.2	22.8-23.7	1,235.6	30.1	29.3-30.9	1,056.8	18.4	17.9-18.9
Nasal cavity, middle ear & sinuses	68.4	0.7	0.7-0.8	39.8	1.0	0.8-1.1	28.6	0.6	0.5-0.7	9.6	0.1	0.1-0.1	5.4	0.1	0.1-0.2	4.2	0.1	0.0-0.1
Larynx	243.4	2.5	2.3-2.6	192.4	4.5	4.2-4.8	51.0	0.9	0.8-1.1	72.6	0.7	0.6-0.8	58.8	1.4	1.2-1.6	13.8	0.2	0.2-0.3
Lung and bronchus	4,311.0	43.9	43.3-44.5	2,144.2	51.5	50.5-52.5	2,166.8	38.6	37.8-39.3	2,197.8	22.3	21.9-22.7	1,164.0	28.4	27.6-29.1	1,033.8	18.0	17.5-18.5
Pleura	2.2	0.0	0.0-0.0	1.4	0.0	0.0-0.1	0.8	0.0	0.0-0.0	4.8	0.0	0.0-0.1	3.6	0.1	0.1-0.1	1.2	0.0	0.0-0.0
Trachea, mediastinum, other respiratory	16.4	0.2	0.1-0.2	11.4	0.3	0.2-0.4	5.0	0.1	0.1-0.2	7.6	0.1	0.1-0.1	3.8	0.1	0.1-0.1	3.8	0.1	0.0-0.1
Bones & joints	95.6	1.2	1.1-1.3	58.2	1.5	1.3-1.7	37.4	0.9	0.7-1.0	37.2	0.4	0.4-0.5	22.2	0.6	0.5-0.7	15.0	0.3	0.2-0.4
Soft tissue (including heart)	328.0	3.6	3.4-3.8	172.8	4.2	3.9-4.5	155.2	3.2	2.9-3.4	104.0	1.1	1.0-1.2	50.8	1.2	1.1-1.4	53.2	1.0	0.9-1.2
Skin*	1,033.2	10.9	10.6-11.2	571.0	14.0	13.5-14.5	462.2	8.8	8.4-9.2	136.0	1.4	1.3-1.5	84.0	2.1	1.9-2.3	52.0	0.9	0.8-1.0
Melanoma of the skin	911.4	9.6	9.3-9.9	506.2	12.4	11.9-12.9	405.2	7.7	7.4-8.1	84.4	0.9	0.8-1.0	49.4	1.2	1.1-1.4	35.0	0.6	0.5-0.7
Breast	6,482.6	69.6	68.8-70.4	60.2	1.5	1.3-1.6	6,422.4	126.1	124.7-127.6	995.6	10.3	10.0-10.6	8.0	0.2	0.1-0.3	987.6	18.0	17.5-18.5
Breast (in situ)#	2,198.8	24.2	23.7-24.6	10.6	0.3	0.2-0.3	2,188.2	44.6	43.7-45.5									
Female genital system							2,896.2	55.1	54.2-56.0							880.6	15.8	15.4-16.3
Cervix uteri							415.2	8.6	8.2-9.0							110.8	2.2	2.0-2.4
Corpus uterus and NOS							1,654.0	30.5	29.9-31.2							386.6	6.8	6.5-7.1
Ovary							568.0	11.1	10.7-11.5							331.6	6.0	5.7-6.3
Vagina							34.0	0.6	0.5-0.7							9.2	0.2	0.1-0.2
Vulva							113.2	2.1	1.9-2.3							25.8	0.4	0.4-0.5
Other female genital organs							111.8	2.1	1.9-2.3							16.6	0.3	0.2-0.4
Male genital system				5,832.2	131.3	129.7-132.8							684.6	17.6	17.0-18.2			
Prostate				5,560.4	124.9	123.4-126.4							668.6	17.2	16.6-17.8			
Testis				225.4	5.3	5.0-5.6							7.0	0.2	0.1-0.2			
Penis				35.8	0.9	0.7-1.0							7.8	0.2	0.1-0.3			
Other male genital organs				10.6	0.3	0.2-0.3							1.2	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	3,003.2	31.0	30.5-31.5	2,061.0	49.7	48.7-50.7	942.2	17.3	16.8-17.8	521.2	5.3	5.1-5.5	346.0	8.8	8.3-9.2	175.2	3.0	2.8-3.2
Urinary bladder (including in situ)	1,542.2	15.8	15.4-16.1	1,131.4	27.8	27.1-28.6	410.8	7.3	7.0-7.6	294.6	3.0	2.8-3.1	198.6	5.1	4.8-5.5	96.0	1.6	1.5-1.8
Kidney and renal pelvis	1,388.6	14.5	14.2-14.9	886.4	20.8	20.2-21.4	502.2	9.5	9.1-9.9	213.4	2.2	2.1-2.3	139.8	3.4	3.2-3.7	73.6	1.3	1.2-1.4
Ureter	40.0	0.4	0.3-0.5	24.4	0.6	0.5-0.7	15.6	0.3	0.2-0.3	6.0	0.1	0.0-0.1	3.4	0.1	0.1-0.1	2.6	0.0	0.0-0.1
Other urinary organs	32.4	0.3	0.3-0.4	18.8	0.5	0.4-0.6	13.6	0.2	0.2-0.3	7.2	0.1	0.1-0.1	4.2	0.1	0.1-0.2	3.0	0.1	0.0-0.1
Eye & orbit	76.0	0.8	0.7-0.9	37.2	0.9	0.8-1.0	38.8	0.8	0.7-0.9	5.2	0.1	0.0-0.1	2.2	0.1	0.0-0.1	3.0	0.1	0.0-0.1
Brain / other central nervous system (all behaviors)	1,904.0	20.6	20.2-21.0	715.0	17.3	16.7-17.9	1,189.0	23.2	22.6-23.8	341.6	3.6	3.5-3.8	182.6	4.4	4.1-4.7	159.0	3.0	2.8-3.2
Malignant brain / other central nervous system	525.6	5.8	5.6-6.1	291.2	7.0	6.7-7.4	234.4	4.8	4.5-5.1	290.4	3.1	2.9-3.3	160.4	3.9	3.6-4.2	130.0	2.5	2.3-2.7
Malignant brain	489.0	5.4	5.2-5.6	272.6	6.6	6.2-6.9	216.4	4.4	4.1-4.7									
Malignant other central nervous system	36.6	0.4	0.4-0.5	18.6	0.5	0.4-0.6	18.0	0.4	0.3-0.5									
Benign brain / other central nervous system#	1,378.4	14.7	14.4-15.1	423.8	10.3	9.8-10.7	954.6	18.4	17.8-18.9	51.2	0.5	0.5-0.6	22.2	0.5	0.4-0.7	29.0	0.5	0.4-0.6
Benign brain	99.8	1.2	1.1-1.3	48.8	1.2	1.1-1.4	51.0	1.1	1.0-1.3									
Benign other central nervous system	1,278.6	13.6	13.2-13.9	375.0	9.1	8.6-9.5	903.6	17.2	16.7-17.8									
Endocrine system	1,843.4	20.7	20.3-21.1	482.0	11.5	11.1-12.0	1,361.4	29.1	28.3-29.8	74.0	0.8	0.7-0.9	29.2	0.7	0.6-0.9	44.8	0.8	0.7-0.9
Thyroid	1,730.0	19.4	19.0-19.9	427.0	10.2	9.8-10.7	1,303.0	27.8	27.1-28.5	47.8	0.5	0.4-0.6	18.2	0.5	0.4-0.6	29.6	0.5	0.4-0.6
Other endocrine (including thymus)	113.4	1.3	1.1-1.4	55.0	1.3	1.2-1.5	58.4	1.2	1.1-1.4	26.2	0.3	0.2-0.4	11.0	0.3	0.2-0.4	15.2	0.3	0.2-0.4
Lymphomas	2,095.4	22.3	21.9-22.8	1,106.2	26.8	26.0-27.5	989.2	18.9	18.4-19.5	428.4	4.4	4.2-4.6	239.6	5.9	5.6-6.3	188.8	3.3	3.1-3.5
Hodgkin lymphoma	251.0	2.9	2.7-3.0	136.0	3.3	3.1-3.6	115.0	2.5	2.3-2.7	22.6	0.2	0.2-0.3	13.0	0.3	0.2-0.4	9.6	0.2	0.1-0.3
Non-Hodgkin lymphomas	1,844.4	19.5	19.1-19.9	970.2	23.4	22.8-24.1	874.2	16.5	16.0-17.0	405.8	4.2	4.0-4.4	226.6	5.6	5.3-6.0	179.2	3.1	2.9-3.3
Myeloma	846.2	8.7	8.4-8.9	435.2	10.3	9.9-10.8	411.0	7.5	7.1-7.8	262.0	2.6	2.5-2.8	136.6	3.3	3.1-3.6	125.4	2.2	2.0-2.3
Leukemias	1,243.2	13.4	13.0-13.7	695.0	17.1	16.5-17.7	548.2	10.5	10.1-11.0	459.2	4.8	4.6-5.0	245.8	6.2	5.9-6.6	213.4	3.9	3.6-4.1
Lymphocytic leukemias	596.8	6.5	6.2-6.7	351.0	8.6	8.2-9.0	245.8	4.8	4.5-5.1	114.4	1.2	1.1-1.3	66.0	1.7	1.5-1.9	48.4	0.9	0.8-1.0
Acute lymphocytic leukemia	140.6	1.8	1.7-1.9	78.6	2.1	1.9-2.3	62.0	1.6	1.4-1.7	33.4	0.4	0.3-0.5	18.2	0.5	0.4-0.6	15.2	0.3	0.3-0.4
Chronic lymphocytic leukemia	420.6	4.3	4.1-4.5	245.4	5.9	5.6-6.3	175.2	3.1	2.9-3.3	73.8	0.7	0.7-0.8	44.0	1.1	1.0-1.3	29.8	0.5	0.4-0.6
Other lymphocytic leukemias	35.6	0.4	0.3-0.4	27.0	0.6	0.5-0.8	8.6	0.2	0.1-0.2	7.2	0.1	0.1-0.1	3.8	0.1	0.1-0.2	3.4	0.1	0.0-0.1
Myeloid and monocytic leukemias	564.4	6.0	5.8-6.3	302.8	7.5	7.1-7.9	261.6	5.0	4.7-5.3	253.2	2.7	2.5-2.8	131.8	3.3	3.1-3.6	121.4	2.2	2.0-2.4
Acute myeloid leukemia	370.0	4.0	3.8-4.1	193.4	4.8	4.5-5.1	176.6	3.3	3.1-3.6	217.8	2.3	2.2-2.4	113.0	2.9	2.6-3.1	104.8	1.9	1.8-2.1
Acute monocytic leukemia	12.2	0.1	0.1-0.2	7.2	0.2	0.1-0.3	5.0	0.1	0.1-0.2	0.8	0.0	0.0-0.0	0.2	0.0	0.0-0.0	0.6	0.0	0.0-0.0
Chronic myeloid leukemia	168.6	1.8	1.7-1.9	94.4	2.3	2.1-2.5	74.2	1.4	1.3-1.6	22.4	0.2	0.2-0.3	12.2	0.3	0.2-0.4	10.2	0.2	0.1-0.2
Other myeloid/monocytic leukemias	13.6	0.1	0.1-0.2	7.8	0.2	0.1-0.3	5.8	0.1	0.1-0.2	12.2	0.1	0.1-0.2	6.4	0.2	0.1-0.2	5.8	0.1	0.1-0.2
Other leukemias	82.0	0.9	0.8-1.0	41.2	1.0	0.9-1.1	40.8	0.8	0.7-0.9	91.6	0.9	0.9-1.0	48.0	1.2	1.0-1.3	43.6	0.8	0.7-0.9
Other acute leukemias	18.0	0.2	0.2-0.2	9.4	0.2	0.2-0.3	8.6	0.2	0.1-0.2	20.8	0.2	0.2-0.3	10.2	0.3	0.2-0.3	10.6	0.2	0.1-0.2

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	64.0	0.7	0.6-0.7	31.8	0.8	0.6-0.9	32.2	0.6	0.5-0.7	70.8	0.7	0.7-0.8	37.8	0.9	0.8-1.1	33.0	0.6	0.5-0.7
Mesothelioma	52.2	0.5	0.5-0.6	32.4	0.8	0.7-1.0	19.8	0.4	0.3-0.5									
Kaposi sarcoma	104.2	1.1	1.0-1.2	93.6	2.2	2.0-2.5	10.6	0.2	0.1-0.3									
Myelodysplastic syndromes	309.4	3.2	3.1-3.4	168.2	4.4	4.1-4.7	141.2	2.5	2.3-2.7									
Chronic myeloproliferative disorders [^]	371.8	3.9	3.7-4.1	171.4	4.1	3.8-4.3	200.4	3.8	3.5-4.0									
Ill defined and unspecified sites	721.4	7.4	7.1-7.6	340.8	8.4	8.0-8.8	380.6	6.6	6.3-6.9	838.0	8.5	8.3-8.8	414.0	10.2	9.8-10.7	424.0	7.3	7.0-7.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York State Excl New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	73,383.6	501.9	500.2-503.6	37,437.6	546.8	544.2-549.3	35,946.0	471.9	469.6-474.2	21,818.2	143.4	142.6-144.3	11,060.2	166.1	164.6-167.5	10,758.0	127.7	126.5-128.8
Oral cavity and pharynx	1,840.2	12.4	12.1-12.6	1,280.2	18.3	17.8-18.7	560.0	7.1	6.9-7.4	343.0	2.2	2.1-2.3	237.6	3.4	3.2-3.6	105.4	1.2	1.1-1.4
Lip	67.2	0.5	0.4-0.5	44.8	0.7	0.6-0.8	22.4	0.3	0.2-0.3	3.0	0.0	0.0-0.0	1.4	0.0	0.0-0.1	1.6	0.0	0.0-0.0
Tongue	621.8	4.1	4.0-4.3	436.8	6.1	5.8-6.4	185.0	2.4	2.2-2.5	94.0	0.6	0.6-0.7	63.0	0.9	0.8-1.0	31.0	0.4	0.3-0.4
Salivary gland	200.6	1.4	1.3-1.5	110.8	1.8	1.6-1.9	89.8	1.2	1.1-1.3	32.0	0.2	0.2-0.3	19.4	0.3	0.2-0.4	12.6	0.2	0.1-0.2
Floor of mouth	83.8	0.6	0.5-0.6	54.6	0.8	0.7-0.9	29.2	0.4	0.3-0.4	3.6	0.0	0.0-0.0	2.0	0.0	0.0-0.1	1.6	0.0	0.0-0.0
Gum & other mouth	251.2	1.7	1.6-1.8	140.0	2.1	1.9-2.2	111.2	1.4	1.3-1.5	54.2	0.3	0.3-0.4	34.0	0.5	0.4-0.6	20.2	0.2	0.2-0.3
Nasopharynx	63.8	0.5	0.4-0.5	44.6	0.7	0.6-0.8	19.2	0.3	0.2-0.3	20.4	0.1	0.1-0.2	14.6	0.2	0.2-0.3	5.8	0.1	0.1-0.1
Tonsil	339.8	2.2	2.1-2.4	281.0	3.9	3.7-4.1	58.8	0.7	0.6-0.8	34.8	0.2	0.2-0.3	28.6	0.4	0.3-0.5	6.2	0.1	0.0-0.1
Oropharynx	97.4	0.6	0.6-0.7	80.2	1.1	1.0-1.2	17.2	0.2	0.2-0.3	42.6	0.3	0.2-0.3	32.4	0.4	0.4-0.5	10.2	0.1	0.1-0.2
Hypopharynx	91.8	0.6	0.5-0.7	71.2	1.0	0.9-1.1	20.6	0.2	0.2-0.3	16.6	0.1	0.1-0.1	12.6	0.2	0.1-0.2	4.0	0.0	0.0-0.1
Other buccal cavity and pharynx	22.8	0.1	0.1-0.2	16.2	0.2	0.2-0.3	6.6	0.1	0.1-0.1	41.8	0.3	0.2-0.3	29.6	0.4	0.4-0.5	12.2	0.1	0.1-0.2
Digestive system	12,070.8	81.7	81.1-82.4	6,663.0	98.5	97.4-99.6	5,407.8	67.7	66.9-68.6	5,652.8	37.1	36.6-37.5	3,180.2	46.9	46.1-47.6	2,472.6	29.0	28.5-29.6
Esophagus	763.2	5.0	4.8-5.2	590.6	8.5	8.2-8.8	172.6	2.1	1.9-2.2	615.8	4.0	3.9-4.1	487.4	7.0	6.7-7.3	128.4	1.5	1.4-1.6
Stomach	1,047.6	7.2	7.0-7.4	641.0	9.5	9.2-9.9	406.6	5.2	5.0-5.5	370.8	2.5	2.4-2.6	218.4	3.3	3.1-3.5	152.4	1.9	1.7-2.0
Small intestine	424.2	2.9	2.8-3.1	234.2	3.5	3.3-3.7	190.0	2.5	2.3-2.7	68.8	0.5	0.4-0.5	39.6	0.6	0.5-0.7	29.2	0.4	0.3-0.4
Colorectal	5,366.4	37.2	36.8-37.7	2,778.8	42.1	41.4-42.9	2,587.6	33.1	32.5-33.7	1,768.4	11.7	11.5-12.0	900.6	13.7	13.3-14.1	867.8	10.1	9.8-10.5
Colon excluding rectum	3,801.2	26.2	25.8-26.6	1,862.8	28.4	27.8-29.0	1,938.4	24.4	23.9-24.9	1,379.8	9.1	8.9-9.4	679.6	10.4	10.0-10.7	700.2	8.1	7.8-8.4
Cecum	756.0	5.0	4.9-5.2	332.0	5.0	4.8-5.3	424.0	5.0	4.8-5.3									
Appendix	270.8	2.2	2.1-2.3	114.6	1.9	1.7-2.0	156.2	2.5	2.3-2.7									
Ascending colon	741.6	5.0	4.8-5.1	331.2	5.0	4.7-5.2	410.4	4.9	4.7-5.1									
Hepatic flexure	171.4	1.2	1.1-1.2	88.2	1.4	1.2-1.5	83.2	1.0	0.9-1.1									
Transverse colon	359.4	2.4	2.3-2.5	180.6	2.8	2.6-3.0	178.8	2.1	2.0-2.3									
Splenic flexure	100.2	0.7	0.6-0.8	50.4	0.8	0.7-0.9	49.8	0.6	0.5-0.7									
Descending colon	206.8	1.5	1.4-1.6	120.8	1.9	1.7-2.0	86.0	1.1	1.0-1.3									
Sigmoid colon	945.2	6.7	6.5-6.9	529.0	8.0	7.7-8.3	416.2	5.6	5.3-5.8									
Large intestine, NOS	249.8	1.6	1.6-1.7	116.0	1.8	1.6-1.9	133.8	1.5	1.4-1.7									
Rectum & rectosigmoid	1,565.2	11.0	10.8-11.3	916.0	13.8	13.4-14.2	649.2	8.6	8.3-9.0	388.6	2.6	2.5-2.7	221.0	3.3	3.1-3.5	167.6	2.0	1.9-2.2
Rectosigmoid junction	346.0	2.4	2.3-2.6	192.6	2.9	2.7-3.1	153.4	2.1	1.9-2.2									
Rectum	1,219.2	8.6	8.4-8.8	723.4	10.9	10.5-11.3	495.8	6.6	6.3-6.8									
Anus, anal canal & anorectum	317.2	2.2	2.0-2.3	106.4	1.6	1.4-1.7	210.8	2.7	2.5-2.9	47.0	0.3	0.3-0.4	18.6	0.3	0.2-0.3	28.4	0.3	0.3-0.4
Liver and intrahepatic bile duct	1,171.0	7.5	7.3-7.7	828.4	11.5	11.1-11.8	342.6	4.2	4.0-4.4	785.6	5.1	4.9-5.2	527.2	7.5	7.2-7.8	258.4	3.1	2.9-3.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York State Excl New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	909.6	5.8	5.6-6.0	693.8	9.5	9.2-9.8	215.8	2.6	2.5-2.8	525.4	3.3	3.2-3.5	392.4	5.5	5.2-5.7	133.0	1.6	1.4-1.7
Intrahepatic bile duct	261.4	1.7	1.6-1.8	134.6	2.0	1.8-2.2	126.8	1.6	1.4-1.7	260.2	1.7	1.6-1.8	134.8	2.0	1.8-2.2	125.4	1.5	1.4-1.7
Gallbladder	170.0	1.1	1.1-1.2	55.2	0.8	0.7-0.9	114.8	1.4	1.3-1.5	77.0	0.5	0.5-0.6	25.8	0.4	0.3-0.5	51.2	0.6	0.5-0.7
Other biliary	265.6	1.8	1.7-1.9	147.2	2.2	2.0-2.3	118.4	1.4	1.3-1.6	80.2	0.5	0.5-0.6	40.0	0.6	0.5-0.7	40.2	0.5	0.4-0.5
Pancreas	2,290.6	15.1	14.8-15.4	1,180.0	17.3	16.8-17.8	1,110.6	13.3	12.9-13.7	1,742.6	11.4	11.1-11.6	882.6	13.0	12.6-13.4	860.0	10.0	9.7-10.3
Retroperitoneum	61.4	0.4	0.4-0.5	32.4	0.5	0.4-0.6	29.0	0.4	0.3-0.5	9.0	0.1	0.0-0.1	5.4	0.1	0.1-0.1	3.6	0.0	0.0-0.1
Peritoneum, omentum & mesentery	65.4	0.4	0.4-0.5	5.2	0.1	0.1-0.1	60.2	0.7	0.6-0.8	33.6	0.2	0.2-0.3	7.0	0.1	0.1-0.1	26.6	0.3	0.3-0.4
Other digestive organs	128.2	0.9	0.8-0.9	63.6	0.9	0.8-1.1	64.6	0.8	0.7-0.9	54.0	0.4	0.3-0.4	27.6	0.4	0.3-0.5	26.4	0.3	0.3-0.4
Respiratory system	10,237.2	66.8	66.2-67.4	5,030.0	72.8	71.9-73.7	5,207.2	62.4	61.7-63.2	5,410.2	35.1	34.7-35.6	2,769.2	40.7	40.0-41.4	2,641.0	31.0	30.4-31.5
Nasal cavity, middle ear & sinuses	111.8	0.8	0.7-0.9	65.8	1.0	0.9-1.1	46.0	0.6	0.5-0.7	16.2	0.1	0.1-0.1	9.2	0.1	0.1-0.2	7.0	0.1	0.1-0.1
Larynx	462.4	3.0	2.9-3.1	364.6	5.1	4.9-5.4	97.8	1.2	1.1-1.4	125.8	0.8	0.7-0.9	98.8	1.4	1.3-1.5	27.0	0.3	0.3-0.4
Lung and bronchus	9,633.2	62.7	62.2-63.3	4,579.2	66.3	65.4-67.2	5,054.0	60.5	59.7-61.2	5,250.4	34.1	33.7-34.5	2,649.4	39.0	38.3-39.7	2,601.0	30.5	30.0-31.1
Pleura	3.2	0.0	0.0-0.0	1.6	0.0	0.0-0.0	1.6	0.0	0.0-0.0	9.4	0.1	0.0-0.1	7.0	0.1	0.1-0.2	2.4	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	26.6	0.2	0.2-0.3	18.8	0.3	0.3-0.4	7.8	0.1	0.1-0.2	8.4	0.1	0.0-0.1	4.8	0.1	0.0-0.1	3.6	0.0	0.0-0.1
Bones & joints	139.4	1.2	1.1-1.3	80.2	1.4	1.2-1.5	59.2	1.0	0.9-1.1	52.2	0.4	0.4-0.5	30.8	0.5	0.4-0.6	21.4	0.3	0.3-0.4
Soft tissue (including heart)	471.6	3.5	3.4-3.7	263.8	4.2	4.0-4.4	207.8	3.0	2.8-3.2	186.2	1.3	1.2-1.4	97.0	1.5	1.4-1.7	89.2	1.2	1.1-1.3
Skin*	3,630.2	25.5	25.1-25.9	2,123.8	32.2	31.5-32.8	1,506.4	20.8	20.3-21.3	451.8	3.0	2.8-3.1	295.6	4.6	4.3-4.8	156.2	1.8	1.7-1.9
Melanoma of the skin	3,302.4	23.3	22.9-23.6	1,922.4	29.0	28.4-29.6	1,380.0	19.2	18.7-19.7	303.4	2.0	1.9-2.1	193.8	3.0	2.8-3.2	109.6	1.3	1.2-1.4
Breast	10,354.2	74.1	73.4-74.8	96.2	1.4	1.3-1.6	10,258.0	139.3	138.0-140.5	1,515.0	10.2	10.0-10.5	16.6	0.3	0.2-0.3	1,498.4	18.5	18.0-18.9
Breast (in situ)#	2,832.6	21.1	20.7-21.4	9.6	0.1	0.1-0.2	2,823.0	40.4	39.7-41.1									
Female genital system							4,223.2	55.4	54.6-56.1							1,225.4	14.8	14.4-15.2
Cervix uteri							393.2	6.6	6.3-6.9							122.4	1.7	1.6-1.9
Corpus uterus and NOS							2,513.8	31.6	31.0-32.1							456.0	5.4	5.2-5.6
Ovary							841.4	11.3	10.9-11.6							534.4	6.4	6.2-6.7
Vagina							49.0	0.6	0.6-0.7							14.2	0.2	0.1-0.2
Vulva							234.8	3.0	2.8-3.1							59.8	0.7	0.6-0.7
Other female genital organs							191.0	2.4	2.2-2.5							38.6	0.5	0.4-0.5
Male genital system				10,315.8	141.5	140.3-142.8							1,067.6	16.7	16.3-17.2			
Prostate				9,885.0	133.4	132.2-134.6							1,037.8	16.2	15.8-16.7			
Testis				353.8	6.9	6.6-7.3							15.0	0.3	0.2-0.3			
Penis				59.4	0.9	0.8-1.0							12.2	0.2	0.1-0.2			
Other male genital organs				17.6	0.3	0.2-0.3							2.6	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York State Excl New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	6,638.4	44.6	44.1-45.1	4,709.6	70.0	69.1-70.9	1,928.8	24.0	23.5-24.5	1,138.6	7.4	7.2-7.6	772.2	11.8	11.5-12.2	366.4	4.1	4.0-4.3
Urinary bladder (including in situ)	3,819.0	25.1	24.7-25.5	2,868.6	42.8	42.1-43.5	950.4	11.2	10.9-11.6	663.6	4.3	4.1-4.4	473.6	7.4	7.1-7.7	190.0	2.1	2.0-2.2
Kidney and renal pelvis	2,655.0	18.4	18.1-18.7	1,731.2	25.6	25.0-26.1	923.8	12.2	11.8-12.5	442.4	2.9	2.8-3.0	281.0	4.2	3.9-4.4	161.4	1.9	1.8-2.0
Ureter	100.0	0.7	0.6-0.7	61.8	0.9	0.8-1.0	38.2	0.4	0.4-0.5	16.0	0.1	0.1-0.1	6.2	0.1	0.1-0.1	9.8	0.1	0.1-0.1
Other urinary organs	64.4	0.4	0.4-0.5	48.0	0.7	0.6-0.8	16.4	0.2	0.2-0.2	16.6	0.1	0.1-0.1	11.4	0.2	0.1-0.2	5.2	0.1	0.0-0.1
Eye & orbit	128.0	0.9	0.9-1.0	65.6	1.0	0.9-1.1	62.4	0.9	0.8-1.0	10.4	0.1	0.1-0.1	5.4	0.1	0.1-0.1	5.0	0.1	0.0-0.1
Brain / other central nervous system (all behaviors)	3,062.4	22.7	22.4-23.1	1,228.0	19.6	19.1-20.1	1,834.4	25.6	25.1-26.2	731.2	5.1	4.9-5.3	403.6	6.1	5.9-6.4	327.6	4.2	4.0-4.5
Malignant brain / other central nervous system	892.6	6.9	6.7-7.1	500.4	8.1	7.7-8.4	392.2	5.8	5.5-6.1	610.0	4.3	4.1-4.4	349.6	5.3	5.0-5.5	260.4	3.4	3.2-3.6
Malignant brain	844.4	6.4	6.2-6.7	476.2	7.6	7.3-8.0	368.2	5.4	5.1-5.7									
Malignant other central nervous system	48.2	0.4	0.4-0.5	24.2	0.4	0.3-0.5	24.0	0.4	0.3-0.5									
Benign brain / other central nervous system#	2,169.8	15.9	15.6-16.2	727.6	11.5	11.1-11.9	1,442.2	19.8	19.3-20.3	121.2	0.8	0.8-0.9	54.0	0.9	0.8-1.0	67.2	0.8	0.7-0.9
Benign brain	209.6	1.8	1.7-1.9	107.8	1.9	1.7-2.1	101.8	1.7	1.6-1.9									
Benign other central nervous system	1,960.2	14.1	13.8-14.4	619.8	9.6	9.3-10.0	1,340.4	18.1	17.6-18.6									
Endocrine system	2,218.0	18.6	18.2-18.9	663.6	10.9	10.5-11.3	1,554.4	26.2	25.6-26.8	113.6	0.8	0.7-0.9	51.0	0.8	0.7-0.9	62.6	0.8	0.7-0.9
Thyroid	2,087.2	17.5	17.2-17.9	594.0	9.8	9.4-10.1	1,493.2	25.3	24.7-25.9	77.0	0.5	0.5-0.6	34.4	0.5	0.5-0.6	42.6	0.5	0.4-0.6
Other endocrine (including thymus)	130.8	1.0	0.9-1.1	69.6	1.1	1.0-1.3	61.2	0.9	0.8-1.0	36.6	0.3	0.2-0.3	16.6	0.3	0.2-0.3	20.0	0.3	0.2-0.3
Lymphomas	3,528.6	25.1	24.7-25.4	1,909.8	29.4	28.8-30.1	1,618.8	21.5	21.1-22.0	805.4	5.3	5.2-5.5	448.4	6.9	6.6-7.2	357.0	4.2	4.0-4.4
Hodgkin lymphoma	368.6	3.2	3.0-3.3	199.2	3.5	3.2-3.7	169.4	2.9	2.7-3.1	39.6	0.3	0.2-0.3	24.6	0.4	0.3-0.5	15.0	0.2	0.2-0.2
Non-Hodgkin lymphomas	3,160.0	21.9	21.5-22.3	1,710.6	26.0	25.4-26.6	1,449.4	18.6	18.2-19.1	765.8	5.1	4.9-5.2	423.8	6.5	6.3-6.8	342.0	4.0	3.8-4.2
Myeloma	1,138.2	7.6	7.4-7.8	643.2	9.5	9.1-9.8	495.0	6.1	5.9-6.4	410.4	2.7	2.6-2.8	216.2	3.3	3.1-3.5	194.2	2.2	2.1-2.4
Leukemias	2,453.2	17.2	16.9-17.5	1,454.6	22.3	21.8-22.9	998.6	13.0	12.6-13.4	884.2	5.9	5.8-6.1	514.0	8.1	7.8-8.4	370.2	4.3	4.1-4.6
Lymphocytic leukemias	1,303.4	9.0	8.8-9.3	803.0	12.1	11.7-12.5	500.4	6.5	6.2-6.7	233.2	1.6	1.5-1.6	138.0	2.2	2.0-2.4	95.2	1.1	1.0-1.2
Acute lymphocytic leukemia	171.0	1.6	1.5-1.7	96.0	1.8	1.7-2.0	75.0	1.4	1.2-1.5	44.8	0.4	0.3-0.4	25.2	0.4	0.4-0.5	19.6	0.3	0.2-0.4
Chronic lymphocytic leukemia	1,053.8	6.9	6.7-7.1	649.2	9.4	9.1-9.7	404.6	4.8	4.6-5.0	171.4	1.1	1.0-1.2	103.0	1.6	1.5-1.8	68.4	0.7	0.6-0.8
Other lymphocytic leukemias	78.6	0.6	0.5-0.6	57.8	0.9	0.8-1.0	20.8	0.3	0.2-0.3	17.0	0.1	0.1-0.1	9.8	0.1	0.1-0.2	7.2	0.1	0.1-0.1
Myeloid and monocytic leukemias	1,031.4	7.3	7.1-7.5	588.0	9.2	8.9-9.6	443.4	5.8	5.6-6.1	502.0	3.4	3.3-3.5	293.0	4.6	4.3-4.8	209.0	2.5	2.4-2.7
Acute myeloid leukemia	683.2	4.8	4.7-5.0	389.2	6.1	5.8-6.4	294.0	3.8	3.6-4.1	430.0	2.9	2.8-3.0	252.0	3.9	3.7-4.1	178.0	2.2	2.0-2.3
Acute monocytic leukemia	28.8	0.2	0.2-0.2	18.0	0.3	0.2-0.3	10.8	0.1	0.1-0.2	3.0	0.0	0.0-0.0	1.6	0.0	0.0-0.1	1.4	0.0	0.0-0.0
Chronic myeloid leukemia	302.8	2.2	2.1-2.3	172.2	2.7	2.6-2.9	130.6	1.7	1.6-1.9	37.2	0.2	0.2-0.3	20.0	0.3	0.3-0.4	17.2	0.2	0.2-0.2
Other myeloid/monocytic leukemias	16.6	0.1	0.1-0.1	8.6	0.1	0.1-0.2	8.0	0.1	0.1-0.1	31.8	0.2	0.2-0.2	19.4	0.3	0.2-0.4	12.4	0.1	0.1-0.2
Other leukemias	118.4	0.8	0.8-0.9	63.6	1.0	0.9-1.1	54.8	0.7	0.6-0.8	149.0	1.0	0.9-1.1	83.0	1.3	1.2-1.5	66.0	0.8	0.7-0.8
Other acute leukemias	34.2	0.2	0.2-0.3	18.2	0.3	0.2-0.4	16.0	0.2	0.2-0.2	60.8	0.4	0.4-0.5	34.2	0.5	0.5-0.6	26.6	0.3	0.3-0.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York State Excl New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	84.2	0.6	0.5-0.7	45.4	0.7	0.6-0.8	38.8	0.5	0.4-0.6	88.2	0.6	0.5-0.6	48.8	0.8	0.7-0.9	39.4	0.5	0.4-0.5
Mesothelioma	125.4	0.9	0.8-0.9	90.4	1.4	1.3-1.6	35.0	0.4	0.4-0.5									
Kaposi sarcoma	25.4	0.2	0.2-0.2	21.6	0.3	0.3-0.4	3.8	0.0	0.0-0.1									
Myelodysplastic syndromes	758.2	5.0	4.8-5.2	442.8	7.0	6.7-7.3	315.4	3.6	3.4-3.8									
Chronic myeloproliferative disorders [^]	774.4	5.5	5.3-5.6	369.4	5.7	5.5-6.0	405.0	5.2	5.0-5.4									
Ill defined and unspecified sites	1,420.6	9.4	9.2-9.6	713.6	10.9	10.5-11.2	707.0	8.2	8.0-8.5	1,941.4	12.7	12.4-12.9	1,008.8	15.2	14.8-15.7	932.6	10.8	10.4-11.1

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Bronx

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	6,325.0	422.9	418.2-427.7	3,095.2	486.3	478.4-494.2	3,229.8	382.7	376.7-388.7	2,009.4	134.9	132.2-137.6	990.2	165.5	160.8-170.3	1,019.2	115.6	112.4-118.9
Oral cavity and pharynx	150.4	10.0	9.3-10.7	101.2	15.7	14.3-17.2	49.2	5.7	5.0-6.5	39.6	2.7	2.3-3.1	28.2	4.5	3.8-5.4	11.4	1.3	1.0-1.7
Lip	3.4	0.2	0.1-0.4	2.6	0.4	0.2-0.7	0.8	0.1	0.0-0.3	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Tongue	34.0	2.2	1.9-2.6	22.8	3.5	2.9-4.2	11.2	1.3	0.9-1.6	9.4	0.6	0.5-0.8	6.2	1.0	0.7-1.4	3.2	0.4	0.2-0.6
Salivary gland	13.8	1.0	0.8-1.2	6.6	1.1	0.7-1.5	7.2	0.9	0.6-1.3	2.4	0.2	0.1-0.3	0.8	0.1	0.0-0.4	1.6	0.2	0.1-0.4
Floor of mouth	5.6	0.4	0.2-0.5	4.0	0.6	0.3-0.9	1.6	0.2	0.1-0.4	0.6	0.0	0.0-0.1	0.6	0.1	0.0-0.2	0.0	0.0	0.0-0.1
Gum & other mouth	23.8	1.6	1.3-1.9	11.8	1.9	1.4-2.5	12.0	1.4	1.0-1.8	5.0	0.3	0.2-0.5	3.4	0.5	0.3-0.8	1.6	0.2	0.1-0.3
Nasopharynx	12.0	0.8	0.6-1.0	9.0	1.4	1.0-1.9	3.0	0.4	0.2-0.6	4.2	0.3	0.2-0.5	2.8	0.5	0.3-0.8	1.4	0.2	0.1-0.4
Tonsil	30.8	2.0	1.7-2.4	23.4	3.6	3.0-4.3	7.4	0.8	0.6-1.1	3.4	0.2	0.1-0.3	3.2	0.5	0.3-0.7	0.2	0.0	0.0-0.1
Oropharynx	11.4	0.7	0.6-1.0	9.2	1.4	1.0-1.9	2.2	0.3	0.1-0.5	6.0	0.4	0.3-0.6	4.4	0.7	0.5-1.1	1.6	0.2	0.1-0.4
Hypopharynx	14.4	1.0	0.8-1.2	11.0	1.8	1.3-2.3	3.4	0.4	0.2-0.6	3.2	0.2	0.1-0.4	2.8	0.5	0.3-0.8	0.4	0.0	0.0-0.2
Other buccal cavity and pharynx	1.2	0.1	0.0-0.2	0.8	0.1	0.0-0.3	0.4	0.0	0.0-0.2	5.4	0.4	0.2-0.5	4.0	0.7	0.4-1.0	1.4	0.2	0.1-0.4
Digestive system	1,315.0	88.1	86.0-90.3	717.4	114.1	110.3-118.0	597.6	69.3	66.8-71.9	599.8	40.1	38.7-41.6	332.6	54.5	51.9-57.3	267.2	30.0	28.4-31.7
Esophagus	48.0	3.2	2.8-3.6	35.2	5.7	4.8-6.6	12.8	1.4	1.1-1.8	32.2	2.1	1.8-2.4	22.6	3.6	2.9-4.3	9.6	1.1	0.8-1.4
Stomach	144.8	10.0	9.2-10.7	80.6	13.3	12.0-14.7	64.2	7.7	6.8-8.6	57.6	4.0	3.5-4.5	35.6	6.0	5.1-7.0	22.0	2.6	2.1-3.1
Small intestine	43.0	2.9	2.5-3.3	20.8	3.4	2.8-4.1	22.2	2.6	2.2-3.2	5.2	0.4	0.2-0.5	2.8	0.5	0.3-0.8	2.4	0.3	0.1-0.5
Colorectal	521.2	35.4	34.0-36.8	267.2	43.0	40.7-45.4	254.0	29.9	28.3-31.6	180.4	12.2	11.4-13.1	90.2	15.3	13.9-16.8	90.2	10.1	9.2-11.1
Colon excluding rectum	365.4	24.9	23.7-26.0	181.6	29.4	27.5-31.4	183.8	21.6	20.2-23.1	148.6	10.1	9.3-10.8	70.0	11.9	10.6-13.2	78.6	8.8	8.0-9.8
Cecum	71.4	4.8	4.4-5.4	30.0	4.9	4.1-5.7	41.4	4.8	4.1-5.5									
Appendix	19.8	1.4	1.1-1.7	6.2	1.0	0.7-1.5	13.6	1.7	1.3-2.2									
Ascending colon	64.8	4.5	4.0-5.0	31.6	5.3	4.5-6.2	33.2	3.9	3.3-4.6									
Hepatic flexure	16.4	1.1	0.9-1.3	7.4	1.2	0.9-1.7	9.0	1.0	0.7-1.3									
Transverse colon	32.6	2.2	1.9-2.6	18.4	2.9	2.4-3.6	14.2	1.7	1.3-2.1									
Splenic flexure	12.2	0.8	0.6-1.1	6.6	1.1	0.7-1.5	5.6	0.7	0.4-1.0									
Descending colon	27.0	1.8	1.5-2.1	15.4	2.4	1.9-3.0	11.6	1.4	1.0-1.8									
Sigmoid colon	98.6	6.7	6.1-7.3	55.0	8.7	7.7-9.9	43.6	5.2	4.5-6.0									
Large intestine, NOS	22.6	1.5	1.2-1.8	11.0	1.8	1.4-2.4	11.6	1.3	1.0-1.7									
Rectum & rectosigmoid	155.8	10.5	9.8-11.3	85.6	13.6	12.3-15.0	70.2	8.3	7.5-9.3	31.8	2.2	1.8-2.5	20.2	3.4	2.8-4.2	11.6	1.3	1.0-1.7
Rectosigmoid junction	34.2	2.3	2.0-2.7	19.0	3.0	2.4-3.7	15.2	1.8	1.4-2.2									
Rectum	121.6	8.2	7.6-8.9	66.6	10.5	9.4-11.8	55.0	6.5	5.8-7.4									
Anus, anal canal & anorectum	43.2	2.9	2.5-3.3	20.4	3.1	2.5-3.7	22.8	2.7	2.2-3.3	6.6	0.4	0.3-0.6	3.4	0.5	0.3-0.9	3.2	0.4	0.2-0.6
Liver and intrahepatic bile duct	218.2	14.0	13.2-14.9	151.2	22.8	21.2-24.5	67.0	7.5	6.7-8.3	135.2	8.8	8.2-9.5	89.8	14.1	12.8-15.5	45.4	5.0	4.4-5.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Bronx

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	187.0	12.0	11.2-12.8	134.8	20.2	18.7-21.9	52.2	5.8	5.1-6.6	104.0	6.8	6.2-7.4	76.0	11.9	10.7-13.2	28.0	3.1	2.6-3.7
Intrahepatic bile duct	31.2	2.0	1.7-2.4	16.4	2.6	2.0-3.2	14.8	1.7	1.3-2.1	31.2	2.0	1.7-2.4	13.8	2.2	1.7-2.8	17.4	1.9	1.5-2.4
Gallbladder	39.0	2.6	2.2-3.0	13.8	2.2	1.7-2.8	25.2	2.9	2.4-3.4	18.4	1.2	1.0-1.5	5.8	0.9	0.6-1.4	12.6	1.4	1.1-1.8
Other biliary	30.8	2.1	1.7-2.4	14.2	2.3	1.8-2.9	16.6	1.9	1.5-2.3	7.0	0.5	0.3-0.7	2.8	0.5	0.3-0.9	4.2	0.5	0.3-0.7
Pancreas	200.8	13.4	12.5-14.2	103.8	16.7	15.3-18.2	97.0	11.0	10.0-12.0	147.4	9.8	9.1-10.6	75.8	12.5	11.3-13.9	71.6	8.0	7.2-8.9
Retroperitoneum	6.6	0.4	0.3-0.6	4.0	0.6	0.4-0.9	2.6	0.3	0.2-0.5	1.2	0.1	0.0-0.2	0.4	0.1	0.0-0.2	0.8	0.1	0.0-0.2
Peritoneum, omentum & mesentery	6.2	0.4	0.3-0.6	0.8	0.1	0.0-0.3	5.4	0.6	0.4-0.9	2.6	0.2	0.1-0.3	0.4	0.1	0.0-0.2	2.2	0.2	0.1-0.4
Other digestive organs	13.2	0.9	0.7-1.2	5.4	0.9	0.6-1.4	7.8	0.9	0.6-1.2	6.0	0.4	0.3-0.6	3.0	0.5	0.3-0.8	3.0	0.3	0.2-0.6
Respiratory system	717.0	47.7	46.1-49.3	377.0	61.0	58.2-63.9	340.0	38.5	36.7-40.4	396.8	26.4	25.2-27.6	215.6	35.3	33.2-37.6	181.2	20.2	18.9-21.6
Nasal cavity, middle ear & sinuses	12.8	0.9	0.7-1.1	7.0	1.1	0.7-1.5	5.8	0.7	0.5-1.0	3.2	0.2	0.1-0.4	1.6	0.2	0.1-0.5	1.6	0.2	0.1-0.4
Larynx	55.4	3.7	3.2-4.1	41.6	6.6	5.7-7.6	13.8	1.6	1.3-2.1	16.6	1.1	0.9-1.4	13.0	2.1	1.6-2.7	3.6	0.4	0.2-0.6
Lung and bronchus	644.4	42.9	41.4-44.4	325.2	52.9	50.3-55.6	319.2	36.0	34.3-37.9	374.4	24.9	23.8-26.1	199.6	32.7	30.7-34.8	174.8	19.5	18.2-20.9
Pleura	0.6	0.0	0.0-0.1	0.6	0.1	0.0-0.2	0.0	0.0	0.0-0.1	1.0	0.1	0.0-0.2	0.6	0.1	0.0-0.3	0.4	0.1	0.0-0.2
Trachea, mediastinum, other respiratory	3.8	0.3	0.2-0.4	2.6	0.4	0.2-0.7	1.2	0.1	0.0-0.3	1.6	0.1	0.0-0.2	0.8	0.1	0.0-0.4	0.8	0.1	0.0-0.2
Bones & joints	16.6	1.2	0.9-1.5	10.8	1.6	1.2-2.1	5.8	0.8	0.5-1.1	8.2	0.6	0.4-0.8	5.0	0.7	0.5-1.1	3.2	0.4	0.2-0.6
Soft tissue (including heart)	44.8	3.1	2.7-3.6	22.2	3.5	2.9-4.3	22.6	2.9	2.3-3.5	12.8	0.8	0.6-1.1	5.4	0.8	0.5-1.2	7.4	0.9	0.6-1.2
Skin*	75.2	5.2	4.7-5.8	40.8	6.9	6.0-8.0	34.4	4.1	3.5-4.7	14.8	1.0	0.8-1.2	9.6	1.6	1.2-2.1	5.2	0.6	0.4-0.8
Melanoma of the skin	58.4	4.0	3.6-4.5	32.2	5.5	4.7-6.5	26.2	3.1	2.6-3.7	6.6	0.4	0.3-0.6	4.0	0.7	0.4-1.0	2.6	0.3	0.1-0.5
Breast	932.8	63.6	61.7-65.5	7.8	1.3	0.9-1.7	925.0	111.6	108.3-114.9	168.2	11.4	10.6-12.2	1.8	0.3	0.1-0.6	166.4	19.3	18.0-20.7
Breast (in situ)#	288.6	19.6	18.6-20.7	2.0	0.4	0.2-0.7	286.6	34.8	33.0-36.6									
Female genital system							462.8	54.8	52.6-57.1							157.8	18.1	16.9-19.5
Cervix uteri							72.0	9.3	8.3-10.3							22.4	2.8	2.3-3.3
Corpus uterus and NOS							265.8	30.6	29.0-32.3							76.8	8.7	7.8-9.6
Ovary							89.0	10.6	9.7-11.7							46.2	5.3	4.6-6.0
Vagina							6.6	0.8	0.5-1.1							2.6	0.3	0.2-0.5
Vulva							15.8	1.9	1.5-2.4							5.6	0.7	0.4-0.9
Other female genital organs							13.6	1.6	1.2-2.0							4.2	0.5	0.3-0.7
Male genital system				970.0	145.8	141.7-150.1							127.4	23.1	21.4-25.0			
Prostate				937.0	140.8	136.7-145.0							124.2	22.6	20.8-24.5			
Testis				21.4	3.2	2.6-3.8							2.2	0.4	0.2-0.7			
Penis				9.2	1.4	1.0-1.9							1.0	0.2	0.1-0.4			
Other male genital organs				2.4	0.4	0.2-0.7							0.0	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Bronx

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	428.2	28.6	27.4-29.9	280.8	45.7	43.2-48.2	147.4	17.0	15.8-18.3	86.8	5.9	5.4-6.5	54.2	9.5	8.4-10.7	32.6	3.6	3.1-4.2
Urinary bladder (including in situ)	193.4	13.1	12.2-13.9	137.8	23.3	21.5-25.1	55.6	6.3	5.6-7.1	44.2	3.0	2.6-3.5	28.0	5.0	4.2-6.0	16.2	1.8	1.4-2.2
Kidney and renal pelvis	226.8	15.0	14.1-15.9	139.0	21.7	20.1-23.4	87.8	10.2	9.3-11.3	41.6	2.8	2.5-3.3	26.0	4.4	3.7-5.2	15.6	1.7	1.4-2.2
Ureter	4.2	0.3	0.2-0.4	2.2	0.4	0.2-0.7	2.0	0.2	0.1-0.4	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Other urinary organs	3.8	0.3	0.2-0.4	1.8	0.3	0.1-0.5	2.0	0.2	0.1-0.5	0.8	0.1	0.0-0.2	0.2	0.0	0.0-0.2	0.6	0.1	0.0-0.2
Eye & orbit	11.6	0.8	0.6-1.0	6.4	1.0	0.7-1.4	5.2	0.6	0.4-0.9	0.8	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.4	0.0	0.0-0.1
Brain / other central nervous system (all behaviors)	305.4	20.9	19.8-21.9	107.8	17.1	15.6-18.6	197.6	23.7	22.2-25.3	53.2	3.6	3.2-4.1	29.2	4.7	4.0-5.6	24.0	2.8	2.3-3.4
Malignant brain / other central nervous system	75.4	5.2	4.7-5.7	42.4	6.6	5.7-7.6	33.0	4.0	3.4-4.7	45.4	3.1	2.7-3.5	25.0	4.0	3.4-4.8	20.4	2.4	2.0-3.0
Malignant brain	69.8	4.8	4.3-5.3	39.0	6.1	5.2-7.0	30.8	3.7	3.2-4.4									
Malignant other central nervous system	5.6	0.4	0.3-0.6	3.4	0.5	0.3-0.9	2.2	0.3	0.1-0.5									
Benign brain / other central nervous system#	230.0	15.7	14.8-16.6	65.4	10.5	9.3-11.7	164.6	19.7	18.4-21.1	7.8	0.5	0.4-0.7	4.2	0.7	0.4-1.1	3.6	0.4	0.2-0.6
Benign brain	15.6	1.0	0.8-1.3	7.2	1.0	0.7-1.4	8.4	1.0	0.7-1.4									
Benign other central nervous system	214.4	14.6	13.7-15.5	58.2	9.4	8.4-10.6	156.2	18.7	17.3-20.0									
Endocrine system	219.2	15.4	14.5-16.4	48.4	7.6	6.7-8.7	170.8	22.1	20.6-23.6	11.0	0.8	0.6-1.0	4.2	0.7	0.4-1.1	6.8	0.8	0.6-1.1
Thyroid	203.8	14.3	13.5-15.3	41.8	6.6	5.7-7.6	162.0	21.0	19.5-22.5	7.0	0.5	0.3-0.7	3.0	0.5	0.3-0.9	4.0	0.5	0.3-0.7
Other endocrine (including thymus)	15.4	1.1	0.8-1.3	6.6	1.0	0.7-1.4	8.8	1.1	0.8-1.5	4.0	0.3	0.2-0.4	1.2	0.2	0.1-0.5	2.8	0.3	0.2-0.6
Lymphomas	318.4	21.8	20.7-22.9	166.0	26.4	24.6-28.3	152.4	18.4	17.1-19.8	73.4	5.0	4.5-5.5	42.2	6.9	6.0-8.0	31.2	3.6	3.1-4.2
Hodgkin lymphoma	41.2	2.9	2.5-3.3	22.2	3.4	2.8-4.1	19.0	2.5	2.0-3.0	4.6	0.3	0.2-0.5	3.0	0.5	0.3-0.8	1.6	0.2	0.1-0.4
Non-Hodgkin lymphomas	277.2	18.9	17.9-19.9	143.8	23.0	21.3-24.8	133.4	15.9	14.7-17.2	68.8	4.7	4.2-5.2	39.2	6.5	5.6-7.5	29.6	3.4	2.9-4.0
Myeloma	171.4	11.3	10.6-12.1	85.0	13.4	12.1-14.8	86.4	10.0	9.1-11.0	52.8	3.5	3.1-4.0	29.2	4.8	4.0-5.6	23.6	2.6	2.2-3.2
Leukemias	178.0	12.0	11.2-12.9	94.2	14.9	13.6-16.4	83.8	10.0	9.1-11.1	71.8	4.8	4.4-5.4	39.0	6.5	5.6-7.5	32.8	3.8	3.2-4.4
Lymphocytic leukemias	81.4	5.5	5.0-6.1	47.0	7.4	6.4-8.4	34.4	4.1	3.5-4.8	16.0	1.1	0.9-1.4	10.2	1.8	1.3-2.3	5.8	0.6	0.4-0.9
Acute lymphocytic leukemia	27.0	1.9	1.6-2.2	16.0	2.3	1.8-2.9	11.0	1.5	1.1-2.0	5.8	0.4	0.3-0.6	4.0	0.6	0.4-1.0	1.8	0.2	0.1-0.4
Chronic lymphocytic leukemia	49.4	3.3	2.9-3.7	28.0	4.6	3.8-5.4	21.4	2.4	2.0-2.9	9.8	0.7	0.5-0.9	6.2	1.1	0.8-1.6	3.6	0.4	0.2-0.6
Other lymphocytic leukemias	5.0	0.3	0.2-0.5	3.0	0.5	0.3-0.8	2.0	0.2	0.1-0.4	0.4	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.4	0.0	0.0-0.2
Myeloid and monocytic leukemias	83.2	5.6	5.1-6.2	41.8	6.7	5.8-7.7	41.4	4.9	4.3-5.7	38.0	2.6	2.2-3.0	20.6	3.4	2.8-4.2	17.4	2.0	1.6-2.5
Acute myeloid leukemia	53.0	3.6	3.2-4.1	27.6	4.5	3.8-5.3	25.4	3.1	2.5-3.7	33.8	2.3	2.0-2.7	18.0	3.0	2.4-3.7	15.8	1.9	1.5-2.3
Acute monocytic leukemia	1.0	0.1	0.0-0.2	0.6	0.1	0.0-0.3	0.4	0.0	0.0-0.2	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Chronic myeloid leukemia	26.4	1.8	1.5-2.1	12.2	1.9	1.5-2.5	14.2	1.7	1.3-2.1	3.4	0.2	0.1-0.3	2.0	0.3	0.1-0.6	1.4	0.1	0.1-0.3
Other myeloid/monocytic leukemias	2.8	0.2	0.1-0.3	1.4	0.2	0.1-0.4	1.4	0.2	0.1-0.3	0.8	0.1	0.0-0.1	0.6	0.1	0.0-0.3	0.2	0.0	0.0-0.1
Other leukemias	13.4	0.9	0.7-1.2	5.4	0.8	0.5-1.2	8.0	1.0	0.7-1.4	17.8	1.2	0.9-1.5	8.2	1.3	0.9-1.8	9.6	1.1	0.8-1.5
Other acute leukemias	2.6	0.2	0.1-0.3	0.8	0.1	0.0-0.3	1.8	0.2	0.1-0.4	2.8	0.2	0.1-0.3	1.2	0.2	0.1-0.4	1.6	0.2	0.1-0.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Bronx**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	10.8	0.7	0.5-1.0	4.6	0.7	0.4-1.0	6.2	0.8	0.5-1.1	15.0	1.0	0.8-1.3	7.0	1.2	0.8-1.6	8.0	0.9	0.7-1.3
Mesothelioma	6.2	0.4	0.3-0.6	4.8	0.9	0.5-1.3	1.4	0.2	0.1-0.4									
Kaposi sarcoma	19.2	1.3	1.1-1.6	17.2	2.6	2.1-3.3	2.0	0.3	0.1-0.5									
Myelodysplastic syndromes	41.4	2.9	2.5-3.3	22.2	3.9	3.2-4.7	19.2	2.2	1.8-2.8									
Chronic myeloproliferative disorders [^]	66.0	4.4	4.0-5.0	28.8	4.6	3.9-5.5	37.2	4.3	3.7-5.0									
Ill defined and unspecified sites	105.4	7.0	6.4-7.7	51.8	8.7	7.6-9.8	53.6	5.9	5.2-6.6	142.0	9.5	8.8-10.2	70.4	12.0	10.7-13.3	71.6	7.9	7.1-8.8

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Kings (Brooklyn)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	12,018.8	430.7	427.2-434.2	5,739.8	472.2	466.6-477.8	6,279.0	406.1	401.5-410.8	3,465.4	123.0	121.1-124.8	1,656.4	143.0	139.9-146.2	1,809.0	110.2	107.9-112.6
Oral cavity and pharynx	254.8	9.1	8.6-9.7	165.0	13.6	12.7-14.6	89.8	5.7	5.1-6.2	53.8	1.9	1.7-2.2	37.4	3.2	2.7-3.7	16.4	1.0	0.8-1.2
Lip	6.6	0.2	0.2-0.3	4.4	0.4	0.2-0.6	2.2	0.1	0.1-0.3	0.4	0.0	0.0-0.0	0.0	0.0	0.0-0.1	0.4	0.0	0.0-0.1
Tongue	63.6	2.3	2.0-2.5	43.2	3.5	3.1-4.0	20.4	1.3	1.0-1.6	9.6	0.3	0.3-0.5	6.2	0.5	0.4-0.8	3.4	0.2	0.1-0.3
Salivary gland	32.0	1.1	1.0-1.3	14.8	1.3	1.0-1.6	17.2	1.1	0.9-1.3	3.6	0.1	0.1-0.2	1.8	0.2	0.1-0.3	1.8	0.1	0.0-0.2
Floor of mouth	8.4	0.3	0.2-0.4	5.8	0.5	0.3-0.7	2.6	0.2	0.1-0.3	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Gum & other mouth	44.6	1.6	1.4-1.8	23.4	2.0	1.6-2.4	21.2	1.3	1.1-1.6	8.2	0.3	0.2-0.4	4.2	0.3	0.2-0.5	4.0	0.2	0.1-0.4
Nasopharynx	37.4	1.4	1.2-1.6	26.0	2.1	1.8-2.5	11.4	0.8	0.6-1.0	11.2	0.4	0.3-0.5	8.8	0.7	0.5-1.0	2.4	0.2	0.1-0.3
Tonsil	29.0	1.0	0.9-1.2	22.8	1.8	1.5-2.2	6.2	0.4	0.3-0.6	2.8	0.1	0.1-0.2	2.8	0.3	0.1-0.4	0.0	0.0	0.0-0.1
Oropharynx	16.0	0.5	0.4-0.7	12.2	1.0	0.7-1.2	3.8	0.2	0.1-0.4	9.0	0.3	0.2-0.4	6.6	0.6	0.4-0.8	2.4	0.1	0.1-0.3
Hypopharynx	14.2	0.5	0.4-0.7	10.0	0.8	0.6-1.1	4.2	0.3	0.2-0.4	1.4	0.0	0.0-0.1	1.2	0.1	0.0-0.2	0.2	0.0	0.0-0.1
Other buccal cavity and pharynx	3.0	0.1	0.1-0.2	2.4	0.2	0.1-0.4	0.6	0.0	0.0-0.1	7.2	0.3	0.2-0.4	5.6	0.5	0.3-0.7	1.6	0.1	0.0-0.2
Digestive system	2,349.6	83.6	82.1-85.2	1,255.8	104.1	101.5-106.7	1,093.8	68.2	66.4-70.1	1,063.4	37.6	36.6-38.7	573.0	48.6	46.8-50.5	490.4	29.5	28.3-30.7
Esophagus	83.8	2.9	2.6-3.2	59.0	4.8	4.3-5.4	24.8	1.5	1.3-1.8	55.0	1.9	1.7-2.1	42.4	3.5	3.0-4.0	12.6	0.8	0.6-1.0
Stomach	301.8	10.7	10.2-11.3	175.0	14.6	13.6-15.6	126.8	7.9	7.3-8.6	141.4	5.1	4.7-5.5	83.6	7.3	6.6-8.0	57.8	3.5	3.1-4.0
Small intestine	68.6	2.5	2.2-2.8	33.0	2.8	2.3-3.2	35.6	2.3	1.9-2.6	8.4	0.3	0.2-0.4	4.2	0.4	0.2-0.5	4.2	0.3	0.2-0.4
Colorectal	1,047.2	37.7	36.6-38.7	538.4	45.0	43.3-46.8	508.8	32.1	30.9-33.4	350.0	12.4	11.8-13.0	172.0	14.8	13.9-15.9	178.0	10.7	10.0-11.4
Colon excluding rectum	740.8	26.6	25.7-27.4	363.4	30.5	29.1-32.0	377.4	23.7	22.6-24.8	286.4	10.1	9.6-10.6	138.6	12.0	11.1-12.9	147.8	8.8	8.2-9.5
Cecum	127.6	4.5	4.2-4.9	55.0	4.6	4.1-5.2	72.6	4.5	4.0-4.9									
Appendix	33.0	1.2	1.0-1.4	13.6	1.1	0.9-1.4	19.4	1.3	1.1-1.6									
Ascending colon	137.0	4.9	4.5-5.3	59.8	5.0	4.5-5.6	77.2	4.7	4.3-5.3									
Hepatic flexure	34.0	1.2	1.0-1.4	17.8	1.5	1.2-1.9	16.2	1.0	0.8-1.2									
Transverse colon	68.2	2.4	2.2-2.7	34.6	2.9	2.5-3.4	33.6	2.1	1.8-2.4									
Splenic flexure	21.6	0.8	0.6-0.9	11.8	1.0	0.8-1.3	9.8	0.6	0.4-0.8									
Descending colon	64.2	2.3	2.0-2.6	35.0	2.9	2.5-3.4	29.2	1.8	1.5-2.2									
Sigmoid colon	194.2	7.0	6.6-7.5	109.0	9.0	8.2-9.8	85.2	5.6	5.0-6.1									
Large intestine, NOS	61.0	2.2	2.0-2.5	26.8	2.4	2.0-2.8	34.2	2.1	1.8-2.4									
Rectum & rectosigmoid	306.4	11.1	10.5-11.7	175.0	14.5	13.6-15.6	131.4	8.5	7.8-9.2	63.6	2.3	2.1-2.6	33.4	2.9	2.5-3.4	30.2	1.9	1.6-2.2
Rectosigmoid junction	72.2	2.6	2.3-2.9	39.6	3.3	2.8-3.8	32.6	2.1	1.8-2.5									
Rectum	234.2	8.5	8.0-9.0	135.4	11.3	10.4-12.1	98.8	6.4	5.8-7.0									
Anus, anal canal & anorectum	53.4	1.9	1.7-2.2	22.0	1.8	1.5-2.1	31.4	2.0	1.7-2.3	6.8	0.2	0.2-0.4	3.8	0.3	0.2-0.5	3.0	0.2	0.1-0.3
Liver and intrahepatic bile duct	276.4	9.6	9.1-10.2	194.2	15.6	14.6-16.6	82.2	5.0	4.5-5.5	167.8	5.8	5.5-6.3	110.2	9.0	8.2-9.8	57.6	3.4	3.0-3.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Kings (Brooklyn)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	228.2	7.9	7.5-8.4	170.6	13.6	12.7-14.6	57.6	3.5	3.1-3.9	120.0	4.2	3.8-4.5	87.2	7.1	6.4-7.8	32.8	1.9	1.6-2.3
Intrahepatic bile duct	48.2	1.7	1.5-1.9	23.6	2.0	1.6-2.4	24.6	1.5	1.2-1.8	47.8	1.7	1.5-1.9	23.0	1.9	1.6-2.3	24.8	1.5	1.2-1.8
Gallbladder	47.2	1.7	1.4-1.9	14.0	1.2	0.9-1.5	33.2	2.0	1.7-2.4	21.2	0.7	0.6-0.9	5.0	0.4	0.3-0.6	16.2	1.0	0.8-1.2
Other biliary	49.6	1.8	1.6-2.0	25.4	2.2	1.8-2.6	24.2	1.5	1.2-1.8	14.2	0.5	0.4-0.6	7.8	0.7	0.5-0.9	6.4	0.4	0.3-0.5
Pancreas	384.6	13.6	13.0-14.2	180.2	14.9	14.0-16.0	204.4	12.5	11.7-13.3	282.2	10.0	9.5-10.5	134.8	11.5	10.6-12.4	147.4	8.9	8.2-9.5
Retroperitoneum	13.8	0.5	0.4-0.7	6.4	0.5	0.4-0.8	7.4	0.5	0.3-0.7	3.2	0.1	0.1-0.2	1.8	0.2	0.1-0.3	1.4	0.1	0.0-0.2
Peritoneum, omentum & mesentery	6.8	0.2	0.2-0.3	0.6	0.0	0.0-0.1	6.2	0.4	0.3-0.5	3.2	0.1	0.1-0.2	0.8	0.1	0.0-0.2	2.4	0.1	0.1-0.2
Other digestive organs	16.4	0.6	0.5-0.7	7.6	0.6	0.4-0.9	8.8	0.5	0.4-0.7	10.0	0.3	0.3-0.5	6.6	0.6	0.4-0.8	3.4	0.2	0.1-0.3
Respiratory system	1,298.6	45.8	44.7-47.0	693.6	58.3	56.3-60.3	605.0	37.1	35.8-38.5	656.4	23.1	22.3-23.9	371.4	31.8	30.3-33.3	285.0	17.1	16.2-18.1
Nasal cavity, middle ear & sinuses	19.0	0.7	0.6-0.9	11.4	1.0	0.7-1.3	7.6	0.5	0.3-0.7	1.2	0.0	0.0-0.1	0.8	0.1	0.0-0.2	0.4	0.0	0.0-0.1
Larynx	65.8	2.3	2.0-2.6	51.2	4.2	3.7-4.8	14.6	0.9	0.7-1.1	21.6	0.8	0.6-0.9	19.2	1.7	1.3-2.0	2.4	0.1	0.1-0.2
Lung and bronchus	1,209.0	42.7	41.6-43.8	627.6	52.9	51.0-54.8	581.4	35.6	34.3-36.9	630.4	22.2	21.4-23.0	349.4	29.9	28.5-31.4	281.0	16.9	16.0-17.8
Pleura	0.8	0.0	0.0-0.1	0.4	0.0	0.0-0.1	0.4	0.0	0.0-0.1	0.6	0.0	0.0-0.1	0.6	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	4.0	0.2	0.1-0.2	3.0	0.2	0.1-0.4	1.0	0.1	0.0-0.2	2.6	0.1	0.0-0.2	1.4	0.1	0.0-0.2	1.2	0.1	0.0-0.2
Bones & joints	30.6	1.2	1.0-1.4	18.2	1.5	1.2-1.9	12.4	0.9	0.7-1.2	10.2	0.4	0.3-0.5	6.0	0.5	0.3-0.7	4.2	0.3	0.2-0.5
Soft tissue (including heart)	99.8	3.7	3.4-4.1	50.0	4.2	3.7-4.8	49.8	3.4	3.0-3.8	30.8	1.1	1.0-1.3	14.8	1.3	1.0-1.6	16.0	1.0	0.8-1.3
Skin*	263.6	9.6	9.1-10.1	137.8	11.8	10.9-12.7	125.8	8.2	7.5-8.8	34.8	1.2	1.0-1.4	20.4	1.8	1.4-2.1	14.4	0.8	0.6-1.1
Melanoma of the skin	230.2	8.4	7.9-8.9	122.2	10.4	9.6-11.3	108.0	7.0	6.4-7.6	21.6	0.8	0.6-1.0	12.2	1.1	0.8-1.4	9.4	0.6	0.4-0.8
Breast	1,877.8	69.4	68.0-70.8	19.0	1.6	1.3-2.0	1,858.8	123.9	121.4-126.5	322.8	11.5	11.0-12.1	2.0	0.2	0.1-0.3	320.8	20.0	19.0-21.0
Breast (in situ)#	607.4	22.9	22.1-23.8	3.0	0.3	0.1-0.4	604.4	41.6	40.1-43.2									
Female genital system							883.6	56.8	55.1-58.6							283.8	17.5	16.6-18.4
Cervix uteri							134.4	9.3	8.6-10.0							34.6	2.3	2.0-2.7
Corpus uteris and NOS							505.2	31.7	30.5-33.0							129.2	7.8	7.2-8.4
Ovary							166.6	11.0	10.2-11.8							106.2	6.6	6.0-7.2
Vagina							11.2	0.7	0.5-0.9							2.4	0.1	0.1-0.2
Vulva							34.6	2.1	1.8-2.5							7.2	0.4	0.3-0.6
Other female genital organs							31.6	2.0	1.7-2.4							4.2	0.3	0.2-0.4
Male genital system				1,715.0	135.5	132.6-138.4							197.0	17.9	16.8-19.1			
Prostate				1,630.8	128.9	126.0-131.8							194.4	17.7	16.6-18.8			
Testis				70.0	5.4	4.8-6.0							0.8	0.1	0.0-0.2			
Penis				11.4	0.9	0.7-1.2							1.8	0.2	0.1-0.3			
Other male genital organs				2.8	0.3	0.1-0.4							0.0	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Kings (Brooklyn)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	854.0	30.5	29.5-31.4	589.2	49.6	47.8-51.4	264.8	16.7	15.8-17.6	141.4	5.0	4.6-5.4	96.2	8.5	7.8-9.3	45.2	2.6	2.3-3.0
Urinary bladder (including in situ)	427.8	15.2	14.6-15.9	320.2	27.6	26.2-29.0	107.6	6.7	6.1-7.3	80.8	2.8	2.6-3.1	54.6	5.0	4.4-5.6	26.2	1.5	1.3-1.8
Kidney and renal pelvis	404.0	14.5	13.8-15.1	256.8	20.9	19.8-22.1	147.2	9.4	8.7-10.2	57.6	2.0	1.8-2.3	40.0	3.4	2.9-3.9	17.6	1.1	0.8-1.3
Ureter	11.4	0.4	0.3-0.5	6.4	0.6	0.4-0.8	5.0	0.3	0.2-0.5	1.6	0.1	0.0-0.1	0.6	0.1	0.0-0.2	1.0	0.1	0.0-0.1
Other urinary organs	10.8	0.4	0.3-0.5	5.8	0.5	0.4-0.8	5.0	0.3	0.2-0.4	1.4	0.0	0.0-0.1	1.0	0.1	0.0-0.2	0.4	0.0	0.0-0.1
Eye & orbit	22.6	0.8	0.7-1.0	9.8	0.8	0.6-1.1	12.8	0.9	0.6-1.1	1.6	0.1	0.0-0.1	1.0	0.1	0.0-0.2	0.6	0.0	0.0-0.1
Brain / other central nervous system (all behaviors)	592.4	21.8	21.0-22.6	214.2	17.7	16.7-18.9	378.2	24.9	23.8-26.1	100.4	3.7	3.3-4.0	53.0	4.4	3.9-5.0	47.4	3.0	2.6-3.5
Malignant brain / other central nervous system	164.4	6.1	5.7-6.5	88.6	7.2	6.6-8.0	75.8	5.2	4.6-5.7	81.6	3.0	2.7-3.3	44.8	3.7	3.3-4.3	36.8	2.4	2.1-2.8
Malignant brain	149.8	5.6	5.2-6.0	81.4	6.6	6.0-7.3	68.4	4.7	4.2-5.2									
Malignant other central nervous system	14.6	0.5	0.4-0.7	7.2	0.6	0.4-0.8	7.4	0.5	0.3-0.7									
Benign brain / other central nervous system#	428.0	15.7	15.0-16.4	125.6	10.5	9.7-11.4	302.4	19.7	18.7-20.8	18.8	0.7	0.5-0.8	8.2	0.7	0.5-1.0	10.6	0.6	0.5-0.8
Benign brain	31.2	1.2	1.1-1.5	14.8	1.2	1.0-1.5	16.4	1.2	1.0-1.6									
Benign other central nervous system	396.8	14.5	13.8-15.1	110.8	9.3	8.5-10.1	286.0	18.5	17.5-19.5									
Endocrine system	577.6	21.6	20.8-22.4	149.6	12.1	11.2-13.0	428.0	29.9	28.6-31.2	26.0	0.9	0.8-1.1	9.0	0.8	0.6-1.1	17.0	1.0	0.8-1.3
Thyroid	543.0	20.3	19.5-21.1	131.6	10.7	9.8-11.5	411.4	28.7	27.5-30.0	14.8	0.5	0.4-0.7	4.2	0.4	0.2-0.6	10.6	0.6	0.5-0.8
Other endocrine (including thymus)	34.6	1.3	1.1-1.5	18.0	1.4	1.1-1.8	16.6	1.2	0.9-1.5	11.2	0.4	0.3-0.5	4.8	0.4	0.3-0.6	6.4	0.4	0.3-0.6
Lymphomas	593.4	21.7	20.9-22.5	316.4	26.5	25.2-27.8	277.0	18.0	17.1-19.0	117.4	4.2	3.9-4.6	60.4	5.2	4.7-5.9	57.0	3.5	3.1-3.9
Hodgkin lymphoma	82.0	3.1	2.8-3.4	44.4	3.6	3.2-4.2	37.6	2.6	2.3-3.0	6.4	0.2	0.2-0.3	3.4	0.3	0.2-0.5	3.0	0.2	0.1-0.3
Non-Hodgkin lymphomas	511.4	18.6	17.9-19.4	272.0	22.8	21.6-24.1	239.4	15.4	14.5-16.3	111.0	4.0	3.7-4.3	57.0	4.9	4.4-5.6	54.0	3.3	2.9-3.7
Myeloma	248.6	8.9	8.4-9.4	123.0	10.4	9.6-11.2	125.6	7.9	7.3-8.5	78.6	2.7	2.5-3.0	39.8	3.4	3.0-3.9	38.8	2.3	2.0-2.6
Leukemias	351.2	12.9	12.3-13.5	191.8	16.3	15.3-17.4	159.4	10.3	9.6-11.1	125.6	4.6	4.2-5.0	65.6	5.7	5.1-6.4	60.0	3.8	3.4-4.3
Lymphocytic leukemias	161.8	5.9	5.5-6.4	90.8	7.7	7.0-8.5	71.0	4.6	4.2-5.2	31.6	1.1	1.0-1.3	16.4	1.4	1.1-1.8	15.2	0.9	0.7-1.1
Acute lymphocytic leukemia	38.6	1.6	1.4-1.8	20.8	1.8	1.5-2.2	17.8	1.4	1.1-1.7	10.0	0.4	0.3-0.5	5.2	0.5	0.3-0.7	4.8	0.3	0.2-0.5
Chronic lymphocytic leukemia	115.0	4.1	3.7-4.4	64.4	5.5	4.9-6.1	50.6	3.1	2.7-3.5	19.4	0.7	0.5-0.8	9.6	0.8	0.6-1.1	9.8	0.6	0.4-0.7
Other lymphocytic leukemias	8.2	0.3	0.2-0.4	5.6	0.4	0.3-0.6	2.6	0.2	0.1-0.3	2.2	0.1	0.0-0.1	1.6	0.1	0.1-0.3	0.6	0.0	0.0-0.1
Myeloid and monocytic leukemias	164.6	6.0	5.6-6.5	89.2	7.6	6.9-8.3	75.4	4.9	4.4-5.4	67.4	2.5	2.2-2.8	35.6	3.1	2.6-3.6	31.8	2.0	1.7-2.4
Acute myeloid leukemia	107.4	3.9	3.6-4.3	56.2	4.8	4.3-5.4	51.2	3.3	2.9-3.7	58.0	2.1	1.9-2.4	30.4	2.7	2.2-3.1	27.6	1.8	1.5-2.1
Acute monocytic leukemia	5.6	0.2	0.1-0.3	3.4	0.3	0.2-0.5	2.2	0.2	0.1-0.3	0.2	0.0	0.0-0.0	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Chronic myeloid leukemia	47.8	1.8	1.5-2.0	26.4	2.2	1.8-2.6	21.4	1.4	1.1-1.7	6.0	0.2	0.1-0.3	3.8	0.3	0.2-0.5	2.2	0.1	0.1-0.2
Other myeloid/monocytic leukemias	3.8	0.1	0.1-0.2	3.2	0.3	0.1-0.4	0.6	0.0	0.0-0.1	3.2	0.1	0.1-0.2	1.4	0.1	0.0-0.2	1.8	0.1	0.1-0.2
Other leukemias	24.8	0.9	0.7-1.1	11.8	1.0	0.8-1.3	13.0	0.8	0.6-1.1	26.6	1.0	0.8-1.2	13.6	1.2	0.9-1.5	13.0	0.9	0.7-1.1
Other acute leukemias	4.4	0.2	0.1-0.2	2.2	0.2	0.1-0.3	2.2	0.1	0.1-0.2	5.0	0.2	0.1-0.3	2.2	0.2	0.1-0.4	2.8	0.2	0.1-0.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Kings (Brooklyn)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	20.4	0.7	0.6-0.9	9.6	0.8	0.6-1.1	10.8	0.7	0.5-0.9	21.6	0.8	0.6-1.0	11.4	1.0	0.7-1.3	10.2	0.7	0.5-0.9
Mesothelioma	14.4	0.5	0.4-0.6	7.8	0.7	0.5-0.9	6.6	0.4	0.3-0.6									
Kaposi sarcoma	24.4	0.9	0.7-1.1	21.6	1.8	1.5-2.2	2.8	0.2	0.1-0.3									
Myelodysplastic syndromes	73.8	2.7	2.4-2.9	41.4	3.8	3.3-4.3	32.4	1.9	1.6-2.3									
Chronic myeloproliferative disorders [^]	97.2	3.5	3.2-3.8	45.0	3.7	3.2-4.2	52.2	3.3	2.9-3.7									
Ill defined and unspecified sites	223.8	7.9	7.4-8.4	101.2	8.7	8.0-9.5	122.6	7.3	6.7-7.9	240.2	8.5	8.0-9.0	117.6	10.2	9.4-11.1	122.6	7.3	6.7-7.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York (Manhattan)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	8,601.8	436.2	432.0-440.5	4,116.6	470.0	463.5-476.5	4,485.2	419.0	413.3-424.7	2,303.2	111.2	109.1-113.2	1,103.8	127.8	124.4-131.2	1,199.4	100.4	97.8-103.1
Oral cavity and pharynx	217.0	10.9	10.2-11.5	144.8	16.3	15.1-17.5	72.2	6.5	5.8-7.3	40.8	2.0	1.7-2.2	27.8	3.2	2.7-3.8	13.0	1.0	0.8-1.3
Lip	5.8	0.3	0.2-0.4	3.4	0.4	0.2-0.6	2.4	0.2	0.1-0.4	0.6	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.2	0.0	0.0-0.1
Tongue	69.4	3.4	3.1-3.8	45.4	5.0	4.4-5.8	24.0	2.1	1.7-2.5	10.0	0.5	0.4-0.6	6.2	0.7	0.5-1.0	3.8	0.3	0.2-0.5
Salivary gland	28.4	1.4	1.2-1.7	16.4	1.9	1.5-2.3	12.0	1.1	0.8-1.4	5.2	0.2	0.2-0.4	3.4	0.4	0.2-0.7	1.8	0.1	0.1-0.3
Floor of mouth	7.4	0.4	0.3-0.5	4.6	0.5	0.3-0.8	2.8	0.2	0.1-0.4	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Gum & other mouth	29.6	1.5	1.2-1.7	14.2	1.6	1.2-2.0	15.4	1.3	1.1-1.7	4.0	0.2	0.1-0.3	2.6	0.3	0.2-0.5	1.4	0.1	0.0-0.2
Nasopharynx	14.2	0.8	0.6-1.0	10.2	1.2	0.9-1.6	4.0	0.4	0.2-0.7	3.4	0.2	0.1-0.3	3.0	0.3	0.2-0.5	0.4	0.0	0.0-0.1
Tonsil	37.4	1.9	1.6-2.2	31.6	3.5	3.0-4.1	5.8	0.5	0.3-0.8	2.8	0.1	0.1-0.2	2.2	0.3	0.1-0.5	0.6	0.1	0.0-0.2
Oropharynx	12.0	0.6	0.5-0.8	9.0	1.0	0.8-1.4	3.0	0.3	0.2-0.5	7.4	0.4	0.3-0.5	4.6	0.5	0.3-0.8	2.8	0.2	0.1-0.4
Hypopharynx	10.8	0.5	0.4-0.7	8.4	1.0	0.7-1.3	2.4	0.2	0.1-0.4	2.4	0.1	0.1-0.2	1.4	0.2	0.1-0.3	1.0	0.1	0.0-0.2
Other buccal cavity and pharynx	2.0	0.1	0.0-0.2	1.6	0.2	0.1-0.3	0.4	0.0	0.0-0.2	4.8	0.2	0.1-0.3	3.8	0.4	0.3-0.7	1.0	0.1	0.0-0.2
Digestive system	1,478.2	73.7	72.0-75.5	790.0	90.6	87.8-93.5	688.2	60.4	58.3-62.5	680.2	32.8	31.7-33.9	369.0	42.4	40.5-44.4	311.2	25.6	24.3-26.9
Esophagus	63.8	3.1	2.8-3.5	41.8	4.8	4.1-5.5	22.0	1.8	1.5-2.2	44.0	2.1	1.8-2.4	29.6	3.4	2.8-4.0	14.4	1.2	0.9-1.5
Stomach	142.8	7.2	6.6-7.7	79.8	9.2	8.3-10.1	63.0	5.6	5.0-6.3	67.8	3.3	3.0-3.7	41.8	4.8	4.1-5.5	26.0	2.2	1.8-2.6
Small intestine	44.2	2.2	1.9-2.6	21.4	2.4	2.0-2.9	22.8	2.1	1.7-2.5	6.4	0.3	0.2-0.4	3.8	0.4	0.3-0.7	2.6	0.2	0.1-0.4
Colorectal	614.6	31.1	30.0-32.3	316.8	36.7	34.9-38.6	297.8	26.8	25.4-28.2	195.0	9.5	8.9-10.1	102.6	12.0	11.0-13.1	92.4	7.6	6.9-8.4
Colon excluding rectum	421.4	21.1	20.2-22.1	207.2	24.1	22.6-25.6	214.2	18.9	17.7-20.1	146.2	7.1	6.5-7.6	75.2	8.8	7.9-9.7	71.0	5.8	5.2-6.5
Cecum	75.4	3.7	3.3-4.1	35.6	4.1	3.5-4.8	39.8	3.4	2.9-3.9									
Appendix	30.4	1.6	1.4-1.9	13.6	1.7	1.3-2.1	16.8	1.6	1.2-2.0									
Ascending colon	78.8	3.8	3.5-4.3	33.6	3.9	3.3-4.5	45.2	3.8	3.3-4.3									
Hepatic flexure	24.8	1.2	1.0-1.4	12.6	1.4	1.1-1.8	12.2	1.1	0.8-1.4									
Transverse colon	39.8	2.0	1.7-2.3	18.4	2.2	1.8-2.7	21.4	1.8	1.5-2.2									
Splenic flexure	11.2	0.6	0.4-0.8	6.8	0.8	0.6-1.1	4.4	0.4	0.3-0.6									
Descending colon	27.2	1.4	1.2-1.7	14.8	1.7	1.4-2.2	12.4	1.1	0.9-1.5									
Sigmoid colon	105.6	5.4	5.0-5.9	59.2	6.8	6.0-7.6	46.4	4.4	3.8-5.0									
Large intestine, NOS	28.2	1.4	1.1-1.6	12.6	1.5	1.1-1.9	15.6	1.3	1.0-1.6									
Rectum & rectosigmoid	193.2	10.0	9.4-10.7	109.6	12.7	11.6-13.8	83.6	7.9	7.1-8.7	48.8	2.4	2.1-2.8	27.4	3.2	2.7-3.8	21.4	1.8	1.5-2.2
Rectosigmoid junction	47.0	2.5	2.1-2.8	26.2	3.1	2.6-3.6	20.8	2.0	1.6-2.4									
Rectum	146.2	7.5	7.0-8.1	83.4	9.6	8.7-10.6	62.8	5.9	5.2-6.6									
Anus, anal canal & anorectum	66.4	3.5	3.1-3.9	33.8	4.0	3.4-4.6	32.6	2.9	2.5-3.4	11.2	0.6	0.4-0.7	5.8	0.7	0.5-1.0	5.4	0.4	0.3-0.7
Liver and intrahepatic bile duct	197.0	9.6	9.0-10.3	131.0	14.6	13.5-15.8	66.0	5.6	5.0-6.3	115.0	5.5	5.0-6.0	73.4	8.3	7.4-9.2	41.6	3.4	2.9-3.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York (Manhattan)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	151.8	7.4	6.9-7.9	109.0	12.0	11.0-13.1	42.8	3.6	3.1-4.1	81.6	3.9	3.5-4.3	56.8	6.3	5.6-7.1	24.8	2.0	1.6-2.3
Intrahepatic bile duct	45.2	2.3	2.0-2.6	22.0	2.6	2.1-3.1	23.2	2.0	1.6-2.4	33.4	1.6	1.4-1.9	16.6	1.9	1.5-2.4	16.8	1.5	1.2-1.8
Gallbladder	27.0	1.3	1.1-1.5	10.0	1.1	0.8-1.5	17.0	1.4	1.1-1.7	17.4	0.8	0.7-1.0	5.6	0.6	0.4-0.9	11.8	1.0	0.7-1.2
Other biliary	30.2	1.5	1.2-1.7	16.2	1.9	1.5-2.3	14.0	1.2	0.9-1.5	10.2	0.5	0.4-0.7	4.8	0.5	0.4-0.8	5.4	0.5	0.3-0.7
Pancreas	263.2	12.8	12.1-13.5	129.0	14.8	13.7-16.0	134.2	11.3	10.4-12.2	203.2	9.7	9.1-10.3	97.6	11.2	10.3-12.3	105.6	8.6	7.9-9.4
Retroperitoneum	10.8	0.6	0.4-0.7	4.0	0.5	0.3-0.7	6.8	0.7	0.4-0.9	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.2	0.0	0.0-0.1
Peritoneum, omentum & mesentery	6.8	0.3	0.2-0.5	0.6	0.1	0.0-0.2	6.2	0.6	0.4-0.8	4.4	0.2	0.1-0.4	0.6	0.1	0.0-0.2	3.8	0.4	0.2-0.6
Other digestive organs	11.4	0.6	0.4-0.7	5.6	0.7	0.4-1.0	5.8	0.5	0.3-0.7	5.2	0.3	0.2-0.4	3.2	0.4	0.2-0.6	2.0	0.2	0.1-0.3
Respiratory system	946.6	46.1	44.7-47.4	442.4	50.7	48.6-52.9	504.2	42.7	41.0-44.4	440.8	21.0	20.1-21.9	211.2	24.2	22.8-25.8	229.6	18.7	17.6-19.8
Nasal cavity, middle ear & sinuses	15.4	0.8	0.6-1.0	9.8	1.1	0.8-1.5	5.6	0.5	0.3-0.8	2.2	0.1	0.1-0.2	1.4	0.2	0.1-0.4	0.8	0.1	0.0-0.2
Larynx	44.0	2.2	1.9-2.5	34.6	3.9	3.3-4.5	9.4	0.9	0.6-1.2	13.6	0.6	0.5-0.8	10.4	1.1	0.8-1.5	3.2	0.2	0.1-0.4
Lung and bronchus	882.4	42.8	41.6-44.1	395.0	45.3	43.3-47.4	487.4	41.1	39.5-42.8	422.8	20.2	19.3-21.1	198.0	22.8	21.3-24.2	224.8	18.3	17.2-19.4
Pleura	0.8	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.4	0.0	0.0-0.1	1.6	0.1	0.0-0.2	1.4	0.2	0.1-0.4	0.2	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	4.0	0.2	0.1-0.3	2.6	0.3	0.2-0.5	1.4	0.2	0.1-0.3	0.6	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.6	0.1	0.0-0.2
Bones & joints	17.6	1.1	0.9-1.4	11.0	1.4	1.1-1.9	6.6	0.8	0.5-1.2	5.6	0.3	0.2-0.4	3.6	0.4	0.2-0.7	2.0	0.2	0.1-0.4
Soft tissue (including heart)	72.6	3.9	3.5-4.3	39.6	4.8	4.1-5.5	33.0	3.2	2.7-3.8	27.2	1.4	1.2-1.7	13.4	1.6	1.2-2.0	13.8	1.3	1.0-1.7
Skin*	367.4	18.6	17.7-19.5	209.8	24.3	22.8-25.8	157.6	14.5	13.5-15.6	34.0	1.6	1.4-1.9	21.4	2.5	2.0-3.0	12.6	1.0	0.8-1.3
Melanoma of the skin	340.2	17.2	16.3-18.0	195.2	22.5	21.1-24.0	145.0	13.3	12.4-14.4	22.8	1.1	0.9-1.3	14.0	1.6	1.3-2.1	8.8	0.7	0.5-1.0
Breast	1,414.8	75.2	73.4-77.0	15.2	1.7	1.3-2.2	1,399.6	138.1	134.8-141.5	187.2	9.3	8.7-9.9	1.4	0.1	0.1-0.3	185.8	16.3	15.2-17.4
Breast (in situ)#	528.6	29.8	28.6-31.0	3.4	0.4	0.2-0.6	525.2	56.1	53.9-58.3									
Female genital system							543.6	51.3	49.3-53.3							162.4	14.0	13.0-15.0
Cervix uteri							62.0	6.5	5.8-7.3							17.4	1.6	1.3-2.0
Corpus uterus and NOS							315.6	29.3	27.8-30.8							59.2	5.0	4.5-5.7
Ovary							105.6	10.0	9.2-11.0							72.8	6.3	5.6-7.0
Vagina							6.0	0.6	0.4-0.8							2.2	0.2	0.1-0.4
Vulva							24.6	2.3	1.9-2.7							6.0	0.5	0.3-0.7
Other female genital organs							29.8	2.7	2.2-3.1							4.8	0.4	0.3-0.6
Male genital system				1,216.8	134.1	130.7-137.6							139.8	16.2	15.1-17.5			
Prostate				1,145.6	126.3	123.0-129.6							137.4	16.0	14.8-17.2			
Testis				65.4	7.2	6.4-8.0							1.0	0.1	0.0-0.2			
Penis				4.0	0.5	0.3-0.7							1.4	0.2	0.1-0.3			
Other male genital organs				1.8	0.2	0.1-0.4							0.0	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York (Manhattan)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	599.4	29.8	28.7-30.9	408.4	47.3	45.2-49.4	191.0	17.0	15.9-18.1	103.2	4.8	4.4-5.2	65.4	7.6	6.8-8.5	37.8	2.9	2.5-3.4
Urinary bladder (including in situ)	345.0	16.7	15.9-17.5	245.0	28.4	26.8-30.1	100.0	8.4	7.7-9.2	64.6	2.9	2.6-3.3	41.8	4.9	4.2-5.6	22.8	1.7	1.4-2.1
Kidney and renal pelvis	238.0	12.3	11.6-13.0	153.8	17.7	16.5-19.1	84.2	8.0	7.2-8.8	36.2	1.7	1.5-2.0	22.0	2.5	2.1-3.1	14.2	1.1	0.9-1.5
Ureter	8.2	0.4	0.3-0.5	4.8	0.5	0.4-0.8	3.4	0.3	0.2-0.5	1.0	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.6	0.0	0.0-0.2
Other urinary organs	8.2	0.4	0.3-0.5	4.8	0.6	0.4-0.8	3.4	0.3	0.2-0.5	1.4	0.1	0.0-0.1	1.2	0.1	0.1-0.3	0.2	0.0	0.0-0.1
Eye & orbit	18.4	1.0	0.8-1.3	9.2	1.1	0.8-1.5	9.2	1.0	0.7-1.3	1.4	0.1	0.0-0.2	0.4	0.1	0.0-0.2	1.0	0.1	0.0-0.3
Brain / other central nervous system (all behaviors)	391.8	20.9	20.0-21.9	159.0	19.0	17.6-20.4	232.8	22.6	21.3-24.1	75.0	3.9	3.5-4.4	42.2	5.0	4.3-5.7	32.8	3.0	2.6-3.6
Malignant brain / other central nervous system	117.2	6.5	6.0-7.1	68.6	8.3	7.4-9.2	48.6	5.0	4.4-5.8	64.8	3.4	3.0-3.8	37.8	4.5	3.8-5.2	27.0	2.6	2.1-3.1
Malignant brain	108.8	6.0	5.5-6.6	64.0	7.7	6.8-8.6	44.8	4.6	4.0-5.3									
Malignant other central nervous system	8.4	0.5	0.3-0.7	4.6	0.6	0.4-0.9	3.8	0.4	0.2-0.7									
Benign brain / other central nervous system#	274.6	14.4	13.7-15.2	90.4	10.7	9.7-11.8	184.2	17.6	16.4-18.8	10.2	0.5	0.4-0.7	4.4	0.5	0.3-0.8	5.8	0.5	0.3-0.7
Benign brain	19.0	1.2	0.9-1.5	9.4	1.2	0.9-1.6	9.6	1.1	0.8-1.6									
Benign other central nervous system	255.6	13.3	12.5-14.0	81.0	9.5	8.6-10.5	174.6	16.5	15.3-17.6									
Endocrine system	345.8	19.1	18.2-20.0	97.4	11.4	10.4-12.5	248.4	26.2	24.7-27.8	11.8	0.7	0.5-0.9	4.6	0.6	0.4-1.0	7.2	0.7	0.5-1.0
Thyroid	326.4	17.9	17.0-18.8	89.4	10.4	9.4-11.4	237.0	24.9	23.5-26.5	7.8	0.4	0.3-0.5	2.8	0.3	0.2-0.6	5.0	0.4	0.3-0.6
Other endocrine (including thymus)	19.4	1.2	0.9-1.4	8.0	1.0	0.7-1.4	11.4	1.3	0.9-1.7	4.0	0.3	0.2-0.5	1.8	0.3	0.1-0.6	2.2	0.3	0.1-0.6
Lymphomas	475.8	24.5	23.5-25.5	243.8	28.5	26.9-30.2	232.0	21.4	20.1-22.7	91.2	4.4	4.0-4.8	51.6	6.0	5.3-6.8	39.6	3.2	2.7-3.7
Hodgkin lymphoma	51.0	2.8	2.5-3.2	25.6	3.0	2.5-3.6	25.4	2.6	2.2-3.2	4.2	0.2	0.1-0.3	2.4	0.3	0.1-0.5	1.8	0.1	0.1-0.3
Non-Hodgkin lymphomas	424.8	21.7	20.7-22.6	218.2	25.5	24.0-27.1	206.6	18.8	17.6-20.0	87.0	4.2	3.8-4.6	49.2	5.8	5.1-6.5	37.8	3.0	2.6-3.5
Myeloma	155.2	7.7	7.1-8.2	86.2	9.9	9.0-10.9	69.0	6.0	5.4-6.7	47.4	2.3	2.0-2.6	25.4	2.9	2.4-3.5	22.0	1.8	1.5-2.2
Leukemias	274.4	14.3	13.6-15.1	155.2	18.6	17.3-20.0	119.2	11.0	10.1-12.0	96.6	4.8	4.3-5.2	49.4	6.0	5.3-6.8	47.2	4.0	3.5-4.5
Lymphocytic leukemias	147.6	7.8	7.2-8.4	90.8	11.0	10.0-12.1	56.8	5.3	4.7-6.0	24.6	1.2	1.0-1.5	15.8	1.9	1.5-2.4	8.8	0.7	0.5-1.0
Acute lymphocytic leukemia	22.4	1.6	1.3-2.0	12.4	1.9	1.4-2.5	10.0	1.4	1.0-1.9	5.8	0.3	0.2-0.5	3.4	0.4	0.3-0.7	2.4	0.2	0.1-0.4
Chronic lymphocytic leukemia	115.4	5.6	5.2-6.1	70.4	8.1	7.3-9.0	45.0	3.7	3.3-4.3	16.0	0.7	0.6-0.9	11.2	1.3	1.0-1.7	4.8	0.4	0.2-0.6
Other lymphocytic leukemias	9.8	0.5	0.4-0.7	8.0	1.0	0.7-1.3	1.8	0.2	0.1-0.3	2.8	0.1	0.1-0.2	1.2	0.1	0.0-0.3	1.6	0.1	0.1-0.3
Myeloid and monocytic leukemias	111.0	5.7	5.2-6.2	56.2	6.7	5.9-7.6	54.8	5.0	4.4-5.7	55.2	2.8	2.4-3.1	24.2	3.0	2.5-3.6	31.0	2.6	2.2-3.1
Acute myeloid leukemia	75.8	3.9	3.5-4.4	36.8	4.5	3.8-5.2	39.0	3.6	3.0-4.1	47.6	2.4	2.1-2.7	21.0	2.6	2.1-3.2	26.6	2.3	1.9-2.7
Acute monocytic leukemia	1.2	0.1	0.0-0.1	0.6	0.1	0.0-0.2	0.6	0.1	0.0-0.2	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Chronic myeloid leukemia	32.8	1.7	1.4-2.0	18.4	2.2	1.7-2.7	14.4	1.3	1.0-1.7	4.0	0.2	0.1-0.3	1.8	0.2	0.1-0.4	2.2	0.2	0.1-0.4
Other myeloid/monocytic leukemias	1.2	0.1	0.0-0.1	0.4	0.0	0.0-0.2	0.8	0.1	0.0-0.2	3.4	0.2	0.1-0.3	1.4	0.2	0.1-0.4	2.0	0.2	0.1-0.3
Other leukemias	15.8	0.8	0.6-1.0	8.2	0.9	0.7-1.3	7.6	0.7	0.5-1.0	16.8	0.8	0.6-1.0	9.4	1.1	0.8-1.5	7.4	0.6	0.4-0.8
Other acute leukemias	2.8	0.2	0.1-0.3	1.4	0.2	0.1-0.4	1.4	0.2	0.1-0.3	4.0	0.2	0.1-0.3	1.6	0.2	0.1-0.4	2.4	0.2	0.1-0.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
New York (Manhattan)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	13.0	0.6	0.5-0.8	6.8	0.8	0.5-1.1	6.2	0.6	0.4-0.8	12.8	0.6	0.5-0.8	7.8	0.9	0.7-1.3	5.0	0.4	0.3-0.6
Mesothelioma	9.8	0.5	0.4-0.6	5.6	0.7	0.4-1.0	4.2	0.4	0.2-0.6									
Kaposi sarcoma	32.2	1.7	1.5-2.1	31.2	3.6	3.1-4.3	1.0	0.1	0.0-0.2									
Myelodysplastic syndromes	73.6	3.5	3.2-3.9	36.8	4.4	3.8-5.1	36.8	3.0	2.6-3.5									
Chronic myeloproliferative disorders [^]	90.2	4.6	4.1-5.0	42.0	4.9	4.2-5.6	48.2	4.3	3.7-4.9									
Ill defined and unspecified sites	135.2	6.7	6.2-7.2	62.6	7.4	6.6-8.3	72.6	6.1	5.5-6.8	168.8	8.0	7.5-8.6	81.6	9.4	8.5-10.4	87.2	7.0	6.4-7.8

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Queens

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	11,454.4	415.5	412.0-419.0	5,505.4	440.9	435.6-446.3	5,949.0	403.7	399.0-408.5	3,194.4	113.1	111.3-114.9	1,593.0	133.0	130.1-136.1	1,601.4	99.9	97.6-102.1
Oral cavity and pharynx	249.0	9.0	8.5-9.5	155.0	12.2	11.3-13.1	94.0	6.3	5.8-7.0	52.4	1.9	1.6-2.1	34.8	2.8	2.4-3.2	17.6	1.1	0.9-1.4
Lip	4.0	0.1	0.1-0.2	2.8	0.2	0.1-0.4	1.2	0.1	0.0-0.2	0.4	0.0	0.0-0.0	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Tongue	70.2	2.5	2.2-2.8	42.8	3.3	2.9-3.8	27.4	1.8	1.5-2.1	13.2	0.5	0.4-0.6	8.2	0.7	0.5-0.9	5.0	0.3	0.2-0.5
Salivary gland	35.4	1.3	1.1-1.6	18.0	1.5	1.2-1.8	17.4	1.3	1.0-1.6	5.2	0.2	0.1-0.3	3.2	0.3	0.2-0.5	2.0	0.1	0.1-0.3
Floor of mouth	8.0	0.3	0.2-0.4	4.6	0.3	0.2-0.5	3.4	0.2	0.1-0.4	0.0	0.0	0.0-0.0	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Gum & other mouth	43.8	1.6	1.4-1.8	22.2	1.8	1.5-2.2	21.6	1.4	1.1-1.7	7.2	0.3	0.2-0.4	4.2	0.3	0.2-0.5	3.0	0.2	0.1-0.3
Nasopharynx	33.2	1.3	1.1-1.5	22.6	1.8	1.5-2.2	10.6	0.8	0.6-1.1	10.4	0.4	0.3-0.5	7.0	0.5	0.4-0.8	3.4	0.2	0.1-0.4
Tonsil	28.2	1.0	0.8-1.2	22.4	1.7	1.4-2.0	5.8	0.4	0.3-0.6	2.4	0.1	0.0-0.2	2.0	0.2	0.1-0.3	0.4	0.0	0.0-0.1
Oropharynx	10.2	0.4	0.3-0.5	7.0	0.5	0.4-0.8	3.2	0.2	0.1-0.3	5.4	0.2	0.1-0.3	4.2	0.3	0.2-0.5	1.2	0.1	0.0-0.2
Hypopharynx	13.0	0.4	0.3-0.6	10.6	0.8	0.6-1.1	2.4	0.1	0.1-0.3	2.4	0.1	0.0-0.1	1.8	0.1	0.1-0.3	0.6	0.0	0.0-0.1
Other buccal cavity and pharynx	3.0	0.1	0.1-0.2	2.0	0.1	0.1-0.3	1.0	0.1	0.0-0.1	5.8	0.2	0.1-0.3	4.0	0.3	0.2-0.5	1.8	0.1	0.0-0.2
Digestive system	2,338.0	83.9	82.4-85.5	1,261.0	101.3	98.8-103.9	1,077.0	69.9	68.0-71.9	1,017.2	35.8	34.8-36.8	548.8	44.7	43.0-46.5	468.4	28.8	27.6-30.0
Esophagus	92.0	3.2	2.9-3.5	67.6	5.3	4.7-5.9	24.4	1.5	1.2-1.8	64.2	2.2	2.0-2.5	48.6	3.9	3.4-4.5	15.6	0.9	0.7-1.2
Stomach	324.4	11.8	11.2-12.4	185.4	15.2	14.2-16.2	139.0	9.3	8.6-10.0	127.8	4.6	4.2-5.0	77.2	6.4	5.8-7.1	50.6	3.2	2.8-3.7
Small intestine	68.6	2.5	2.2-2.8	36.8	3.0	2.6-3.5	31.8	2.1	1.8-2.5	9.2	0.3	0.2-0.4	4.4	0.4	0.2-0.6	4.8	0.3	0.2-0.5
Colorectal	1,000.2	36.3	35.3-37.4	519.4	42.0	40.3-43.6	480.8	31.8	30.5-33.1	314.2	11.1	10.6-11.7	153.0	12.7	11.8-13.6	161.2	9.9	9.2-10.6
Colon excluding rectum	705.2	25.5	24.7-26.4	352.4	28.6	27.3-30.0	352.8	23.0	21.9-24.2	260.2	9.2	8.7-9.7	122.8	10.3	9.5-11.1	137.4	8.4	7.8-9.1
Cecum	123.2	4.4	4.0-4.7	53.8	4.4	3.9-5.0	69.4	4.3	3.9-4.8									
Appendix	37.8	1.5	1.3-1.8	17.4	1.5	1.2-1.8	20.4	1.6	1.3-1.9									
Ascending colon	133.0	4.7	4.4-5.1	63.2	5.2	4.6-5.8	69.8	4.3	3.9-4.8									
Hepatic flexure	31.2	1.1	0.9-1.3	18.0	1.5	1.2-1.9	13.2	0.8	0.6-1.1									
Transverse colon	60.0	2.2	1.9-2.4	27.4	2.3	1.9-2.7	32.6	2.1	1.8-2.5									
Splenic flexure	20.6	0.8	0.6-0.9	12.4	1.0	0.8-1.3	8.2	0.5	0.4-0.7									
Descending colon	52.4	1.9	1.7-2.2	29.2	2.3	1.9-2.7	23.2	1.6	1.3-1.9									
Sigmoid colon	194.2	7.1	6.6-7.6	104.8	8.3	7.6-9.1	89.4	6.1	5.5-6.7									
Large intestine, NOS	52.8	1.8	1.6-2.1	26.2	2.1	1.8-2.5	26.6	1.6	1.4-2.0									
Rectum & rectosigmoid	295.0	10.8	10.2-11.4	167.0	13.3	12.4-14.3	128.0	8.8	8.1-9.5	54.0	1.9	1.7-2.1	30.2	2.4	2.0-2.8	23.8	1.5	1.2-1.8
Rectosigmoid junction	73.6	2.7	2.4-3.0	40.4	3.2	2.7-3.7	33.2	2.3	1.9-2.6									
Rectum	221.4	8.1	7.6-8.6	126.6	10.2	9.4-11.0	94.8	6.5	5.9-7.1									
Anus, anal canal & anorectum	42.6	1.5	1.3-1.7	17.2	1.3	1.1-1.6	25.4	1.6	1.3-1.9	5.6	0.2	0.1-0.3	2.8	0.2	0.1-0.4	2.8	0.2	0.1-0.3
Liver and intrahepatic bile duct	275.4	9.6	9.1-10.2	194.8	15.1	14.1-16.1	80.6	5.2	4.7-5.7	171.0	6.0	5.6-6.4	115.0	9.1	8.4-9.9	56.0	3.5	3.1-4.0

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Queens

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	220.6	7.7	7.2-8.2	165.4	12.7	11.9-13.7	55.2	3.5	3.1-4.0	115.0	4.0	3.7-4.3	87.2	6.9	6.2-7.6	27.8	1.7	1.4-2.0
Intrahepatic bile duct	54.8	1.9	1.7-2.2	29.4	2.3	1.9-2.7	25.4	1.6	1.3-1.9	56.0	2.0	1.7-2.2	27.8	2.2	1.9-2.6	28.2	1.8	1.5-2.1
Gallbladder	56.2	2.0	1.8-2.3	17.8	1.5	1.2-1.8	38.4	2.5	2.1-2.9	28.2	1.0	0.8-1.2	9.0	0.8	0.6-1.0	19.2	1.2	0.9-1.4
Other biliary	73.2	2.7	2.4-3.0	37.8	3.2	2.7-3.7	35.4	2.3	2.0-2.7	14.2	0.5	0.4-0.6	6.2	0.5	0.3-0.7	8.0	0.5	0.3-0.7
Pancreas	369.2	13.0	12.4-13.6	169.6	13.7	12.8-14.7	199.6	12.3	11.5-13.1	267.8	9.3	8.8-9.9	124.6	10.0	9.2-10.9	143.2	8.6	8.0-9.3
Retroperitoneum	9.6	0.4	0.3-0.5	5.4	0.4	0.3-0.6	4.2	0.3	0.2-0.5	3.4	0.1	0.1-0.2	2.8	0.2	0.1-0.4	0.6	0.0	0.0-0.1
Peritoneum, omentum & mesentery	7.6	0.3	0.2-0.4	1.0	0.1	0.0-0.2	6.6	0.4	0.3-0.6	6.2	0.2	0.2-0.3	1.8	0.2	0.1-0.3	4.4	0.3	0.2-0.4
Other digestive organs	19.0	0.7	0.6-0.8	8.2	0.7	0.5-0.9	10.8	0.7	0.5-1.0	5.4	0.2	0.1-0.3	3.4	0.3	0.2-0.5	2.0	0.1	0.1-0.3
Respiratory system	1,272.4	44.9	43.8-46.0	678.0	55.1	53.2-57.1	594.4	37.3	36.0-38.7	595.2	20.9	20.1-21.7	334.6	27.8	26.5-29.2	260.6	15.8	15.0-16.7
Nasal cavity, middle ear & sinuses	17.4	0.6	0.5-0.8	9.8	0.8	0.6-1.1	7.6	0.5	0.4-0.7	2.2	0.1	0.0-0.2	1.0	0.1	0.0-0.2	1.2	0.1	0.0-0.2
Larynx	60.6	2.1	1.9-2.4	51.0	4.0	3.5-4.6	9.6	0.6	0.4-0.8	16.6	0.6	0.5-0.7	13.8	1.1	0.9-1.4	2.8	0.2	0.1-0.3
Lung and bronchus	1,190.4	42.0	40.9-43.1	614.4	50.0	48.3-51.9	576.0	36.1	34.8-37.5	573.2	20.1	19.4-20.9	317.6	26.5	25.1-27.8	255.6	15.5	14.7-16.4
Pleura	0.0	0.0	0.0-0.0	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	1.0	0.0	0.0-0.1	0.6	0.0	0.0-0.1	0.4	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	4.0	0.2	0.1-0.3	2.8	0.2	0.1-0.4	1.2	0.1	0.0-0.2	2.2	0.1	0.0-0.1	1.6	0.1	0.1-0.3	0.6	0.0	0.0-0.1
Bones & joints	24.6	1.1	0.9-1.3	14.8	1.4	1.1-1.8	9.8	0.8	0.6-1.1	10.8	0.5	0.3-0.6	6.2	0.6	0.4-0.8	4.6	0.3	0.2-0.5
Soft tissue (including heart)	94.0	3.6	3.3-4.0	52.6	4.4	3.9-5.0	41.4	3.0	2.6-3.5	25.4	0.9	0.8-1.1	14.6	1.2	0.9-1.5	10.8	0.8	0.6-1.0
Skin*	229.6	8.4	7.9-8.9	130.0	10.9	10.0-11.8	99.6	6.7	6.1-7.4	40.2	1.5	1.3-1.7	26.0	2.2	1.9-2.7	14.2	0.9	0.7-1.2
Melanoma of the skin	198.4	7.2	6.8-7.7	111.0	9.3	8.5-10.1	87.4	5.9	5.3-6.5	25.0	0.9	0.8-1.1	15.0	1.3	1.0-1.6	10.0	0.7	0.5-0.9
Breast	1,823.0	67.8	66.4-69.2	14.6	1.2	0.9-1.5	1,808.4	125.6	122.9-128.3	256.4	9.2	8.7-9.7	2.2	0.2	0.1-0.3	254.2	16.3	15.4-17.3
Breast (in situ)#	631.6	23.8	23.0-24.7	1.8	0.1	0.1-0.3	629.8	44.9	43.3-46.5									
Female genital system							803.2	54.5	52.8-56.3							223.4	14.2	13.4-15.1
Cervix uteri							124.6	9.3	8.6-10.1							31.0	2.1	1.8-2.5
Corpus uteris and NOS							451.0	29.5	28.2-30.7							99.4	6.2	5.6-6.8
Ovary							161.2	11.4	10.6-12.3							83.6	5.3	4.8-5.9
Vagina							7.8	0.5	0.4-0.7							2.0	0.1	0.1-0.2
Vulva							29.6	1.9	1.6-2.2							5.2	0.3	0.2-0.4
Other female genital organs							29.0	2.0	1.7-2.3							2.2	0.2	0.1-0.3
Male genital system				1,566.0	118.9	116.2-121.6							182.8	16.0	15.0-17.1			
Prostate				1,499.6	113.1	110.5-115.7							176.8	15.5	14.5-16.6			
Testis				54.4	4.8	4.2-5.4							2.0	0.2	0.1-0.3			
Penis				9.2	0.8	0.6-1.0							3.2	0.3	0.2-0.4			
Other male genital organs				2.8	0.2	0.1-0.4							0.8	0.1	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Queens

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	844.4	30.3	29.4-31.3	586.4	48.1	46.4-49.9	258.0	16.7	15.7-17.6	142.4	5.0	4.7-5.4	97.4	8.4	7.6-9.2	45.0	2.8	2.4-3.2
Urinary bladder (including in situ)	431.6	15.3	14.6-15.9	322.2	26.9	25.6-28.3	109.4	6.7	6.2-7.4	78.2	2.7	2.5-3.0	55.6	4.9	4.3-5.5	22.6	1.4	1.1-1.7
Kidney and renal pelvis	393.8	14.4	13.7-15.1	251.4	20.2	19.0-21.3	142.4	9.6	8.8-10.3	59.2	2.1	1.9-2.4	38.6	3.2	2.8-3.7	20.6	1.3	1.1-1.6
Ureter	11.8	0.4	0.3-0.5	8.0	0.7	0.5-0.9	3.8	0.2	0.1-0.4	2.4	0.1	0.0-0.1	1.8	0.2	0.1-0.3	0.6	0.0	0.0-0.1
Other urinary organs	7.2	0.3	0.2-0.4	4.8	0.4	0.3-0.6	2.4	0.1	0.1-0.3	2.6	0.1	0.0-0.2	1.4	0.1	0.0-0.2	1.2	0.1	0.0-0.2
Eye & orbit	17.2	0.6	0.5-0.8	9.8	0.8	0.6-1.1	7.4	0.5	0.4-0.7	0.8	0.0	0.0-0.1	0.4	0.0	0.0-0.1	0.4	0.0	0.0-0.1
Brain / other central nervous system (all behaviors)	488.0	18.6	17.8-19.4	185.8	15.7	14.6-16.7	302.2	21.0	19.9-22.1	89.4	3.3	3.0-3.7	46.0	3.8	3.4-4.4	43.4	2.9	2.5-3.3
Malignant brain / other central nervous system	132.2	5.2	4.8-5.6	72.6	6.1	5.5-6.8	59.6	4.4	3.9-5.0	77.0	2.9	2.6-3.2	41.4	3.5	3.0-4.0	35.6	2.4	2.0-2.8
Malignant brain	126.4	5.0	4.6-5.4	70.2	5.9	5.3-6.5	56.2	4.1	3.7-4.7									
Malignant other central nervous system	5.8	0.3	0.2-0.4	2.4	0.2	0.1-0.4	3.4	0.3	0.1-0.4									
Benign brain / other central nervous system#	355.8	13.4	12.7-14.0	113.2	9.6	8.8-10.4	242.6	16.6	15.6-17.6	12.4	0.5	0.3-0.6	4.6	0.4	0.2-0.6	7.8	0.5	0.4-0.7
Benign brain	27.8	1.2	1.0-1.4	13.4	1.2	0.9-1.6	14.4	1.2	0.9-1.5									
Benign other central nervous system	328.0	12.2	11.6-12.8	99.8	8.3	7.6-9.1	228.2	15.4	14.5-16.4									
Endocrine system	530.4	21.5	20.7-22.4	133.8	11.2	10.4-12.1	396.6	31.4	30.0-32.9	21.6	0.8	0.6-1.0	9.4	0.8	0.6-1.0	12.2	0.8	0.6-1.0
Thyroid	492.4	20.1	19.3-20.9	115.6	9.7	8.9-10.6	376.8	30.0	28.6-31.4	15.2	0.5	0.4-0.7	6.6	0.5	0.4-0.8	8.6	0.5	0.4-0.7
Other endocrine (including thymus)	38.0	1.5	1.3-1.7	18.2	1.5	1.2-1.8	19.8	1.4	1.2-1.8	6.4	0.3	0.2-0.4	2.8	0.2	0.1-0.4	3.6	0.3	0.2-0.4
Lymphomas	553.4	20.6	19.9-21.5	298.6	24.7	23.5-26.1	254.8	17.4	16.4-18.4	118.0	4.2	3.8-4.5	69.2	5.9	5.3-6.5	48.8	2.9	2.5-3.3
Hodgkin lymphoma	60.8	2.6	2.3-2.9	34.6	3.0	2.6-3.5	26.2	2.2	1.8-2.6	4.8	0.2	0.1-0.3	2.6	0.2	0.1-0.3	2.2	0.2	0.1-0.3
Non-Hodgkin lymphomas	492.6	18.1	17.4-18.8	264.0	21.7	20.5-22.9	228.6	15.2	14.3-16.2	113.2	4.0	3.7-4.4	66.6	5.7	5.1-6.3	46.6	2.8	2.4-3.2
Myeloma	216.0	7.6	7.2-8.1	111.6	8.9	8.1-9.7	104.4	6.6	6.1-7.3	68.4	2.4	2.1-2.6	33.6	2.8	2.4-3.3	34.8	2.1	1.8-2.4
Leukemias	341.4	13.0	12.4-13.7	197.0	16.8	15.7-17.9	144.4	10.0	9.3-10.8	128.0	4.6	4.3-5.0	73.0	6.3	5.6-7.0	55.0	3.5	3.1-4.0
Lymphocytic leukemias	158.6	6.1	5.7-6.6	94.8	8.1	7.3-8.8	63.8	4.5	4.0-5.1	33.4	1.2	1.0-1.4	18.8	1.6	1.3-2.0	14.6	1.0	0.8-1.2
Acute lymphocytic leukemia	44.6	2.1	1.8-2.4	26.0	2.5	2.1-3.0	18.6	1.7	1.4-2.1	9.8	0.4	0.3-0.5	5.0	0.4	0.3-0.6	4.8	0.4	0.2-0.6
Chronic lymphocytic leukemia	105.6	3.7	3.4-4.0	62.0	5.0	4.5-5.6	43.6	2.7	2.4-3.1	21.8	0.7	0.6-0.9	12.8	1.1	0.9-1.4	9.0	0.5	0.4-0.7
Other lymphocytic leukemias	8.4	0.3	0.2-0.4	6.8	0.5	0.4-0.7	1.6	0.1	0.0-0.2	1.8	0.1	0.0-0.1	1.0	0.1	0.0-0.2	0.8	0.1	0.0-0.2
Myeloid and monocytic leukemias	160.4	6.0	5.6-6.5	89.4	7.7	7.0-8.4	71.0	4.8	4.3-5.4	72.8	2.6	2.4-2.9	41.2	3.6	3.1-4.1	31.6	2.0	1.7-2.4
Acute myeloid leukemia	104.4	3.9	3.6-4.3	56.4	4.8	4.2-5.4	48.0	3.2	2.8-3.7	61.2	2.2	2.0-2.5	34.8	3.0	2.6-3.5	26.4	1.7	1.4-2.0
Acute monocytic leukemia	3.2	0.1	0.1-0.2	1.8	0.2	0.1-0.3	1.4	0.1	0.0-0.2	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Chronic myeloid leukemia	47.6	1.8	1.6-2.1	28.6	2.5	2.1-2.9	19.0	1.3	1.0-1.6	7.0	0.3	0.2-0.4	3.6	0.3	0.2-0.5	3.4	0.2	0.1-0.4
Other myeloid/monocytic leukemias	5.2	0.2	0.1-0.3	2.6	0.2	0.1-0.4	2.6	0.2	0.1-0.3	4.2	0.2	0.1-0.2	2.6	0.2	0.1-0.4	1.6	0.1	0.0-0.2
Other leukemias	22.4	0.8	0.7-1.0	12.8	1.1	0.8-1.4	9.6	0.7	0.5-0.9	21.8	0.8	0.6-0.9	13.0	1.1	0.8-1.4	8.8	0.5	0.4-0.7
Other acute leukemias	6.4	0.2	0.2-0.3	4.2	0.4	0.2-0.6	2.2	0.1	0.1-0.3	5.8	0.2	0.1-0.3	4.2	0.4	0.2-0.6	1.6	0.1	0.0-0.2

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Queens

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	16.0	0.6	0.5-0.8	8.6	0.7	0.5-1.0	7.4	0.5	0.4-0.7	16.0	0.6	0.4-0.7	8.8	0.7	0.5-1.0	7.2	0.4	0.3-0.6
Mesothelioma	15.0	0.6	0.4-0.7	9.6	0.8	0.6-1.1	5.4	0.4	0.2-0.5									
Kaposi sarcoma	23.0	0.9	0.7-1.1	19.2	1.6	1.3-1.9	3.8	0.3	0.2-0.4									
Myelodysplastic syndromes	98.8	3.6	3.3-3.9	56.6	5.1	4.5-5.8	42.2	2.6	2.3-3.0									
Chronic myeloproliferative disorders [^]	80.2	3.0	2.7-3.3	37.8	3.0	2.6-3.5	42.4	2.9	2.5-3.3									
Ill defined and unspecified sites	202.6	7.1	6.7-7.6	100.4	8.3	7.6-9.1	102.2	6.2	5.7-6.8	234.4	8.3	7.8-8.8	118.6	9.9	9.1-10.8	115.8	7.1	6.5-7.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Richmond (Staten Island)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	3,041.6	517.4	509.0-525.9	1,474.0	548.2	535.3-561.2	1,567.6	499.0	487.7-510.6	844.2	141.6	137.2-146.0	411.2	161.8	154.7-169.2	433.0	127.5	122.0-133.1
Oral cavity and pharynx	60.4	10.0	8.9-11.2	42.0	15.1	13.0-17.4	18.4	5.6	4.5-6.9	11.6	1.8	1.4-2.4	8.2	2.9	2.0-3.9	3.4	0.9	0.5-1.5
Lip	0.8	0.2	0.0-0.4	0.6	0.3	0.1-0.8	0.2	0.1	0.0-0.4	0.2	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.2	0.1	0.0-0.4
Tongue	18.6	3.0	2.4-3.7	13.0	4.5	3.4-5.7	5.6	1.6	1.1-2.4	2.0	0.3	0.1-0.6	1.0	0.4	0.1-0.9	1.0	0.3	0.1-0.7
Salivary gland	8.4	1.5	1.1-2.1	4.6	1.9	1.2-2.9	3.8	1.3	0.8-2.1	1.8	0.3	0.1-0.6	1.4	0.6	0.2-1.2	0.4	0.1	0.0-0.5
Floor of mouth	1.2	0.2	0.1-0.4	1.0	0.3	0.1-0.8	0.2	0.0	0.0-0.4	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Gum & other mouth	9.4	1.5	1.1-2.0	5.0	1.9	1.2-2.8	4.4	1.2	0.8-1.9	1.6	0.2	0.1-0.5	1.0	0.3	0.1-0.9	0.6	0.2	0.0-0.5
Nasopharynx	4.2	0.8	0.5-1.2	3.0	1.2	0.6-2.0	1.2	0.4	0.1-0.9	3.2	0.5	0.3-0.9	2.2	0.8	0.4-1.4	1.0	0.3	0.1-0.7
Tonsil	11.2	1.8	1.4-2.4	9.2	3.2	2.3-4.3	2.0	0.6	0.3-1.2	0.6	0.1	0.0-0.3	0.6	0.2	0.0-0.6	0.0	0.0	0.0-0.3
Oropharynx	3.4	0.6	0.3-0.9	2.4	0.8	0.4-1.5	1.0	0.3	0.1-0.8	0.6	0.1	0.0-0.3	0.4	0.1	0.0-0.5	0.2	0.0	0.0-0.4
Hypopharynx	2.2	0.4	0.2-0.7	2.2	0.8	0.4-1.5	0.0	0.0	0.0-0.3	0.4	0.1	0.0-0.2	0.4	0.1	0.0-0.5	0.0	0.0	0.0-0.3
Other buccal cavity and pharynx	1.0	0.1	0.0-0.3	1.0	0.3	0.1-0.7	0.0	0.0	0.0-0.3	1.2	0.2	0.1-0.4	1.2	0.4	0.2-1.0	0.0	0.0	0.0-0.3
Digestive system	528.0	88.3	84.9-91.9	301.0	111.5	105.7-117.5	227.0	69.2	65.1-73.4	249.0	41.0	38.7-43.4	135.8	51.2	47.3-55.3	113.2	32.9	30.2-35.8
Esophagus	28.4	4.5	3.8-5.3	22.2	7.7	6.3-9.4	6.2	1.9	1.3-2.7	17.6	2.8	2.2-3.5	14.0	4.9	3.8-6.2	3.6	1.1	0.6-1.7
Stomach	47.0	8.1	7.1-9.3	29.0	11.5	9.6-13.6	18.0	5.5	4.4-6.8	22.0	3.8	3.1-4.6	12.2	4.8	3.6-6.2	9.8	3.0	2.2-4.1
Small intestine	15.4	2.6	2.0-3.3	9.2	3.3	2.4-4.5	6.2	2.0	1.4-2.9	2.2	0.3	0.2-0.6	1.2	0.4	0.2-1.0	1.0	0.3	0.1-0.7
Colorectal	240.6	41.0	38.7-43.4	130.2	49.3	45.5-53.4	110.4	34.0	31.2-37.1	80.6	13.4	12.1-14.9	42.6	16.6	14.4-19.1	38.0	10.9	9.4-12.6
Colon excluding rectum	177.4	30.1	28.1-32.2	93.0	35.4	32.2-38.9	84.4	25.7	23.3-28.4	66.4	11.1	9.9-12.4	33.6	13.1	11.2-15.4	32.8	9.5	8.1-11.1
Cecum	27.6	4.6	3.9-5.5	11.0	4.0	3.0-5.3	16.6	4.9	3.9-6.1									
Appendix	10.8	2.0	1.5-2.6	5.8	2.3	1.5-3.3	5.0	1.6	1.1-2.5									
Ascending colon	36.8	6.3	5.4-7.3	21.2	8.4	6.9-10.3	15.6	4.6	3.6-5.8									
Hepatic flexure	6.8	1.1	0.8-1.6	3.8	1.4	0.8-2.2	3.0	1.0	0.5-1.6									
Transverse colon	15.4	2.6	2.0-3.2	8.8	3.2	2.3-4.4	6.6	2.1	1.4-2.9									
Splenic flexure	5.8	1.1	0.7-1.6	2.8	1.2	0.6-2.0	3.0	1.0	0.5-1.6									
Descending colon	11.2	1.9	1.4-2.4	6.0	2.2	1.5-3.2	5.2	1.6	1.1-2.4									
Sigmoid colon	47.6	8.1	7.1-9.2	25.6	9.6	8.0-11.5	22.0	6.9	5.6-8.4									
Large intestine, NOS	15.4	2.5	2.0-3.2	8.0	3.0	2.1-4.1	7.4	2.1	1.5-3.0									
Rectum & rectosigmoid	63.2	10.9	9.7-12.2	37.2	13.9	11.9-16.1	26.0	8.3	6.9-9.9	14.2	2.3	1.8-3.0	9.0	3.5	2.5-4.7	5.2	1.4	0.9-2.1
Rectosigmoid junction	15.6	2.7	2.1-3.4	8.6	3.2	2.3-4.4	7.0	2.2	1.5-3.1									
Rectum	47.6	8.2	7.2-9.4	28.6	10.7	8.9-12.6	19.0	6.1	4.9-7.5									
Anus, anal canal & anorectum	11.0	1.8	1.3-2.3	5.0	1.8	1.1-2.7	6.0	1.8	1.2-2.6	2.0	0.3	0.2-0.6	0.8	0.3	0.1-0.9	1.2	0.3	0.1-0.8
Liver and intrahepatic bile duct	65.2	10.3	9.2-11.5	47.2	16.4	14.3-18.7	18.0	5.3	4.2-6.5	39.2	6.3	5.5-7.3	25.4	9.1	7.6-11.0	13.8	4.0	3.1-5.1

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Richmond (Staten Island)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	52.6	8.3	7.3-9.4	40.8	14.1	12.2-16.3	11.8	3.4	2.6-4.5	30.0	4.8	4.1-5.7	21.4	7.6	6.2-9.3	8.6	2.5	1.8-3.4
Intrahepatic bile duct	12.6	2.0	1.6-2.6	6.4	2.2	1.5-3.2	6.2	1.8	1.2-2.6	9.2	1.5	1.1-2.1	4.0	1.5	0.9-2.4	5.2	1.5	1.0-2.3
Gallbladder	8.6	1.5	1.1-2.1	2.4	0.9	0.5-1.7	6.2	2.0	1.3-2.9	5.2	0.9	0.6-1.3	2.4	1.0	0.5-1.7	2.8	0.8	0.4-1.4
Other biliary	9.6	1.7	1.2-2.2	4.8	1.9	1.2-2.8	4.8	1.5	1.0-2.3	4.2	0.7	0.4-1.0	1.4	0.5	0.2-1.0	2.8	0.8	0.4-1.4
Pancreas	94.2	15.5	14.1-17.0	46.6	17.0	14.8-19.5	47.6	14.1	12.3-16.1	73.4	12.0	10.8-13.3	35.0	13.2	11.2-15.4	38.4	11.1	9.6-12.9
Retroperitoneum	4.2	0.7	0.4-1.2	2.8	1.1	0.6-1.9	1.4	0.4	0.2-1.0	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Peritoneum, omentum & mesentery	1.6	0.3	0.1-0.6	0.4	0.1	0.0-0.5	1.2	0.4	0.1-0.9	1.2	0.2	0.1-0.4	0.0	0.0	0.0-0.3	1.2	0.3	0.1-0.8
Other digestive organs	2.2	0.4	0.2-0.7	1.2	0.4	0.1-1.0	1.0	0.3	0.1-0.8	1.4	0.3	0.1-0.5	0.8	0.4	0.1-1.0	0.6	0.2	0.0-0.6
Respiratory system	406.8	67.2	64.3-70.3	198.2	75.2	70.4-80.1	208.6	62.0	58.2-66.0	203.2	34.1	32.0-36.3	102.8	40.6	37.1-44.4	100.4	29.7	27.1-32.5
Nasal cavity, middle ear & sinuses	3.8	0.6	0.4-1.0	1.8	0.7	0.3-1.3	2.0	0.6	0.3-1.1	0.8	0.1	0.0-0.4	0.6	0.3	0.1-0.8	0.2	0.0	0.0-0.4
Larynx	17.6	2.9	2.3-3.6	14.0	5.2	4.0-6.6	3.6	1.1	0.6-1.8	4.2	0.7	0.4-1.0	2.4	0.9	0.4-1.5	1.8	0.5	0.2-1.0
Lung and bronchus	384.8	63.6	60.8-66.6	182.0	69.1	64.6-73.9	202.8	60.3	56.6-64.2	197.0	33.1	31.0-35.3	99.4	39.3	35.8-43.0	97.6	28.8	26.3-31.6
Pleura	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3	0.6	0.1	0.0-0.4	0.4	0.2	0.0-0.7	0.2	0.1	0.0-0.4
Trachea, mediastinum, other respiratory	0.6	0.1	0.0-0.3	0.4	0.2	0.0-0.6	0.2	0.1	0.0-0.4	0.6	0.1	0.0-0.4	0.0	0.0	0.0-0.3	0.6	0.2	0.0-0.7
Bones & joints	6.2	1.2	0.8-1.8	3.4	1.4	0.8-2.3	2.8	1.1	0.6-1.9	2.4	0.5	0.3-0.9	1.4	0.7	0.3-1.5	1.0	0.4	0.1-0.9
Soft tissue (including heart)	16.8	3.1	2.5-3.9	8.4	3.2	2.3-4.4	8.4	3.1	2.2-4.3	7.8	1.3	0.9-1.8	2.6	1.0	0.5-1.7	5.2	1.7	1.1-2.5
Skin*	97.4	16.9	15.4-18.5	52.6	20.4	17.9-23.1	44.8	14.2	12.4-16.3	12.2	2.1	1.6-2.7	6.6	2.8	1.9-3.9	5.6	1.7	1.1-2.5
Melanoma of the skin	84.2	14.4	13.0-15.9	45.6	17.5	15.2-20.0	38.6	12.1	10.4-14.1	8.4	1.5	1.1-2.1	4.2	1.9	1.2-2.9	4.2	1.3	0.8-2.1
Breast	434.2	75.5	72.2-78.8	3.6	1.3	0.8-2.2	430.6	139.2	133.1-145.4	61.0	10.2	9.0-11.4	0.6	0.2	0.0-0.7	60.4	17.6	15.6-19.8
Breast (in situ)#	142.6	25.7	23.8-27.8	0.4	0.2	0.0-0.7	142.2	48.5	44.8-52.3									
Female genital system							203.0	63.8	59.8-68.0							53.2	15.7	13.8-17.7
Cervix uteri							22.2	7.9	6.4-9.6							5.4	1.7	1.1-2.5
Corpus uteri and NOS							116.4	34.9	32.0-37.9							22.0	6.5	5.3-7.8
Ovary							45.6	15.0	13.0-17.1							22.8	6.6	5.4-8.0
Vagina							2.4	0.9	0.4-1.5							0.0	0.0	0.0-0.3
Vulva							8.6	2.6	1.9-3.6							1.8	0.5	0.2-1.1
Other female genital organs							7.8	2.5	1.8-3.5							1.2	0.4	0.1-0.8
Male genital system				364.4	127.2	121.2-133.3							37.6	16.4	14.1-18.9			
Prostate				347.4	119.5	113.8-125.4							35.8	15.6	13.4-18.2			
Testis				14.2	6.6	5.1-8.3							1.0	0.4	0.1-1.0			
Penis				2.0	0.8	0.4-1.5							0.4	0.1	0.0-0.5			
Other male genital organs				0.8	0.3	0.1-0.8							0.4	0.2	0.0-0.7			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Richmond (Staten Island)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	277.2	46.3	43.8-48.8	196.2	73.7	69.0-78.6	81.0	24.4	22.0-27.0	47.4	8.0	7.0-9.1	32.8	13.4	11.4-15.7	14.6	4.2	3.3-5.4
Urinary bladder (including in situ)	144.4	24.0	22.2-25.8	106.2	40.7	37.2-44.4	38.2	11.2	9.6-12.9	26.8	4.6	3.8-5.4	18.6	7.9	6.4-9.8	8.2	2.4	1.7-3.3
Kidney and renal pelvis	126.0	21.2	19.5-23.0	85.4	31.4	28.4-34.6	40.6	12.6	10.9-14.5	18.8	3.1	2.5-3.9	13.2	5.1	4.0-6.6	5.6	1.6	1.1-2.4
Ureter	4.4	0.7	0.4-1.0	3.0	1.1	0.6-1.8	1.4	0.4	0.2-0.9	0.8	0.1	0.0-0.3	0.6	0.2	0.0-0.7	0.2	0.1	0.0-0.4
Other urinary organs	2.4	0.4	0.2-0.7	1.6	0.6	0.2-1.2	0.8	0.3	0.1-0.7	1.0	0.2	0.1-0.4	0.4	0.1	0.0-0.5	0.6	0.2	0.0-0.6
Eye & orbit	6.2	1.1	0.7-1.6	2.0	0.7	0.3-1.4	4.2	1.4	0.9-2.2	0.6	0.1	0.0-0.3	0.0	0.0	0.0-0.3	0.6	0.2	0.0-0.5
Brain / other central nervous system (all behaviors)	126.4	22.7	20.9-24.6	48.2	19.1	16.7-21.7	78.2	25.7	23.1-28.5	23.6	4.0	3.3-4.8	12.2	4.5	3.4-5.9	11.4	3.5	2.6-4.5
Malignant brain / other central nervous system	36.4	6.7	5.7-7.8	19.0	7.5	6.1-9.3	17.4	5.9	4.7-7.4	21.6	3.7	3.0-4.5	11.4	4.3	3.2-5.6	10.2	3.1	2.3-4.2
Malignant brain	34.2	6.3	5.4-7.3	18.0	7.2	5.7-8.9	16.2	5.5	4.3-6.9									
Malignant other central nervous system	2.2	0.4	0.2-0.7	1.0	0.4	0.1-0.9	1.2	0.4	0.1-1.0									
Benign brain / other central nervous system#	90.0	16.0	14.5-17.6	29.2	11.5	9.7-13.6	60.8	19.8	17.5-22.2	2.0	0.3	0.2-0.7	0.8	0.3	0.1-0.8	1.2	0.3	0.1-0.8
Benign brain	6.2	1.3	0.9-1.8	4.0	1.6	1.0-2.5	2.2	0.9	0.5-1.7									
Benign other central nervous system	83.8	14.7	13.3-16.2	25.2	9.9	8.2-11.8	58.6	18.8	16.6-21.2									
Endocrine system	170.4	32.9	30.7-35.3	52.8	20.8	18.3-23.6	117.6	44.3	40.7-48.2	3.6	0.6	0.4-1.0	2.0	0.8	0.4-1.5	1.6	0.5	0.2-1.0
Thyroid	164.4	31.8	29.6-34.2	48.6	19.2	16.8-21.9	115.8	43.7	40.1-47.5	3.0	0.5	0.3-0.8	1.6	0.6	0.3-1.3	1.4	0.4	0.1-0.8
Other endocrine (including thymus)	6.0	1.1	0.7-1.5	4.2	1.6	1.0-2.5	1.8	0.6	0.3-1.3	0.6	0.1	0.0-0.4	0.4	0.2	0.0-0.7	0.2	0.1	0.0-0.5
Lymphomas	154.4	27.3	25.3-29.3	81.4	31.9	28.8-35.2	73.0	23.4	20.9-26.0	28.4	5.0	4.2-5.9	16.2	6.6	5.2-8.3	12.2	3.6	2.8-4.7
Hodgkin lymphoma	16.0	3.3	2.6-4.1	9.2	3.9	2.8-5.3	6.8	2.7	1.8-3.8	2.6	0.4	0.2-0.8	1.6	0.6	0.2-1.2	1.0	0.4	0.1-0.9
Non-Hodgkin lymphomas	138.4	23.9	22.1-25.9	72.2	27.9	25.0-31.1	66.2	20.7	18.4-23.1	25.8	4.5	3.8-5.4	14.6	6.0	4.7-7.6	11.2	3.3	2.5-4.3
Myeloma	55.0	9.2	8.1-10.4	29.4	11.2	9.4-13.2	25.6	7.7	6.4-9.2	14.8	2.4	1.9-3.1	8.6	3.2	2.3-4.3	6.2	1.8	1.2-2.6
Leukemias	98.2	17.4	15.9-19.1	56.8	22.0	19.5-24.8	41.4	13.6	11.8-15.7	37.2	6.5	5.5-7.5	18.8	7.7	6.2-9.5	18.4	5.5	4.4-6.9
Lymphocytic leukemias	47.4	8.4	7.4-9.6	27.6	10.6	8.8-12.6	19.8	6.7	5.4-8.2	8.8	1.5	1.1-2.0	4.8	2.0	1.2-2.9	4.0	1.2	0.7-1.9
Acute lymphocytic leukemia	8.0	1.9	1.3-2.5	3.4	1.6	0.9-2.6	4.6	2.1	1.3-3.1	2.0	0.4	0.2-0.7	0.6	0.3	0.1-0.8	1.4	0.5	0.2-1.0
Chronic lymphocytic leukemia	35.2	5.8	5.0-6.8	20.6	7.7	6.2-9.4	14.6	4.4	3.4-5.6	6.8	1.1	0.8-1.6	4.2	1.7	1.0-2.6	2.6	0.7	0.4-1.2
Other lymphocytic leukemias	4.2	0.7	0.4-1.1	3.6	1.3	0.7-2.1	0.6	0.2	0.0-0.7	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Myeloid and monocytic leukemias	45.2	8.1	7.0-9.3	26.2	10.3	8.6-12.3	19.0	6.2	4.9-7.6	19.8	3.5	2.8-4.3	10.2	4.3	3.2-5.6	9.6	3.0	2.2-4.0
Acute myeloid leukemia	29.4	5.3	4.4-6.2	16.4	6.6	5.2-8.2	13.0	4.2	3.2-5.4	17.2	3.0	2.4-3.7	8.8	3.7	2.7-5.0	8.4	2.6	1.8-3.6
Acute monocytic leukemia	1.2	0.2	0.1-0.5	0.8	0.3	0.1-0.8	0.4	0.2	0.0-0.6	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Chronic myeloid leukemia	14.0	2.5	2.0-3.2	8.8	3.4	2.4-4.6	5.2	1.7	1.1-2.6	2.0	0.3	0.2-0.6	1.0	0.4	0.1-1.0	1.0	0.3	0.1-0.7
Other myeloid/monocytic leukemias	0.6	0.1	0.0-0.3	0.2	0.1	0.0-0.5	0.4	0.1	0.0-0.5	0.6	0.1	0.0-0.4	0.4	0.2	0.0-0.6	0.2	0.1	0.0-0.5
Other leukemias	5.6	0.9	0.6-1.4	3.0	1.1	0.6-1.8	2.6	0.8	0.4-1.4	8.6	1.5	1.1-2.0	3.8	1.5	0.9-2.4	4.8	1.4	0.9-2.1
Other acute leukemias	1.8	0.3	0.1-0.6	0.8	0.3	0.1-0.8	1.0	0.3	0.1-0.7	3.2	0.5	0.3-0.9	1.0	0.4	0.1-1.0	2.2	0.5	0.3-1.0

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Richmond (Staten Island)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	3.8	0.6	0.4-1.0	2.2	0.8	0.4-1.5	1.6	0.5	0.2-1.1	5.4	1.0	0.6-1.4	2.8	1.1	0.6-1.9	2.6	0.8	0.4-1.5
Mesothelioma	6.8	1.2	0.8-1.7	4.6	2.0	1.3-3.0	2.2	0.6	0.3-1.2									
Kaposi sarcoma	5.4	1.0	0.6-1.5	4.4	1.8	1.1-2.7	1.0	0.4	0.1-0.9									
Myelodysplastic syndromes	21.8	3.8	3.1-4.6	11.2	4.8	3.6-6.3	10.6	3.1	2.3-4.2									
Chronic myeloproliferative disorders [^]	38.2	6.9	5.9-8.0	17.8	6.9	5.5-8.5	20.4	6.9	5.6-8.4									
Ill defined and unspecified sites	54.4	9.5	8.4-10.7	24.8	9.7	8.0-11.6	29.6	9.2	7.7-10.9	52.6	9.0	8.0-10.2	25.8	10.1	8.4-12.0	26.8	8.1	6.7-9.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Erie

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	6,498.8	534.0	528.0-540.1	3,265.0	587.3	578.0-596.6	3,233.8	499.2	491.1-507.4	2,056.4	161.0	157.8-164.2	1,024.4	189.0	183.7-194.4	1,032.0	142.3	138.3-146.4
Oral cavity and pharynx	170.2	13.6	12.7-14.6	118.4	20.5	18.9-22.3	51.8	7.8	6.8-8.9	38.8	2.9	2.5-3.4	28.6	4.9	4.1-5.8	10.2	1.4	1.0-1.8
Lip	6.6	0.5	0.4-0.7	4.0	0.7	0.4-1.1	2.6	0.4	0.2-0.7	0.6	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.0	0.0	0.0-0.2
Tongue	56.8	4.6	4.0-5.1	39.6	6.8	5.9-7.9	17.2	2.6	2.1-3.3	9.0	0.6	0.5-0.9	6.2	1.0	0.7-1.5	2.8	0.4	0.2-0.6
Salivary gland	17.8	1.5	1.2-1.9	10.8	2.1	1.5-2.7	7.0	1.1	0.7-1.5	3.6	0.3	0.2-0.5	2.6	0.5	0.3-0.9	1.0	0.1	0.0-0.3
Floor of mouth	8.2	0.6	0.5-0.9	5.2	0.9	0.6-1.3	3.0	0.4	0.2-0.8	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Gum & other mouth	22.2	1.8	1.5-2.2	11.8	2.0	1.5-2.7	10.4	1.6	1.1-2.1	4.6	0.4	0.2-0.5	3.6	0.6	0.4-1.0	1.0	0.2	0.0-0.4
Nasopharynx	5.0	0.4	0.3-0.7	3.6	0.7	0.4-1.1	1.4	0.2	0.1-0.5	1.6	0.1	0.1-0.3	0.8	0.1	0.0-0.4	0.8	0.1	0.0-0.3
Tonsil	29.8	2.4	2.0-2.8	24.6	4.1	3.4-4.9	5.2	0.8	0.5-1.3	5.6	0.4	0.3-0.6	4.8	0.8	0.5-1.2	0.8	0.1	0.0-0.3
Oropharynx	8.4	0.7	0.5-0.9	7.2	1.2	0.8-1.7	1.2	0.2	0.1-0.4	6.4	0.5	0.3-0.7	4.6	0.7	0.5-1.1	1.8	0.2	0.1-0.5
Hypopharynx	12.6	1.0	0.7-1.2	9.6	1.7	1.2-2.2	3.0	0.4	0.2-0.7	3.0	0.2	0.1-0.4	2.0	0.4	0.2-0.7	1.0	0.1	0.0-0.4
Other buccal cavity and pharynx	2.8	0.2	0.1-0.3	2.0	0.3	0.2-0.7	0.8	0.1	0.0-0.3	4.2	0.3	0.2-0.5	3.2	0.6	0.3-1.0	1.0	0.1	0.0-0.3
Digestive system	1,062.4	86.5	84.1-88.9	579.4	105.7	101.7-109.7	483.0	70.9	68.0-73.9	512.4	40.0	38.4-41.6	291.8	52.5	49.8-55.4	220.6	30.0	28.2-31.9
Esophagus	70.8	5.6	5.0-6.2	54.8	9.6	8.5-10.9	16.0	2.3	1.8-2.9	56.6	4.3	3.8-4.9	46.2	8.0	7.0-9.2	10.4	1.4	1.0-1.9
Stomach	97.2	8.0	7.3-8.8	59.0	11.0	9.8-12.4	38.2	5.6	4.8-6.5	34.2	2.7	2.3-3.2	20.0	3.7	3.0-4.5	14.2	1.9	1.4-2.4
Small intestine	45.4	3.8	3.3-4.3	26.8	5.0	4.1-5.9	18.6	2.8	2.2-3.5	10.4	0.8	0.6-1.1	6.4	1.2	0.8-1.7	4.0	0.5	0.3-0.8
Colorectal	452.4	37.7	36.1-39.3	222.6	41.6	39.1-44.2	229.8	34.5	32.4-36.6	159.4	12.5	11.7-13.5	81.0	15.0	13.6-16.6	78.4	10.6	9.5-11.7
Colon excluding rectum	318.6	26.4	25.1-27.8	148.4	27.9	25.8-30.0	170.2	25.1	23.4-27.0	115.8	9.0	8.3-9.8	57.6	10.6	9.4-12.0	58.2	7.7	6.8-8.7
Cecum	73.6	5.9	5.3-6.6	27.4	5.1	4.3-6.1	46.2	6.5	5.6-7.4									
Appendix	18.4	1.8	1.4-2.2	7.4	1.5	1.0-2.1	11.0	2.1	1.5-2.7									
Ascending colon	57.0	4.6	4.1-5.2	23.0	4.4	3.6-5.3	34.0	4.7	4.0-5.5									
Hepatic flexure	14.6	1.2	0.9-1.5	6.0	1.1	0.8-1.7	8.6	1.2	0.9-1.7									
Transverse colon	30.2	2.4	2.0-2.8	16.0	3.0	2.4-3.8	14.2	1.9	1.5-2.5									
Splenic flexure	9.4	0.8	0.6-1.0	4.2	0.8	0.5-1.2	5.2	0.7	0.5-1.1									
Descending colon	12.8	1.1	0.8-1.4	7.2	1.4	1.0-1.9	5.6	0.8	0.6-1.3									
Sigmoid colon	80.0	6.9	6.2-7.7	46.0	8.5	7.4-9.7	34.0	5.8	4.9-6.8									
Large intestine, NOS	22.6	1.7	1.4-2.1	11.2	2.1	1.5-2.7	11.4	1.5	1.1-1.9									
Rectum & rectosigmoid	133.8	11.3	10.4-12.2	74.2	13.7	12.3-15.3	59.6	9.3	8.2-10.5	43.6	3.5	3.1-4.0	23.4	4.4	3.6-5.3	20.2	2.9	2.3-3.5
Rectosigmoid junction	25.6	2.1	1.7-2.5	12.8	2.3	1.8-3.0	12.8	1.9	1.4-2.5									
Rectum	108.2	9.2	8.4-10.0	61.4	11.4	10.1-12.8	46.8	7.4	6.4-8.5									
Anus, anal canal & anorectum	27.0	2.3	1.9-2.8	9.6	1.9	1.4-2.6	17.4	2.7	2.1-3.4	5.8	0.5	0.3-0.7	2.2	0.4	0.2-0.8	3.6	0.5	0.3-0.8
Liver and intrahepatic bile duct	112.2	8.5	7.8-9.3	82.0	13.9	12.6-15.4	30.2	4.2	3.5-4.9	74.4	5.7	5.1-6.3	51.8	8.8	7.7-10.0	22.6	3.2	2.6-3.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Erie

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	89.0	6.7	6.1-7.4	69.2	11.6	10.4-13.0	19.8	2.7	2.2-3.4	52.0	3.9	3.4-4.4	40.4	6.8	5.9-7.9	11.6	1.6	1.2-2.1
Intrahepatic bile duct	23.2	1.8	1.5-2.2	12.8	2.3	1.7-2.9	10.4	1.4	1.1-1.9	22.4	1.8	1.4-2.1	11.4	2.0	1.5-2.6	11.0	1.6	1.2-2.1
Gallbladder	13.0	1.1	0.8-1.4	3.0	0.6	0.3-1.0	10.0	1.5	1.1-2.0	5.6	0.5	0.3-0.7	1.4	0.3	0.1-0.6	4.2	0.7	0.4-1.1
Other biliary	22.6	1.8	1.5-2.1	11.6	2.0	1.5-2.6	11.0	1.5	1.1-2.0	6.8	0.5	0.3-0.7	3.2	0.5	0.3-0.9	3.6	0.4	0.3-0.7
Pancreas	200.0	16.0	15.0-17.1	101.4	18.4	16.8-20.2	98.6	14.0	12.7-15.3	150.0	11.8	10.9-12.7	76.0	13.9	12.5-15.4	74.0	10.1	9.1-11.3
Retroperitoneum	4.0	0.4	0.2-0.6	2.4	0.5	0.3-0.9	1.6	0.2	0.1-0.5	0.8	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.2	0.0	0.0-0.2
Peritoneum, omentum & mesentery	4.8	0.4	0.2-0.6	0.2	0.0	0.0-0.2	4.6	0.7	0.4-1.0	3.2	0.2	0.1-0.4	0.6	0.1	0.0-0.3	2.6	0.4	0.2-0.6
Other digestive organs	13.0	1.0	0.8-1.3	6.0	1.1	0.7-1.6	7.0	0.9	0.6-1.3	5.2	0.4	0.3-0.6	2.4	0.4	0.2-0.7	2.8	0.4	0.2-0.7
Respiratory system	923.0	72.3	70.2-74.5	436.0	78.1	74.7-81.5	487.0	68.5	65.7-71.3	514.4	39.8	38.2-41.4	251.6	45.7	43.1-48.4	262.8	35.6	33.7-37.7
Nasal cavity, middle ear & sinuses	9.4	0.8	0.6-1.1	5.2	1.0	0.6-1.5	4.2	0.7	0.4-1.1	1.8	0.2	0.1-0.3	0.8	0.2	0.0-0.4	1.0	0.2	0.0-0.4
Larynx	39.4	3.1	2.7-3.6	29.4	5.0	4.2-6.0	10.0	1.6	1.2-2.1	12.8	1.0	0.7-1.3	9.2	1.6	1.2-2.2	3.6	0.5	0.3-0.9
Lung and bronchus	871.6	68.1	66.1-70.2	400.0	71.8	68.6-75.1	471.6	66.0	63.3-68.8	498.0	38.5	37.0-40.1	240.6	43.7	41.2-46.4	257.4	34.8	32.9-36.9
Pleura	1.2	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.6	0.1	0.0-0.3	0.8	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.2	0.0	0.0-0.2
Trachea, mediastinum, other respiratory	1.4	0.1	0.1-0.3	0.8	0.2	0.0-0.4	0.6	0.1	0.0-0.4	1.0	0.1	0.0-0.2	0.4	0.1	0.0-0.3	0.6	0.1	0.0-0.3
Bones & joints	9.4	1.0	0.7-1.3	4.0	0.8	0.5-1.3	5.4	1.0	0.7-1.5	4.0	0.4	0.2-0.6	2.2	0.4	0.2-0.8	1.8	0.3	0.1-0.6
Soft tissue (including heart)	44.2	4.0	3.5-4.6	23.4	4.6	3.7-5.5	20.8	3.6	2.9-4.5	17.4	1.5	1.2-1.8	10.6	2.1	1.6-2.8	6.8	1.0	0.7-1.5
Skin*	386.4	32.8	31.3-34.4	217.8	39.9	37.5-42.5	168.6	28.0	26.0-30.1	41.8	3.2	2.8-3.7	26.6	5.0	4.2-5.9	15.2	2.0	1.5-2.5
Melanoma of the skin	354.4	30.0	28.6-31.5	200.8	36.7	34.4-39.1	153.6	25.6	23.7-27.6	28.8	2.3	1.9-2.7	18.2	3.4	2.7-4.2	10.6	1.4	1.0-1.9
Breast	894.4	76.9	74.6-79.3	8.6	1.5	1.1-2.1	885.8	141.6	137.2-146.1	154.2	12.4	11.5-13.3	1.8	0.4	0.2-0.7	152.4	21.7	20.1-23.4
Breast (in situ)#	226.4	20.7	19.4-22.0	0.8	0.2	0.0-0.4	225.6	39.0	36.6-41.5									
Female genital system							373.2	58.5	55.7-61.4							117.6	17.2	15.8-18.7
Cervix uteri							34.6	7.1	6.0-8.3							12.0	2.0	1.5-2.6
Corpus uterus and NOS							220.6	33.3	31.2-35.4							38.4	5.4	4.7-6.3
Ovary							71.4	11.1	9.9-12.4							55.4	8.1	7.2-9.2
Vagina							4.4	0.7	0.4-1.1							1.8	0.3	0.1-0.6
Vulva							25.4	3.9	3.3-4.8							7.0	0.9	0.6-1.3
Other female genital organs							16.8	2.5	1.9-3.1							3.0	0.4	0.2-0.7
Male genital system				889.6	149.6	145.1-154.2							100.4	19.1	17.5-20.9			
Prostate				854.8	141.8	137.5-146.2							98.0	18.7	17.0-20.4			
Testis				28.2	6.6	5.5-7.8							0.6	0.1	0.0-0.4			
Penis				6.2	1.2	0.8-1.7							1.6	0.3	0.1-0.6			
Other male genital organs				0.4	0.1	0.0-0.3							0.2	0.0	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Erie

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	580.0	46.6	44.9-48.4	392.0	72.0	68.7-75.3	188.0	27.2	25.4-29.0	103.0	8.0	7.3-8.8	64.8	12.3	10.9-13.7	38.2	5.1	4.4-5.9
Urinary bladder (including in situ)	343.4	27.0	25.7-28.3	242.0	44.4	41.8-47.0	101.4	13.9	12.7-15.3	60.8	4.7	4.2-5.3	40.2	7.8	6.7-9.0	20.6	2.7	2.2-3.3
Kidney and renal pelvis	222.8	18.6	17.4-19.7	139.8	25.7	23.8-27.8	83.0	12.8	11.5-14.1	39.2	3.1	2.7-3.6	22.8	4.1	3.4-5.0	16.4	2.3	1.8-2.9
Ureter	8.6	0.7	0.5-0.9	5.8	1.1	0.7-1.5	2.8	0.4	0.2-0.6	1.2	0.1	0.0-0.2	0.8	0.2	0.0-0.4	0.4	0.0	0.0-0.2
Other urinary organs	5.2	0.4	0.2-0.6	4.4	0.8	0.5-1.2	0.8	0.1	0.0-0.3	1.8	0.1	0.1-0.3	1.0	0.2	0.1-0.5	0.8	0.1	0.0-0.3
Eye & orbit	8.4	0.8	0.5-1.0	4.4	0.9	0.5-1.3	4.0	0.7	0.4-1.1	1.0	0.1	0.0-0.2	0.6	0.1	0.0-0.3	0.4	0.1	0.0-0.3
Brain / other central nervous system (all behaviors)	254.0	22.9	21.6-24.3	103.8	20.2	18.4-22.1	150.2	25.6	23.7-27.6	59.4	5.0	4.4-5.6	32.6	6.2	5.3-7.3	26.8	4.0	3.3-4.8
Malignant brain / other central nervous system	76.0	7.3	6.5-8.1	43.8	8.9	7.7-10.2	32.2	6.0	5.0-7.1	50.0	4.2	3.7-4.8	28.4	5.4	4.5-6.4	21.6	3.3	2.7-4.0
Malignant brain	70.0	6.5	5.9-7.3	40.2	8.0	6.9-9.2	29.8	5.4	4.5-6.4									
Malignant other central nervous system	6.0	0.7	0.5-1.1	3.6	0.9	0.5-1.4	2.4	0.6	0.3-1.1									
Benign brain / other central nervous system#	178.0	15.6	14.6-16.8	60.0	11.3	10.0-12.7	118.0	19.6	17.9-21.3	9.4	0.8	0.6-1.0	4.2	0.9	0.5-1.4	5.2	0.7	0.4-1.1
Benign brain	18.2	1.8	1.4-2.2	7.8	1.6	1.1-2.2	10.4	2.1	1.5-2.7									
Benign other central nervous system	159.8	13.8	12.8-14.9	52.2	9.7	8.6-11.1	107.6	17.5	16.0-19.2									
Endocrine system	154.8	16.1	14.9-17.4	46.0	9.6	8.4-11.0	108.8	22.4	20.5-24.5	8.0	0.7	0.5-1.0	3.6	0.8	0.4-1.2	4.4	0.6	0.4-1.0
Thyroid	146.2	15.3	14.2-16.5	42.8	8.9	7.7-10.3	103.4	21.5	19.6-23.5	4.4	0.4	0.2-0.6	2.2	0.5	0.2-0.9	2.2	0.3	0.1-0.5
Other endocrine (including thymus)	8.6	0.8	0.6-1.1	3.2	0.7	0.4-1.1	5.4	0.9	0.6-1.4	3.6	0.3	0.2-0.5	1.4	0.3	0.1-0.6	2.2	0.4	0.2-0.7
Lymphomas	307.2	26.1	24.7-27.5	166.0	31.7	29.5-34.0	141.2	21.7	20.1-23.5	75.0	5.9	5.3-6.5	46.4	8.8	7.7-10.1	28.6	3.9	3.3-4.7
Hodgkin lymphoma	29.6	3.0	2.5-3.6	17.4	3.8	3.0-4.7	12.2	2.4	1.8-3.1	2.4	0.2	0.1-0.3	1.2	0.2	0.1-0.5	1.2	0.2	0.1-0.4
Non-Hodgkin lymphomas	277.6	23.0	21.8-24.3	148.6	27.9	25.9-30.1	129.0	19.4	17.8-21.0	72.6	5.7	5.1-6.3	45.2	8.6	7.5-9.8	27.4	3.8	3.2-4.5
Myeloma	101.2	8.2	7.5-9.0	51.0	9.5	8.3-10.8	50.2	7.4	6.4-8.4	35.6	2.8	2.4-3.3	19.4	3.8	3.0-4.6	16.2	2.2	1.7-2.7
Leukemias	220.2	18.6	17.4-19.7	132.4	25.1	23.1-27.1	87.8	13.4	12.1-14.8	83.0	6.6	5.9-7.3	49.8	9.7	8.5-11.0	33.2	4.3	3.7-5.1
Lymphocytic leukemias	110.8	9.3	8.5-10.2	71.0	13.1	11.8-14.7	39.8	6.2	5.3-7.2	21.4	1.7	1.4-2.1	13.2	2.6	2.0-3.3	8.2	1.1	0.8-1.5
Acute lymphocytic leukemia	14.6	1.8	1.4-2.2	7.2	1.8	1.2-2.5	7.4	1.7	1.2-2.4	5.2	0.5	0.3-0.8	2.8	0.6	0.3-1.1	2.4	0.4	0.2-0.8
Chronic lymphocytic leukemia	89.2	6.9	6.3-7.6	58.6	10.3	9.1-11.6	30.6	4.2	3.5-5.0	15.2	1.1	0.9-1.4	9.8	1.8	1.3-2.4	5.4	0.6	0.4-0.9
Other lymphocytic leukemias	7.0	0.6	0.4-0.9	5.2	1.1	0.7-1.6	1.8	0.3	0.1-0.5	1.0	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.4	0.1	0.0-0.2
Myeloid and monocytic leukemias	96.6	8.1	7.4-8.9	56.0	10.8	9.5-12.2	40.6	6.1	5.3-7.1	47.6	3.8	3.3-4.3	30.0	5.7	4.8-6.7	17.6	2.4	1.9-3.0
Acute myeloid leukemia	66.2	5.4	4.8-6.1	37.8	7.1	6.1-8.3	28.4	4.2	3.5-5.0	42.8	3.4	2.9-3.9	27.2	5.2	4.3-6.1	15.6	2.1	1.7-2.7
Acute monocytic leukemia	3.2	0.3	0.2-0.5	1.8	0.4	0.2-0.7	1.4	0.2	0.1-0.5	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Chronic myeloid leukemia	26.2	2.3	1.9-2.8	15.6	3.1	2.5-3.9	10.6	1.7	1.2-2.2	2.4	0.2	0.1-0.3	1.2	0.2	0.1-0.5	1.2	0.1	0.0-0.4
Other myeloid/monocytic leukemias	1.0	0.1	0.0-0.2	0.8	0.1	0.0-0.4	0.2	0.0	0.0-0.2	2.2	0.2	0.1-0.3	1.4	0.3	0.1-0.6	0.8	0.1	0.0-0.3
Other leukemias	12.8	1.1	0.9-1.5	5.4	1.1	0.7-1.7	7.4	1.1	0.8-1.6	14.0	1.1	0.9-1.4	6.6	1.4	0.9-1.9	7.4	0.9	0.6-1.2
Other acute leukemias	4.6	0.4	0.2-0.6	2.0	0.5	0.2-0.8	2.6	0.3	0.2-0.6	5.4	0.4	0.3-0.7	2.2	0.5	0.2-0.9	3.2	0.4	0.2-0.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Erie

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	8.2	0.7	0.5-1.0	3.4	0.7	0.4-1.1	4.8	0.8	0.5-1.2	8.6	0.7	0.5-0.9	4.4	0.9	0.6-1.4	4.2	0.5	0.3-0.8
Mesothelioma	11.6	1.0	0.7-1.2	8.6	1.7	1.2-2.3	3.0	0.5	0.3-0.8									
Kaposi sarcoma	1.6	0.1	0.1-0.3	1.4	0.3	0.1-0.6	0.2	0.0	0.0-0.2									
Myelodysplastic syndromes	65.2	5.1	4.6-5.7	36.2	7.0	6.0-8.1	29.0	3.8	3.2-4.5									
Chronic myeloproliferative disorders [^]	74.2	6.2	5.6-6.9	33.4	6.1	5.2-7.2	40.8	6.3	5.4-7.3									
All defined and unspecified sites	145.6	11.6	10.7-12.5	72.6	13.9	12.4-15.4	73.0	9.9	8.9-11.1	199.8	15.4	14.4-16.4	97.8	18.1	16.5-19.8	102.0	13.5	12.3-14.8

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Monroe

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	4,829.6	506.8	500.3-513.5	2,455.4	562.4	552.2-572.7	2,374.2	469.0	460.2-477.9	1,483.6	150.6	147.2-154.2	746.0	176.3	170.6-182.2	737.6	133.7	129.3-138.3
Oral cavity and pharynx	118.2	12.2	11.2-13.3	78.8	17.9	16.1-19.8	39.4	7.3	6.3-8.5	23.6	2.3	1.9-2.8	16.6	3.7	2.9-4.6	7.0	1.2	0.8-1.7
Lip	2.8	0.3	0.2-0.5	1.6	0.4	0.2-0.8	1.2	0.2	0.1-0.5	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Tongue	37.0	3.8	3.3-4.4	23.4	5.3	4.3-6.4	13.6	2.5	1.9-3.2	5.6	0.6	0.4-0.8	3.8	0.8	0.5-1.4	1.8	0.3	0.1-0.7
Salivary gland	11.4	1.2	0.9-1.6	7.8	1.9	1.3-2.6	3.6	0.7	0.4-1.2	1.8	0.2	0.1-0.4	1.2	0.3	0.1-0.6	0.6	0.1	0.0-0.4
Floor of mouth	6.2	0.7	0.5-1.0	4.4	1.1	0.7-1.7	1.8	0.3	0.1-0.6	0.2	0.0	0.0-0.1	0.2	0.1	0.0-0.3	0.0	0.0	0.0-0.2
Gum & other mouth	18.0	1.9	1.5-2.3	7.2	1.6	1.1-2.3	10.8	2.1	1.5-2.7	4.6	0.5	0.3-0.7	3.0	0.7	0.4-1.2	1.6	0.3	0.1-0.6
Nasopharynx	3.2	0.3	0.2-0.6	3.0	0.7	0.4-1.2	0.2	0.0	0.0-0.2	1.2	0.1	0.0-0.3	1.0	0.2	0.1-0.5	0.2	0.0	0.0-0.3
Tonsil	23.6	2.4	1.9-2.9	18.6	4.0	3.2-5.0	5.0	0.9	0.6-1.4	2.8	0.3	0.2-0.5	2.4	0.5	0.3-0.9	0.4	0.1	0.0-0.3
Oropharynx	7.6	0.8	0.5-1.1	6.2	1.4	0.9-2.0	1.4	0.2	0.1-0.5	2.6	0.2	0.1-0.4	1.2	0.2	0.1-0.6	1.4	0.2	0.1-0.5
Hypopharynx	7.2	0.7	0.5-1.0	5.6	1.3	0.8-1.8	1.6	0.3	0.1-0.6	1.6	0.2	0.1-0.3	1.4	0.3	0.1-0.7	0.2	0.0	0.0-0.3
Other buccal cavity and pharynx	1.2	0.1	0.0-0.3	1.0	0.2	0.1-0.5	0.2	0.0	0.0-0.2	3.2	0.3	0.2-0.5	2.4	0.5	0.3-0.9	0.8	0.1	0.0-0.4
Digestive system	757.6	79.0	76.4-81.6	409.8	95.1	90.9-99.4	347.8	66.1	62.9-69.4	396.4	40.0	38.3-41.9	219.0	50.5	47.5-53.7	177.4	31.9	29.7-34.1
Esophagus	44.8	4.5	3.9-5.2	33.4	7.6	6.5-8.9	11.4	2.0	1.5-2.7	45.2	4.5	3.9-5.2	33.4	7.7	6.5-9.0	11.8	2.1	1.6-2.7
Stomach	61.2	6.5	5.7-7.3	38.2	9.0	7.7-10.4	23.0	4.5	3.7-5.5	25.0	2.5	2.1-3.0	14.8	3.4	2.7-4.3	10.2	1.8	1.4-2.5
Small intestine	27.4	2.9	2.4-3.5	15.2	3.6	2.8-4.6	12.2	2.3	1.8-3.1	4.6	0.5	0.3-0.8	2.8	0.7	0.4-1.1	1.8	0.4	0.2-0.8
Colorectal	338.2	36.1	34.3-37.9	173.8	41.1	38.3-44.0	164.4	32.1	29.8-34.5	122.6	12.4	11.4-13.5	63.0	14.7	13.1-16.5	59.6	10.6	9.4-12.0
Colon excluding rectum	241.6	25.7	24.2-27.3	118.8	28.3	26.0-30.8	122.8	23.7	21.8-25.8	94.8	9.6	8.8-10.6	46.6	11.0	9.6-12.5	48.2	8.6	7.5-9.8
Cecum	44.4	4.5	4.0-5.2	20.8	4.9	4.0-6.0	23.6	4.4	3.6-5.3									
Appendix	21.4	2.7	2.2-3.2	10.6	2.7	2.0-3.5	10.8	2.7	2.0-3.6									
Ascending colon	45.0	4.6	4.0-5.2	20.6	4.7	3.8-5.7	24.4	4.5	3.7-5.4									
Hepatic flexure	14.6	1.5	1.2-1.9	6.8	1.7	1.2-2.4	7.8	1.4	1.0-2.0									
Transverse colon	21.4	2.3	1.9-2.8	9.0	2.1	1.6-2.9	12.4	2.4	1.8-3.2									
Splenic flexure	5.8	0.6	0.4-0.9	2.4	0.6	0.3-1.1	3.4	0.6	0.4-1.0									
Descending colon	13.0	1.4	1.1-1.9	7.4	1.8	1.3-2.5	5.6	1.2	0.8-1.7									
Sigmoid colon	62.4	6.7	5.9-7.5	36.2	8.5	7.3-10.0	26.2	5.0	4.1-6.0									
Large intestine, NOS	13.6	1.4	1.1-1.8	5.0	1.3	0.8-1.9	8.6	1.6	1.1-2.1									
Rectum & rectosigmoid	96.6	10.4	9.4-11.4	55.0	12.7	11.2-14.4	41.6	8.4	7.2-9.6	27.8	2.8	2.3-3.3	16.4	3.7	2.9-4.6	11.4	2.0	1.5-2.7
Rectosigmoid junction	17.0	1.8	1.4-2.2	9.8	2.2	1.6-2.9	7.2	1.5	1.0-2.1									
Rectum	79.6	8.6	7.7-9.5	45.2	10.6	9.2-12.1	34.4	6.9	5.9-8.1									
Anus, anal canal & anorectum	19.8	1.9	1.6-2.4	6.4	1.3	0.9-1.9	13.4	2.5	1.9-3.2	3.2	0.3	0.2-0.5	0.4	0.1	0.0-0.3	2.8	0.5	0.3-0.9
Liver and intrahepatic bile duct	72.0	7.2	6.4-8.0	46.8	10.2	8.9-11.6	25.2	4.7	3.9-5.6	57.6	5.8	5.2-6.6	35.8	8.1	6.9-9.4	21.8	4.2	3.4-5.1

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Monroe

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	51.0	5.0	4.4-5.7	38.2	8.1	7.0-9.4	12.8	2.3	1.8-3.0	34.0	3.4	2.9-4.0	24.8	5.5	4.5-6.6	9.2	1.8	1.3-2.4
Intrahepatic bile duct	21.0	2.2	1.8-2.7	8.6	2.0	1.5-2.8	12.4	2.3	1.8-3.1	23.6	2.5	2.0-3.0	11.0	2.6	2.0-3.5	12.6	2.4	1.8-3.0
Gallbladder	10.6	1.0	0.8-1.4	4.4	0.9	0.6-1.4	6.2	1.1	0.8-1.7	4.0	0.4	0.2-0.6	1.0	0.2	0.1-0.5	3.0	0.6	0.3-1.0
Other biliary	15.4	1.5	1.2-1.9	7.6	1.7	1.2-2.4	7.8	1.4	1.0-2.0	4.8	0.5	0.3-0.7	1.4	0.3	0.1-0.7	3.4	0.5	0.3-0.9
Pancreas	147.0	15.1	14.0-16.3	75.4	17.7	15.9-19.6	71.6	13.0	11.6-14.5	123.0	12.4	11.4-13.5	63.8	14.8	13.2-16.6	59.2	10.5	9.3-11.8
Retroperitoneum	5.4	0.6	0.4-0.9	3.0	0.7	0.4-1.1	2.4	0.5	0.2-0.9	1.2	0.1	0.0-0.3	0.4	0.1	0.0-0.3	0.8	0.1	0.0-0.4
Peritoneum, omentum & mesentery	5.8	0.6	0.4-0.8	0.2	0.1	0.0-0.3	5.6	1.0	0.7-1.5	2.2	0.2	0.1-0.4	0.4	0.1	0.0-0.4	1.8	0.4	0.2-0.7
Other digestive organs	10.0	1.0	0.8-1.4	5.4	1.3	0.8-1.9	4.6	0.9	0.5-1.3	3.0	0.3	0.2-0.5	1.8	0.4	0.2-0.7	1.2	0.2	0.1-0.5
Respiratory system	651.8	65.3	63.0-67.6	323.8	73.4	69.8-77.2	328.0	59.7	56.8-62.8	358.6	36.0	34.4-37.8	189.4	44.0	41.1-46.9	169.2	30.4	28.3-32.6
Nasal cavity, middle ear & sinuses	9.2	1.0	0.7-1.4	5.2	1.3	0.8-1.9	4.0	0.8	0.5-1.3	2.4	0.2	0.1-0.4	1.2	0.3	0.1-0.6	1.2	0.2	0.1-0.5
Larynx	27.2	2.7	2.3-3.2	20.4	4.5	3.6-5.5	6.8	1.3	0.9-1.9	9.0	0.9	0.6-1.2	6.2	1.3	0.9-1.9	2.8	0.5	0.3-0.9
Lung and bronchus	614.6	61.5	59.3-63.7	297.8	67.6	64.1-71.2	316.8	57.5	54.6-60.4	346.0	34.8	33.1-36.5	180.8	42.0	39.3-44.9	165.2	29.7	27.6-31.8
Pleura	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2	0.4	0.0	0.0-0.2	0.4	0.1	0.0-0.4	0.0	0.0	0.0-0.2
Trachea, mediastinum, other respiratory	0.8	0.1	0.0-0.2	0.4	0.1	0.0-0.4	0.4	0.1	0.0-0.3	0.8	0.1	0.0-0.3	0.8	0.2	0.1-0.6	0.0	0.0	0.0-0.2
Bones & joints	7.6	1.0	0.7-1.4	3.4	0.9	0.5-1.5	4.2	1.1	0.6-1.7	4.6	0.5	0.3-0.8	2.8	0.7	0.4-1.2	1.8	0.4	0.2-0.7
Soft tissue (including heart)	29.0	3.3	2.7-3.9	18.0	4.5	3.6-5.6	11.0	2.2	1.7-3.0	10.2	1.2	0.9-1.6	4.8	1.2	0.7-1.8	5.4	1.2	0.8-1.8
Skin*	272.6	30.1	28.5-31.9	151.4	36.6	34.0-39.4	121.2	26.0	23.9-28.3	28.0	2.9	2.4-3.4	18.0	4.4	3.6-5.5	10.0	1.8	1.3-2.5
Melanoma of the skin	245.8	27.3	25.8-29.0	134.2	32.6	30.1-35.2	111.6	24.0	22.0-26.2	17.8	1.8	1.5-2.3	11.0	2.7	2.0-3.5	6.8	1.2	0.8-1.8
Breast	731.2	80.4	77.7-83.2	4.8	1.1	0.7-1.7	726.4	148.1	143.1-153.3	98.6	10.4	9.4-11.3	0.4	0.1	0.0-0.3	98.2	18.5	16.8-20.3
Breast (in situ)#	162.2	18.2	16.9-19.6	1.2	0.3	0.1-0.7	161.0	33.9	31.4-36.4									
Female genital system							274.2	53.7	50.8-56.8							89.8	16.1	14.6-17.7
Cervix uteri							23.0	5.5	4.4-6.6							8.8	1.9	1.3-2.5
Corpus uterus and NOS							171.4	32.5	30.3-34.8							38.6	6.8	5.8-7.8
Ovary							47.0	9.6	8.3-11.0							34.0	6.1	5.2-7.1
Vagina							2.0	0.3	0.2-0.6							0.8	0.1	0.0-0.4
Vulva							14.0	2.7	2.1-3.5							3.4	0.5	0.3-0.9
Other female genital organs							16.8	3.1	2.5-3.9							4.2	0.7	0.5-1.2
Male genital system				743.8	160.8	155.5-166.2							78.4	19.4	17.5-21.5			
Prostate				715.2	152.5	147.5-157.8							77.8	19.2	17.4-21.3			
Testis				26.4	7.8	6.5-9.2							0.6	0.2	0.0-0.5			
Penis				1.4	0.3	0.1-0.7							0.0	0.0	0.0-0.2			
Other male genital organs				0.8	0.2	0.0-0.5							0.0	0.0	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Monroe

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	428.0	44.4	42.5-46.4	305.6	71.6	67.9-75.3	122.4	23.4	21.5-25.4	71.6	7.1	6.4-7.9	47.6	11.4	10.0-13.0	24.0	4.0	3.3-4.9
Urinary bladder (including in situ)	234.0	23.6	22.2-25.0	175.4	41.1	38.4-44.0	58.6	10.5	9.3-11.8	40.2	4.0	3.4-4.6	27.8	6.8	5.7-8.0	12.4	2.0	1.5-2.6
Kidney and renal pelvis	183.8	19.8	18.5-21.2	123.4	28.8	26.5-31.3	60.4	12.2	10.8-13.8	29.8	3.0	2.5-3.5	19.0	4.5	3.6-5.5	10.8	1.9	1.4-2.5
Ureter	6.6	0.7	0.5-1.0	4.2	1.0	0.6-1.5	2.4	0.4	0.2-0.8	0.6	0.1	0.0-0.2	0.2	0.1	0.0-0.3	0.4	0.1	0.0-0.3
Other urinary organs	3.6	0.4	0.2-0.6	2.6	0.6	0.3-1.1	1.0	0.2	0.1-0.5	1.0	0.1	0.0-0.3	0.6	0.1	0.0-0.4	0.4	0.1	0.0-0.4
Eye & orbit	6.0	0.7	0.4-1.0	1.4	0.3	0.1-0.6	4.6	1.0	0.6-1.6	1.4	0.1	0.1-0.3	0.6	0.1	0.0-0.5	0.8	0.1	0.0-0.4
Brain / other central nervous system (all behaviors)	184.8	21.1	19.7-22.6	75.2	18.7	16.8-20.8	109.6	23.3	21.2-25.4	49.2	5.4	4.8-6.2	25.8	6.3	5.2-7.5	23.4	4.8	3.9-5.8
Malignant brain / other central nervous system	53.8	6.3	5.5-7.1	28.6	7.1	6.0-8.5	25.2	5.6	4.6-6.7	41.0	4.6	3.9-5.3	21.8	5.3	4.3-6.5	19.2	4.0	3.2-5.0
Malignant brain	52.4	6.1	5.3-6.9	28.2	7.1	5.9-8.4	24.2	5.3	4.3-6.4									
Malignant other central nervous system	1.4	0.2	0.1-0.4	0.4	0.1	0.0-0.4	1.0	0.3	0.1-0.7									
Benign brain / other central nervous system#	131.0	14.9	13.7-16.1	46.6	11.6	10.1-13.2	84.4	17.7	15.9-19.5	8.2	0.9	0.6-1.2	4.0	1.0	0.6-1.6	4.2	0.8	0.5-1.2
Benign brain	10.4	1.3	1.0-1.8	6.2	1.6	1.1-2.3	4.2	1.1	0.7-1.7									
Benign other central nervous system	120.6	13.5	12.4-14.7	40.4	10.0	8.6-11.5	80.2	16.6	14.9-18.4									
Endocrine system	122.0	15.1	13.9-16.4	40.4	10.3	8.9-11.9	81.6	19.6	17.7-21.7	6.0	0.6	0.4-0.9	2.2	0.5	0.3-1.0	3.8	0.7	0.4-1.1
Thyroid	117.0	14.5	13.3-15.8	37.8	9.6	8.2-11.1	79.2	19.1	17.1-21.1	4.8	0.5	0.3-0.8	1.6	0.4	0.2-0.8	3.2	0.6	0.3-1.0
Other endocrine (including thymus)	5.0	0.6	0.4-1.0	2.6	0.7	0.4-1.3	2.4	0.6	0.3-1.0	1.2	0.1	0.0-0.3	0.6	0.1	0.0-0.4	0.6	0.1	0.0-0.4
Lymphomas	232.0	25.4	23.9-27.0	127.8	30.9	28.5-33.5	104.2	21.0	19.2-23.0	58.2	5.9	5.2-6.6	30.6	7.4	6.2-8.7	27.6	4.8	4.0-5.7
Hodgkin lymphoma	26.8	3.6	3.0-4.2	16.8	4.7	3.7-5.9	10.0	2.6	1.9-3.4	2.8	0.3	0.2-0.5	2.0	0.5	0.2-0.9	0.8	0.1	0.0-0.4
Non-Hodgkin lymphomas	205.2	21.8	20.5-23.3	111.0	26.2	24.0-28.6	94.2	18.5	16.8-20.3	55.4	5.6	5.0-6.3	28.6	6.9	5.8-8.1	26.8	4.7	3.9-5.6
Myeloma	70.2	7.1	6.4-7.9	41.4	9.5	8.3-11.0	28.8	5.3	4.4-6.3	28.8	2.9	2.4-3.4	15.0	3.6	2.8-4.5	13.8	2.4	1.8-3.0
Leukemias	138.6	14.7	13.6-15.9	80.6	19.1	17.3-21.2	58.0	11.2	9.9-12.6	58.6	6.1	5.4-6.9	34.4	8.5	7.2-9.9	24.2	4.4	3.6-5.4
Lymphocytic leukemias	72.8	7.6	6.8-8.4	42.4	9.9	8.5-11.3	30.4	5.6	4.8-6.7	15.0	1.6	1.2-2.0	9.6	2.5	1.8-3.3	5.4	1.0	0.6-1.5
Acute lymphocytic leukemia	6.8	0.9	0.6-1.3	4.4	1.2	0.7-1.8	2.4	0.6	0.3-1.1	2.6	0.3	0.2-0.6	1.6	0.4	0.2-0.9	1.0	0.3	0.1-0.6
Chronic lymphocytic leukemia	60.6	6.1	5.4-6.8	35.0	7.9	6.8-9.3	25.6	4.6	3.8-5.5	11.4	1.1	0.9-1.5	7.6	1.9	1.4-2.7	3.8	0.6	0.3-1.0
Other lymphocytic leukemias	5.4	0.6	0.4-0.9	3.0	0.7	0.4-1.2	2.4	0.5	0.2-0.8	1.0	0.1	0.0-0.3	0.4	0.1	0.0-0.4	0.6	0.1	0.0-0.4
Myeloid and monocytic leukemias	59.4	6.5	5.7-7.3	34.6	8.4	7.2-9.8	24.8	5.0	4.1-6.0	35.4	3.7	3.2-4.3	20.4	4.9	4.0-6.0	15.0	2.9	2.2-3.7
Acute myeloid leukemia	38.6	4.2	3.6-4.9	23.2	5.6	4.6-6.7	15.4	3.2	2.5-4.0	27.0	2.9	2.4-3.4	16.4	3.9	3.1-4.9	10.6	2.1	1.6-2.8
Acute monocytic leukemia	2.4	0.3	0.2-0.5	1.6	0.4	0.2-0.8	0.8	0.2	0.0-0.5	0.6	0.1	0.0-0.2	0.2	0.1	0.0-0.3	0.4	0.1	0.0-0.3
Chronic myeloid leukemia	18.0	1.9	1.6-2.4	9.8	2.5	1.8-3.3	8.2	1.5	1.1-2.1	3.6	0.4	0.2-0.6	1.6	0.4	0.2-0.8	2.0	0.4	0.2-0.7
Other myeloid/monocytic leukemias	0.4	0.0	0.0-0.2	0.0	0.0	0.0-0.2	0.4	0.1	0.0-0.4	4.2	0.4	0.3-0.6	2.2	0.5	0.3-1.0	2.0	0.3	0.1-0.6
Other leukemias	6.4	0.7	0.4-0.9	3.6	0.8	0.5-1.3	2.8	0.5	0.3-0.9	8.2	0.8	0.6-1.1	4.4	1.1	0.7-1.6	3.8	0.6	0.3-1.0
Other acute leukemias	1.8	0.2	0.1-0.3	0.8	0.2	0.0-0.5	1.0	0.2	0.1-0.4	3.8	0.4	0.2-0.6	2.4	0.6	0.3-1.0	1.4	0.2	0.1-0.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Monroe

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	4.6	0.5	0.3-0.8	2.8	0.7	0.4-1.1	1.8	0.4	0.2-0.8	4.4	0.4	0.3-0.7	2.0	0.5	0.2-1.0	2.4	0.4	0.2-0.7
Mesothelioma	7.0	0.8	0.5-1.1	4.6	1.2	0.7-1.8	2.4	0.5	0.2-0.9									
Kaposi sarcoma	1.8	0.2	0.1-0.4	1.6	0.4	0.2-0.8	0.2	0.0	0.0-0.2									
Myelodysplastic syndromes	43.0	4.3	3.7-4.9	26.2	6.3	5.2-7.5	16.8	3.0	2.4-3.8									
Chronic myeloproliferative disorders [^]	44.2	4.8	4.1-5.5	18.6	4.5	3.6-5.5	25.6	4.9	4.1-5.9									
Ill defined and unspecified sites	97.0	9.8	9.0-10.8	44.8	10.8	9.4-12.3	52.2	9.2	8.1-10.5	129.8	13.3	12.2-14.4	64.4	15.5	13.8-17.4	65.4	11.8	10.5-13.2

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Nassau

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	8,934.0	499.4	494.6-504.2	4,430.6	537.4	530.2-544.7	4,503.4	476.2	469.6-482.7	2,332.8	122.6	120.3-124.9	1,131.2	139.5	135.8-143.3	1,201.6	111.3	108.4-114.3
Oral cavity and pharynx	195.4	10.9	10.2-11.7	128.8	15.7	14.4-17.0	66.6	7.0	6.2-7.8	30.6	1.6	1.4-1.9	16.8	2.1	1.6-2.6	13.8	1.2	0.9-1.5
Lip	6.2	0.3	0.2-0.5	3.6	0.4	0.3-0.7	2.6	0.2	0.1-0.4	0.6	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.4	0.0	0.0-0.1
Tongue	62.2	3.5	3.1-3.9	42.4	5.1	4.4-5.9	19.8	2.0	1.6-2.5	7.4	0.4	0.3-0.5	4.2	0.5	0.3-0.8	3.2	0.3	0.2-0.5
Salivary gland	27.8	1.6	1.4-2.0	14.8	1.9	1.5-2.5	13.0	1.4	1.1-1.9	4.2	0.2	0.1-0.4	1.8	0.2	0.1-0.5	2.4	0.2	0.1-0.4
Floor of mouth	6.2	0.3	0.2-0.5	4.2	0.5	0.3-0.7	2.0	0.2	0.1-0.4	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Gum & other mouth	29.8	1.7	1.4-2.0	15.6	2.0	1.6-2.5	14.2	1.5	1.2-1.9	5.6	0.3	0.2-0.4	2.0	0.3	0.1-0.5	3.6	0.3	0.2-0.4
Nasopharynx	10.8	0.7	0.5-0.9	7.4	1.0	0.7-1.3	3.4	0.4	0.2-0.7	3.2	0.2	0.1-0.3	2.8	0.3	0.2-0.6	0.4	0.0	0.0-0.2
Tonsil	30.4	1.7	1.4-2.0	25.2	2.9	2.4-3.5	5.2	0.5	0.3-0.8	2.6	0.1	0.1-0.3	1.6	0.2	0.1-0.4	1.0	0.1	0.0-0.3
Oropharynx	9.8	0.5	0.4-0.7	7.2	0.8	0.6-1.2	2.6	0.3	0.1-0.5	3.6	0.2	0.1-0.3	2.2	0.3	0.1-0.5	1.4	0.1	0.0-0.3
Hypopharynx	9.2	0.5	0.4-0.7	6.4	0.8	0.5-1.1	2.8	0.3	0.1-0.5	1.0	0.1	0.0-0.1	0.6	0.1	0.0-0.2	0.4	0.0	0.0-0.2
Other buccal cavity and pharynx	3.0	0.1	0.1-0.3	2.0	0.2	0.1-0.4	1.0	0.1	0.0-0.2	2.4	0.1	0.1-0.2	1.4	0.2	0.1-0.4	1.0	0.1	0.0-0.2
Digestive system	1,492.2	81.6	79.7-83.6	788.6	96.4	93.3-99.5	703.6	69.7	67.3-72.2	652.6	34.3	33.1-35.6	350.6	42.8	40.8-44.9	302.0	27.5	26.1-29.0
Esophagus	71.0	3.8	3.4-4.2	51.8	6.3	5.5-7.1	19.2	1.7	1.4-2.1	53.6	2.9	2.5-3.2	42.0	5.2	4.5-5.9	11.6	1.0	0.8-1.3
Stomach	150.4	8.3	7.7-8.9	86.6	10.6	9.6-11.7	63.8	6.4	5.7-7.2	48.8	2.6	2.3-3.0	26.2	3.2	2.7-3.9	22.6	2.1	1.7-2.6
Small intestine	53.2	3.0	2.7-3.4	32.4	4.0	3.4-4.6	20.8	2.2	1.8-2.8	5.8	0.3	0.2-0.5	3.2	0.4	0.2-0.7	2.6	0.3	0.1-0.5
Colorectal	660.4	37.0	35.7-38.3	328.6	40.9	38.9-43.0	331.8	33.8	32.1-35.5	203.0	10.7	10.1-11.4	99.8	12.5	11.4-13.7	103.2	9.3	8.5-10.2
Colon excluding rectum	480.8	26.7	25.6-27.8	229.2	28.5	26.8-30.3	251.6	25.3	23.8-26.8	167.0	8.8	8.2-9.4	77.0	9.7	8.7-10.7	90.0	8.0	7.3-8.9
Cecum	89.8	4.8	4.4-5.3	39.2	4.8	4.2-5.6	50.6	4.7	4.2-5.4									
Appendix	34.4	2.3	2.0-2.7	14.0	1.9	1.5-2.4	20.4	2.7	2.2-3.3									
Ascending colon	99.8	5.3	4.8-5.8	44.8	5.4	4.7-6.2	55.0	5.2	4.6-5.9									
Hepatic flexure	21.2	1.2	1.0-1.5	11.6	1.5	1.1-1.9	9.6	0.9	0.7-1.3									
Transverse colon	40.2	2.2	1.9-2.5	20.0	2.5	2.1-3.1	20.2	1.9	1.6-2.4									
Splenic flexure	11.2	0.6	0.5-0.8	6.0	0.8	0.5-1.1	5.2	0.5	0.3-0.7									
Descending colon	27.2	1.6	1.3-1.9	16.6	2.0	1.6-2.6	10.6	1.2	0.9-1.5									
Sigmoid colon	125.8	7.1	6.5-7.7	64.0	7.9	7.0-8.8	61.8	6.4	5.7-7.3									
Large intestine, NOS	31.2	1.6	1.4-1.9	13.0	1.6	1.2-2.0	18.2	1.6	1.3-2.1									
Rectum & rectosigmoid	179.6	10.3	9.6-11.1	99.4	12.4	11.3-13.6	80.2	8.5	7.6-9.4	36.0	2.0	1.7-2.3	22.8	2.8	2.3-3.4	13.2	1.3	1.0-1.6
Rectosigmoid junction	49.0	2.8	2.5-3.2	23.8	2.9	2.4-3.5	25.2	2.7	2.2-3.2									
Rectum	130.6	7.5	6.9-8.1	75.6	9.5	8.6-10.6	55.0	5.8	5.1-6.6									
Anus, anal canal & anorectum	32.6	1.8	1.5-2.1	8.4	1.0	0.7-1.3	24.2	2.5	2.0-3.0	3.2	0.2	0.1-0.3	1.8	0.2	0.1-0.4	1.4	0.1	0.0-0.3
Liver and intrahepatic bile duct	121.4	6.4	5.9-7.0	82.8	9.5	8.6-10.4	38.6	3.8	3.3-4.4	84.2	4.4	4.0-4.9	54.8	6.5	5.7-7.3	29.4	2.8	2.3-3.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Nassau

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	95.0	5.0	4.6-5.5	68.4	7.8	7.0-8.7	26.6	2.6	2.2-3.2	52.2	2.7	2.4-3.1	37.8	4.4	3.8-5.1	14.4	1.3	1.0-1.7
Intrahepatic bile duct	26.4	1.4	1.2-1.7	14.4	1.7	1.3-2.1	12.0	1.2	0.9-1.5	32.0	1.7	1.4-2.0	17.0	2.0	1.6-2.5	15.0	1.4	1.1-1.8
Gallbladder	28.2	1.5	1.3-1.8	9.2	1.2	0.9-1.6	19.0	1.8	1.4-2.2	13.0	0.7	0.5-0.9	3.4	0.4	0.2-0.6	9.6	0.9	0.6-1.2
Other biliary	40.8	2.1	1.8-2.4	23.8	2.9	2.4-3.4	17.0	1.5	1.2-1.9	10.2	0.5	0.4-0.7	4.8	0.6	0.4-0.9	5.4	0.5	0.3-0.7
Pancreas	299.4	15.9	15.1-16.7	152.8	18.6	17.2-20.0	146.6	13.8	12.8-14.9	221.2	11.5	10.8-12.2	111.8	13.5	12.4-14.7	109.4	9.9	9.1-10.8
Retroperitoneum	8.8	0.5	0.4-0.7	3.4	0.4	0.3-0.7	5.4	0.5	0.3-0.8	1.0	0.1	0.0-0.1	0.8	0.1	0.0-0.3	0.2	0.0	0.0-0.1
Peritoneum, omentum & mesentery	9.0	0.5	0.4-0.7	1.4	0.2	0.1-0.4	7.6	0.8	0.5-1.1	3.0	0.2	0.1-0.3	0.4	0.0	0.0-0.2	2.6	0.3	0.1-0.5
Other digestive organs	17.0	0.9	0.7-1.1	7.4	0.9	0.6-1.3	9.6	0.9	0.6-1.2	5.6	0.3	0.2-0.5	1.6	0.2	0.1-0.4	4.0	0.4	0.2-0.6
Respiratory system	1,013.0	54.2	52.7-55.7	461.2	56.4	54.1-58.8	551.8	53.0	51.0-55.1	465.6	24.2	23.2-25.3	229.2	27.9	26.3-29.6	236.4	21.6	20.3-22.9
Nasal cavity, middle ear & sinuses	12.6	0.7	0.6-1.0	7.4	1.0	0.7-1.4	5.2	0.5	0.3-0.8	1.4	0.1	0.0-0.2	1.2	0.2	0.1-0.3	0.2	0.0	0.0-0.1
Larynx	45.4	2.4	2.1-2.8	36.4	4.3	3.7-5.0	9.0	0.9	0.6-1.2	11.2	0.6	0.4-0.8	10.0	1.2	0.9-1.6	1.2	0.1	0.0-0.3
Lung and bronchus	951.0	50.7	49.3-52.2	414.8	50.7	48.5-53.0	536.2	51.4	49.5-53.5	451.6	23.5	22.5-24.5	217.0	26.5	24.9-28.1	234.6	21.4	20.2-22.7
Pleura	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.2	0.0	0.0-0.1	0.4	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.0	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	3.6	0.2	0.1-0.4	2.4	0.3	0.2-0.6	1.2	0.1	0.0-0.3	1.0	0.1	0.0-0.1	0.6	0.1	0.0-0.2	0.4	0.0	0.0-0.2
Bones & joints	19.2	1.2	1.0-1.5	11.8	1.6	1.2-2.0	7.4	0.9	0.6-1.3	6.2	0.4	0.3-0.6	4.0	0.5	0.3-0.8	2.2	0.3	0.1-0.5
Soft tissue (including heart)	70.6	4.5	4.0-5.0	39.2	5.2	4.5-6.1	31.4	3.9	3.2-4.6	24.8	1.4	1.2-1.7	12.8	1.7	1.3-2.2	12.0	1.2	0.9-1.6
Skin*	427.2	23.9	22.9-25.0	257.0	31.7	30.0-33.6	170.2	18.3	17.0-19.6	46.0	2.4	2.1-2.7	28.4	3.5	3.0-4.2	17.6	1.5	1.2-1.9
Melanoma of the skin	389.6	21.9	20.9-22.9	234.2	28.9	27.2-30.7	155.4	16.8	15.6-18.1	32.8	1.7	1.5-2.1	21.0	2.7	2.2-3.2	11.8	1.1	0.8-1.4
Breast	1,340.0	78.5	76.6-80.5	15.2	1.9	1.5-2.4	1,324.8	145.9	142.2-149.6	181.0	9.7	9.1-10.4	2.2	0.3	0.1-0.5	178.8	17.3	16.1-18.5
Breast (in situ)#	537.6	33.0	31.7-34.3	1.0	0.1	0.0-0.3	536.6	62.9	60.5-65.5									
Female genital system							542.0	56.4	54.2-58.7							148.8	14.3	13.3-15.5
Cervix uteri							52.0	6.6	5.8-7.5							13.8	1.5	1.1-1.9
Corpus uteri and NOS							321.4	32.0	30.4-33.7							62.4	6.0	5.3-6.7
Ovary							110.4	12.1	11.0-13.2							61.2	5.8	5.2-6.6
Vagina							5.4	0.5	0.3-0.8							1.0	0.1	0.0-0.2
Vulva							26.4	2.6	2.2-3.2							5.6	0.5	0.4-0.8
Other female genital organs							26.4	2.6	2.2-3.1							4.8	0.4	0.3-0.6
Male genital system				1,303.0	148.8	145.1-152.5							113.4	14.1	12.9-15.3			
Prostate				1,258.4	141.7	138.2-145.4							110.8	13.7	12.6-14.9			
Testis				35.2	5.8	5.0-6.8							1.6	0.2	0.1-0.5			
Penis				6.8	0.9	0.6-1.2							1.0	0.1	0.0-0.3			
Other male genital organs				2.6	0.3	0.2-0.6							0.0	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Nassau

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	776.8	42.1	40.7-43.4	551.2	67.2	64.6-69.8	225.6	22.2	20.8-23.6	127.0	6.5	6.0-7.0	86.8	10.7	9.7-11.8	40.2	3.5	3.0-4.1
Urinary bladder (including in situ)	441.8	23.3	22.3-24.3	332.4	40.6	38.6-42.7	109.4	10.1	9.3-11.1	79.4	4.0	3.6-4.4	56.8	7.1	6.3-8.0	22.6	2.0	1.6-2.4
Kidney and renal pelvis	312.4	17.6	16.7-18.5	204.0	24.8	23.2-26.4	108.4	11.3	10.3-12.4	44.2	2.3	2.0-2.7	28.0	3.4	2.8-4.0	16.2	1.4	1.1-1.8
Ureter	15.0	0.8	0.6-1.0	9.6	1.2	0.8-1.5	5.4	0.5	0.3-0.7	2.2	0.1	0.1-0.2	1.0	0.1	0.0-0.3	1.2	0.1	0.0-0.2
Other urinary organs	7.6	0.4	0.3-0.6	5.2	0.6	0.4-1.0	2.4	0.2	0.1-0.4	1.2	0.1	0.0-0.1	1.0	0.1	0.0-0.3	0.2	0.0	0.0-0.1
Eye & orbit	16.8	1.0	0.8-1.2	8.2	1.1	0.7-1.4	8.6	1.0	0.7-1.4	1.6	0.1	0.0-0.2	1.2	0.2	0.1-0.4	0.4	0.0	0.0-0.2
Brain / other central nervous system (all behaviors)	380.8	22.9	21.8-24.0	149.6	19.8	18.3-21.3	231.2	25.4	23.9-27.0	81.4	4.6	4.1-5.1	45.0	5.6	4.9-6.4	36.4	3.8	3.2-4.4
Malignant brain / other central nervous system	113.6	7.2	6.6-7.8	61.2	8.2	7.3-9.2	52.4	6.3	5.5-7.2	69.0	3.9	3.5-4.4	39.8	4.9	4.2-5.7	29.2	3.1	2.6-3.7
Malignant brain	108.2	6.8	6.2-7.4	58.0	7.7	6.8-8.7	50.2	6.0	5.2-6.9									
Malignant other central nervous system	5.4	0.4	0.2-0.6	3.2	0.5	0.3-0.8	2.2	0.3	0.1-0.5									
Benign brain / other central nervous system#	267.2	15.7	14.8-16.6	88.4	11.6	10.5-12.8	178.8	19.1	17.8-20.5	12.4	0.7	0.5-0.9	5.2	0.6	0.4-1.0	7.2	0.7	0.5-1.0
Benign brain	23.2	1.6	1.3-1.9	12.8	1.8	1.4-2.4	10.4	1.3	1.0-1.8									
Benign other central nervous system	244.0	14.1	13.3-14.9	75.6	9.8	8.8-10.8	168.4	17.8	16.5-19.1									
Endocrine system	356.6	24.3	23.2-25.5	111.4	15.1	13.8-16.4	245.2	33.3	31.4-35.4	16.6	1.0	0.8-1.2	7.8	1.0	0.7-1.5	8.8	0.9	0.6-1.2
Thyroid	333.6	22.9	21.8-24.1	97.6	13.3	12.1-14.6	236.0	32.2	30.3-34.2	11.6	0.6	0.5-0.8	5.6	0.7	0.5-1.1	6.0	0.5	0.4-0.8
Other endocrine (including thymus)	23.0	1.4	1.1-1.7	13.8	1.8	1.4-2.3	9.2	1.1	0.8-1.5	5.0	0.3	0.2-0.5	2.2	0.3	0.2-0.6	2.8	0.4	0.2-0.6
Lymphomas	451.2	26.2	25.1-27.3	237.6	30.3	28.5-32.1	213.6	23.0	21.6-24.5	100.6	5.3	4.9-5.8	52.8	6.6	5.8-7.4	47.8	4.4	3.9-5.1
Hodgkin lymphoma	50.0	3.5	3.1-4.0	25.0	3.6	3.0-4.3	25.0	3.5	2.9-4.2	5.2	0.3	0.2-0.4	2.8	0.3	0.2-0.6	2.4	0.2	0.1-0.4
Non-Hodgkin lymphomas	401.2	22.7	21.6-23.7	212.6	26.7	25.1-28.4	188.6	19.5	18.2-20.8	95.4	5.1	4.6-5.6	50.0	6.3	5.5-7.1	45.4	4.2	3.7-4.8
Myeloma	152.4	8.2	7.6-8.9	83.4	10.1	9.2-11.2	69.0	6.7	6.0-7.5	48.2	2.5	2.2-2.8	25.0	3.1	2.6-3.7	23.2	2.1	1.7-2.5
Leukemias	293.4	16.8	15.9-17.7	175.4	22.3	20.8-23.8	118.0	12.6	11.5-13.7	108.0	5.7	5.2-6.2	65.0	8.3	7.4-9.2	43.0	3.8	3.3-4.4
Lymphocytic leukemias	157.4	9.0	8.4-9.7	93.8	11.9	10.9-13.1	63.6	6.7	5.9-7.5	32.8	1.7	1.4-2.0	18.4	2.3	1.9-2.9	14.4	1.2	0.9-1.6
Acute lymphocytic leukemia	26.8	2.0	1.7-2.4	15.2	2.3	1.8-2.9	11.6	1.7	1.3-2.2	6.8	0.4	0.3-0.6	4.4	0.6	0.4-1.0	2.4	0.3	0.1-0.5
Chronic lymphocytic leukemia	123.4	6.5	6.0-7.1	73.4	8.9	8.0-9.9	50.0	4.8	4.2-5.4	24.4	1.2	1.0-1.4	13.0	1.6	1.2-2.0	11.4	0.9	0.7-1.2
Other lymphocytic leukemias	7.2	0.5	0.3-0.6	5.2	0.7	0.5-1.1	2.0	0.2	0.1-0.5	1.6	0.1	0.0-0.2	1.0	0.1	0.0-0.3	0.6	0.0	0.0-0.2
Myeloid and monocytic leukemias	121.6	7.0	6.4-7.6	73.2	9.3	8.3-10.3	48.4	5.2	4.6-6.0	55.6	3.0	2.6-3.3	34.4	4.4	3.7-5.1	21.2	2.0	1.6-2.4
Acute myeloid leukemia	77.0	4.3	3.9-4.8	47.2	5.9	5.2-6.7	29.8	3.1	2.6-3.7	50.6	2.7	2.4-3.1	31.8	4.0	3.4-4.7	18.8	1.8	1.4-2.2
Acute monocytic leukemia	1.6	0.1	0.0-0.2	1.4	0.2	0.1-0.4	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Chronic myeloid leukemia	40.6	2.4	2.1-2.8	23.2	3.0	2.5-3.6	17.4	2.0	1.6-2.6	3.0	0.2	0.1-0.3	1.8	0.2	0.1-0.4	1.2	0.1	0.0-0.2
Other myeloid/monocytic leukemias	2.4	0.1	0.1-0.2	1.4	0.2	0.1-0.4	1.0	0.1	0.0-0.2	2.0	0.1	0.0-0.2	0.8	0.1	0.0-0.3	1.2	0.1	0.0-0.2
Other leukemias	14.4	0.8	0.6-1.0	8.4	1.1	0.8-1.4	6.0	0.6	0.4-0.9	19.6	1.0	0.8-1.3	12.2	1.5	1.2-2.0	7.4	0.6	0.4-0.9
Other acute leukemias	3.0	0.2	0.1-0.3	1.8	0.2	0.1-0.4	1.2	0.1	0.0-0.3	7.8	0.4	0.3-0.5	5.4	0.7	0.4-1.0	2.4	0.2	0.1-0.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Nassau

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	11.4	0.7	0.5-0.9	6.6	0.8	0.6-1.2	4.8	0.5	0.3-0.8	11.8	0.6	0.5-0.8	6.8	0.9	0.6-1.2	5.0	0.5	0.3-0.7
Mesothelioma	16.2	0.9	0.7-1.1	11.2	1.4	1.1-1.8	5.0	0.5	0.3-0.7									
Kaposi sarcoma	4.8	0.3	0.2-0.5	3.6	0.5	0.3-0.8	1.2	0.1	0.0-0.3									
Myelodysplastic syndromes	98.2	5.2	4.7-5.7	56.6	7.3	6.5-8.2	41.6	3.7	3.2-4.2									
Chronic myeloproliferative disorders [^]	101.0	5.9	5.4-6.5	54.4	7.2	6.3-8.1	46.6	4.6	4.0-5.3									
Ill defined and unspecified sites	150.4	8.1	7.5-8.7	71.6	9.2	8.2-10.2	78.8	7.2	6.4-8.0	192.8	9.9	9.3-10.6	95.4	11.7	10.7-12.8	97.4	8.6	7.8-9.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Suffolk

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	9,997.2	522.0	517.3-526.7	5,067.2	571.8	564.6-579.1	4,930.0	489.6	483.3-496.0	2,679.2	136.1	133.7-138.5	1,339.8	156.8	153.0-160.7	1,339.4	122.0	119.1-125.1
Oral cavity and pharynx	237.4	12.0	11.4-12.8	161.8	17.6	16.4-18.9	75.6	7.3	6.5-8.1	37.2	2.0	1.7-2.3	25.4	3.0	2.5-3.5	11.8	1.1	0.9-1.5
Lip	8.0	0.4	0.3-0.5	5.6	0.6	0.4-0.9	2.4	0.2	0.1-0.4	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Tongue	77.8	3.9	3.5-4.3	55.6	5.9	5.2-6.6	22.2	2.1	1.7-2.6	10.2	0.6	0.4-0.7	6.8	0.8	0.6-1.2	3.4	0.3	0.2-0.6
Salivary gland	31.4	1.7	1.4-1.9	16.8	2.0	1.6-2.5	14.6	1.5	1.1-1.9	2.8	0.1	0.1-0.2	1.8	0.2	0.1-0.4	1.0	0.1	0.0-0.3
Floor of mouth	11.0	0.5	0.4-0.7	6.0	0.6	0.4-0.9	5.0	0.4	0.3-0.7	0.8	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.4	0.0	0.0-0.1
Gum & other mouth	30.6	1.6	1.3-1.9	17.0	1.9	1.5-2.4	13.6	1.3	1.0-1.7	7.0	0.3	0.2-0.5	3.8	0.4	0.3-0.7	3.2	0.3	0.2-0.5
Nasopharynx	7.8	0.4	0.3-0.6	4.8	0.6	0.4-0.9	3.0	0.3	0.2-0.6	2.8	0.2	0.1-0.3	2.0	0.3	0.1-0.5	0.8	0.1	0.0-0.3
Tonsil	47.2	2.4	2.1-2.7	39.4	4.1	3.6-4.8	7.8	0.7	0.5-1.0	2.6	0.1	0.1-0.2	2.4	0.3	0.1-0.5	0.2	0.0	0.0-0.1
Oropharynx	11.8	0.6	0.5-0.8	8.4	0.9	0.6-1.2	3.4	0.3	0.2-0.6	3.4	0.2	0.1-0.3	3.0	0.3	0.2-0.6	0.4	0.0	0.0-0.2
Hypopharynx	8.8	0.5	0.3-0.6	6.4	0.7	0.5-1.1	2.4	0.2	0.1-0.4	1.2	0.1	0.0-0.2	1.0	0.1	0.0-0.3	0.2	0.0	0.0-0.2
Other buccal cavity and pharynx	3.0	0.2	0.1-0.3	1.8	0.2	0.1-0.4	1.2	0.1	0.0-0.3	6.2	0.3	0.2-0.5	4.2	0.5	0.3-0.8	2.0	0.2	0.1-0.3
Digestive system	1,657.2	85.3	83.4-87.2	911.4	102.6	99.6-105.7	745.8	71.2	68.8-73.6	723.4	36.6	35.4-37.9	402.2	46.1	44.0-48.2	321.2	29.1	27.7-30.6
Esophagus	89.2	4.4	4.0-4.8	70.2	7.5	6.7-8.4	19.0	1.7	1.4-2.1	71.4	3.5	3.1-3.9	56.6	6.2	5.5-7.0	14.8	1.3	1.0-1.7
Stomach	146.6	7.6	7.0-8.2	85.2	9.6	8.7-10.6	61.4	6.0	5.3-6.7	54.0	2.7	2.4-3.1	29.0	3.3	2.8-3.9	25.0	2.3	1.9-2.8
Small intestine	57.4	3.0	2.6-3.3	30.2	3.3	2.8-3.9	27.2	2.7	2.3-3.2	9.2	0.5	0.4-0.7	4.2	0.5	0.3-0.7	5.0	0.5	0.3-0.7
Colorectal	755.2	39.5	38.2-40.8	398.0	45.6	43.5-47.7	357.2	34.5	32.9-36.2	227.2	11.6	11.0-12.4	117.4	13.9	12.8-15.1	109.8	9.9	9.1-10.8
Colon excluding rectum	535.4	28.0	26.9-29.1	266.6	30.8	29.1-32.5	268.8	25.7	24.3-27.2	181.4	9.3	8.7-9.9	91.4	10.8	9.8-11.9	90.0	8.1	7.4-9.0
Cecum	104.6	5.3	4.8-5.8	49.2	5.6	4.9-6.4	55.4	5.0	4.4-5.7									
Appendix	39.4	2.4	2.0-2.7	15.2	1.9	1.5-2.4	24.2	2.8	2.3-3.3									
Ascending colon	102.6	5.3	4.8-5.8	47.4	5.6	4.9-6.3	55.2	5.1	4.5-5.7									
Hepatic flexure	22.6	1.1	0.9-1.4	11.6	1.3	1.0-1.7	11.0	1.0	0.7-1.3									
Transverse colon	47.8	2.4	2.1-2.8	26.2	3.0	2.5-3.6	21.6	2.0	1.6-2.4									
Splenic flexure	13.4	0.7	0.6-0.9	6.6	0.8	0.5-1.1	6.8	0.7	0.5-1.0									
Descending colon	36.6	2.0	1.7-2.3	21.2	2.5	2.1-3.1	15.4	1.5	1.2-1.9									
Sigmoid colon	138.0	7.2	6.6-7.8	74.4	8.3	7.4-9.2	63.6	6.3	5.6-7.1									
Large intestine, NOS	30.4	1.6	1.3-1.8	14.8	1.8	1.4-2.2	15.6	1.4	1.1-1.8									
Rectum & rectosigmoid	219.8	11.5	10.8-12.2	131.4	14.8	13.6-16.0	88.4	8.8	8.0-9.7	45.8	2.3	2.0-2.7	26.0	3.1	2.6-3.7	19.8	1.8	1.4-2.2
Rectosigmoid junction	57.0	3.0	2.7-3.4	32.8	3.7	3.2-4.4	24.2	2.4	1.9-2.9									
Rectum	162.8	8.5	7.9-9.1	98.6	11.0	10.1-12.1	64.2	6.4	5.7-7.2									
Anus, anal canal & anorectum	40.2	2.1	1.8-2.4	13.8	1.5	1.2-1.9	26.4	2.6	2.2-3.1	5.0	0.2	0.2-0.4	2.6	0.3	0.1-0.5	2.4	0.2	0.1-0.4
Liver and intrahepatic bile duct	155.6	7.7	7.1-8.3	109.8	11.8	10.8-12.9	45.8	4.2	3.7-4.9	98.2	4.9	4.5-5.4	64.6	7.2	6.4-8.0	33.6	3.0	2.6-3.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Suffolk

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	121.6	6.0	5.5-6.5	92.2	9.8	8.9-10.7	29.4	2.8	2.3-3.3	65.0	3.2	2.9-3.6	49.4	5.5	4.8-6.2	15.6	1.4	1.1-1.8
Intrahepatic bile duct	34.0	1.7	1.5-2.0	17.6	2.1	1.6-2.6	16.4	1.5	1.2-1.9	33.2	1.7	1.4-2.0	15.2	1.7	1.3-2.2	18.0	1.6	1.3-2.0
Gallbladder	23.0	1.2	1.0-1.5	8.6	1.0	0.7-1.4	14.4	1.4	1.1-1.7	9.6	0.5	0.4-0.7	3.6	0.4	0.2-0.7	6.0	0.5	0.4-0.8
Other biliary	34.6	1.8	1.5-2.1	18.2	2.1	1.7-2.6	16.4	1.6	1.3-2.0	12.4	0.6	0.5-0.8	7.2	0.9	0.6-1.2	5.2	0.5	0.3-0.7
Pancreas	315.2	16.0	15.2-16.9	159.2	18.0	16.7-19.3	156.0	14.4	13.4-15.5	221.8	11.3	10.6-12.0	110.6	12.6	11.6-13.8	111.2	10.1	9.3-11.0
Retroperitoneum	8.2	0.5	0.3-0.6	4.8	0.6	0.4-0.9	3.4	0.4	0.2-0.6	1.2	0.1	0.0-0.1	0.6	0.1	0.0-0.2	0.6	0.1	0.0-0.2
Peritoneum, omentum & mesentery	7.8	0.4	0.3-0.5	1.0	0.1	0.0-0.3	6.8	0.6	0.4-0.9	5.2	0.3	0.2-0.4	1.0	0.1	0.0-0.3	4.2	0.4	0.2-0.6
Other digestive organs	24.2	1.2	1.0-1.5	12.4	1.4	1.1-1.8	11.8	1.1	0.8-1.4	8.2	0.4	0.3-0.6	4.8	0.6	0.4-0.9	3.4	0.3	0.2-0.5
Respiratory system	1,326.2	66.8	65.2-68.5	632.8	72.2	69.6-74.8	693.4	63.3	61.2-65.5	612.8	30.8	29.7-32.0	305.4	35.4	33.6-37.3	307.4	27.6	26.2-29.0
Nasal cavity, middle ear & sinuses	15.2	0.8	0.6-1.0	9.6	1.1	0.8-1.4	5.6	0.6	0.4-0.9	1.8	0.1	0.0-0.2	1.2	0.1	0.0-0.3	0.6	0.1	0.0-0.2
Larynx	58.0	2.9	2.5-3.2	46.6	5.1	4.5-5.8	11.4	1.1	0.8-1.4	15.6	0.8	0.6-1.0	12.2	1.4	1.0-1.8	3.4	0.3	0.2-0.5
Lung and bronchus	1,249.6	62.9	61.4-64.5	573.6	65.6	63.2-68.1	676.0	61.6	59.5-63.8	594.0	29.9	28.8-31.0	291.2	33.8	32.1-35.7	302.8	27.2	25.8-28.6
Pleura	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	1.0	0.1	0.0-0.1	0.6	0.1	0.0-0.2	0.4	0.0	0.0-0.2
Trachea, mediastinum, other respiratory	3.2	0.2	0.1-0.4	2.8	0.4	0.2-0.7	0.4	0.1	0.0-0.2	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.2	0.0	0.0-0.1
Bones & joints	20.8	1.4	1.1-1.7	10.0	1.4	1.0-1.8	10.8	1.4	1.0-1.9	6.8	0.4	0.3-0.6	4.2	0.5	0.3-0.8	2.6	0.3	0.2-0.6
Soft tissue (including heart)	67.6	3.8	3.4-4.3	36.8	4.4	3.7-5.1	30.8	3.4	2.8-4.0	27.6	1.5	1.2-1.7	14.4	1.7	1.3-2.1	13.2	1.3	1.0-1.7
Skin*	518.8	27.2	26.2-28.3	311.2	35.9	34.1-37.8	207.6	20.9	19.6-22.3	57.6	2.9	2.6-3.3	39.2	4.6	4.0-5.3	18.4	1.6	1.3-2.0
Melanoma of the skin	474.4	24.9	23.9-25.9	283.2	32.4	30.7-34.2	191.2	19.3	18.1-20.7	38.0	1.9	1.6-2.2	25.2	2.9	2.4-3.5	12.8	1.2	0.9-1.5
Breast	1,383.6	74.6	72.8-76.4	12.4	1.4	1.0-1.8	1,371.2	139.9	136.4-143.4	193.4	9.9	9.3-10.6	2.2	0.3	0.1-0.5	191.2	17.8	16.6-19.0
Breast (in situ)#	420.0	23.3	22.3-24.4	0.8	0.1	0.0-0.2	419.2	44.8	42.8-46.8									
Female genital system							577.4	56.4	54.2-58.5							157.2	14.6	13.5-15.6
Cervix uteri							46.0	5.5	4.8-6.4							13.4	1.5	1.1-1.9
Corpus uteris and NOS							341.8	32.2	30.6-33.8							61.2	5.7	5.0-6.4
Ovary							121.2	12.2	11.2-13.2							71.8	6.5	5.8-7.2
Vagina							7.2	0.7	0.5-1.0							2.2	0.2	0.1-0.4
Vulva							27.2	2.5	2.1-3.0							6.0	0.5	0.3-0.7
Other female genital organs							34.0	3.2	2.7-3.8							2.6	0.2	0.1-0.4
Male genital system				1,374.4	146.5	143.0-150.1							133.8	16.4	15.2-17.8			
Prostate				1,316.4	138.2	134.9-141.7							129.8	15.9	14.7-17.2			
Testis				50.2	7.3	6.4-8.3							2.2	0.3	0.1-0.5			
Penis				6.2	0.7	0.5-1.1							1.2	0.2	0.1-0.3			
Other male genital organs				1.6	0.2	0.1-0.4							0.6	0.1	0.0-0.3			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Suffolk

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	908.8	46.8	45.4-48.2	638.6	73.5	71.0-76.2	270.2	25.5	24.1-27.0	150.0	7.6	7.0-8.1	103.0	12.5	11.4-13.6	47.0	4.1	3.6-4.7
Urinary bladder (including in situ)	522.0	26.7	25.7-27.8	389.2	45.5	43.5-47.7	132.8	12.2	11.2-13.1	93.8	4.8	4.3-5.2	67.0	8.3	7.4-9.3	26.8	2.3	1.9-2.7
Kidney and renal pelvis	366.0	19.1	18.2-20.0	233.8	26.2	24.6-27.8	132.2	12.9	11.9-14.0	51.6	2.6	2.3-2.9	33.4	3.8	3.3-4.5	18.2	1.6	1.3-2.0
Ureter	12.6	0.6	0.5-0.8	8.8	1.0	0.8-1.4	3.8	0.3	0.2-0.5	2.0	0.1	0.0-0.2	0.4	0.1	0.0-0.2	1.6	0.1	0.1-0.3
Other urinary organs	8.2	0.4	0.3-0.6	6.8	0.8	0.6-1.1	1.4	0.1	0.1-0.3	2.6	0.1	0.1-0.2	2.2	0.3	0.1-0.5	0.4	0.0	0.0-0.2
Eye & orbit	19.2	1.1	0.8-1.3	11.0	1.2	0.9-1.6	8.2	0.9	0.6-1.3	2.0	0.1	0.0-0.2	0.8	0.1	0.0-0.2	1.2	0.1	0.0-0.3
Brain / other central nervous system (all behaviors)	462.4	25.7	24.7-26.9	180.4	22.0	20.5-23.5	282.0	29.0	27.4-30.7	95.6	4.9	4.5-5.4	52.2	5.8	5.1-6.6	43.4	4.1	3.5-4.7
Malignant brain / other central nervous system	124.6	7.3	6.7-7.9	65.2	8.0	7.1-8.9	59.4	6.6	5.9-7.5	81.4	4.2	3.8-4.6	45.2	5.0	4.4-5.7	36.2	3.5	3.0-4.0
Malignant brain	119.4	6.9	6.4-7.6	62.8	7.7	6.8-8.6	56.6	6.3	5.5-7.1									
Malignant other central nervous system	5.2	0.3	0.2-0.5	2.4	0.3	0.1-0.5	2.8	0.3	0.2-0.6									
Benign brain / other central nervous system#	337.8	18.5	17.6-19.4	115.2	14.0	12.9-15.2	222.6	22.4	21.0-23.8	14.2	0.7	0.6-0.9	7.0	0.8	0.6-1.1	7.2	0.6	0.4-0.9
Benign brain	41.6	2.7	2.3-3.1	22.0	2.9	2.4-3.5	19.6	2.4	2.0-3.0									
Benign other central nervous system	296.2	15.8	15.0-16.7	93.2	11.1	10.1-12.2	203.0	19.9	18.7-21.3									
Endocrine system	364.0	22.7	21.6-23.8	114.6	13.8	12.7-15.1	249.4	31.4	29.6-33.3	15.8	0.8	0.6-1.0	5.6	0.6	0.4-0.9	10.2	0.9	0.7-1.3
Thyroid	342.8	21.4	20.4-22.5	103.8	12.5	11.4-13.7	239.0	30.3	28.5-32.1	11.4	0.6	0.4-0.8	4.0	0.5	0.3-0.7	7.4	0.7	0.5-1.0
Other endocrine (including thymus)	21.2	1.2	1.0-1.5	10.8	1.3	1.0-1.7	10.4	1.2	0.9-1.6	4.4	0.2	0.1-0.4	1.6	0.2	0.1-0.4	2.8	0.3	0.1-0.5
Lymphomas	481.6	26.1	25.0-27.2	260.4	30.7	29.0-32.5	221.2	22.5	21.1-23.9	95.4	4.9	4.5-5.4	53.6	6.4	5.6-7.2	41.8	3.9	3.3-4.4
Hodgkin lymphoma	53.8	3.4	3.0-3.9	27.8	3.5	3.0-4.2	26.0	3.4	2.8-4.0	4.6	0.3	0.2-0.4	2.2	0.3	0.1-0.5	2.4	0.3	0.1-0.5
Non-Hodgkin lymphomas	427.8	22.6	21.7-23.7	232.6	27.2	25.6-28.8	195.2	19.1	17.9-20.4	90.8	4.6	4.2-5.1	51.4	6.1	5.4-6.9	39.4	3.6	3.1-4.2
Myeloma	160.0	8.2	7.6-8.8	91.8	10.3	9.4-11.4	68.2	6.4	5.7-7.1	51.2	2.5	2.2-2.9	29.0	3.4	2.8-4.0	22.2	1.9	1.6-2.3
Leukemias	356.8	19.3	18.3-20.2	209.8	24.8	23.3-26.4	147.0	14.8	13.7-15.9	109.0	5.7	5.2-6.2	64.2	7.9	7.0-8.8	44.8	4.1	3.6-4.7
Lymphocytic leukemias	202.8	10.8	10.2-11.5	121.8	14.1	13.0-15.3	81.0	8.1	7.3-9.0	28.4	1.5	1.2-1.7	16.4	2.0	1.6-2.5	12.0	1.0	0.8-1.4
Acute lymphocytic leukemia	28.2	2.0	1.7-2.4	15.4	2.2	1.7-2.8	12.8	1.8	1.4-2.3	5.0	0.3	0.2-0.4	2.8	0.3	0.2-0.6	2.2	0.3	0.1-0.5
Chronic lymphocytic leukemia	162.6	8.2	7.6-8.8	97.6	10.9	9.9-11.9	65.0	6.0	5.3-6.7	21.6	1.1	0.9-1.3	12.2	1.5	1.2-2.0	9.4	0.8	0.6-1.0
Other lymphocytic leukemias	12.0	0.6	0.5-0.8	8.8	1.0	0.7-1.4	3.2	0.3	0.2-0.5	1.8	0.1	0.0-0.2	1.4	0.2	0.1-0.3	0.4	0.0	0.0-0.2
Myeloid and monocytic leukemias	138.8	7.6	7.0-8.2	79.6	9.7	8.8-10.8	59.2	6.0	5.3-6.8	62.0	3.3	2.9-3.7	36.8	4.5	3.9-5.2	25.2	2.4	1.9-2.8
Acute myeloid leukemia	88.6	4.8	4.4-5.3	49.8	6.0	5.3-6.8	38.8	4.0	3.4-4.7	53.6	2.8	2.5-3.2	30.8	3.7	3.2-4.4	22.8	2.1	1.7-2.5
Acute monocytic leukemia	4.2	0.2	0.1-0.4	2.4	0.3	0.2-0.5	1.8	0.2	0.1-0.4	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.2	0.0	0.0-0.1
Chronic myeloid leukemia	43.8	2.4	2.1-2.8	26.4	3.3	2.8-4.0	17.4	1.7	1.4-2.1	4.8	0.3	0.2-0.4	3.4	0.4	0.3-0.7	1.4	0.2	0.1-0.3
Other myeloid/monocytic leukemias	2.2	0.1	0.1-0.2	1.0	0.1	0.0-0.3	1.2	0.1	0.0-0.3	3.2	0.2	0.1-0.3	2.4	0.3	0.1-0.5	0.8	0.1	0.0-0.2
Other leukemias	15.2	0.8	0.6-1.0	8.4	1.0	0.7-1.4	6.8	0.7	0.4-0.9	18.6	1.0	0.8-1.2	11.0	1.3	1.0-1.8	7.6	0.7	0.5-1.0
Other acute leukemias	5.8	0.3	0.2-0.5	3.2	0.4	0.2-0.7	2.6	0.3	0.1-0.5	9.2	0.5	0.3-0.6	4.8	0.6	0.4-0.9	4.4	0.4	0.3-0.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020**

Suffolk

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	9.4	0.5	0.3-0.6	5.2	0.6	0.4-0.9	4.2	0.4	0.2-0.6	9.4	0.5	0.4-0.7	6.2	0.7	0.5-1.1	3.2	0.3	0.2-0.5
Mesothelioma	14.0	0.8	0.6-1.0	9.6	1.2	0.9-1.6	4.4	0.5	0.3-0.7									
Kaposi sarcoma	4.8	0.3	0.2-0.4	4.4	0.5	0.3-0.8	0.4	0.0	0.0-0.1									
Myelodysplastic syndromes	120.4	6.2	5.7-6.7	68.8	8.6	7.7-9.5	51.6	4.5	4.0-5.1									
Chronic myeloproliferative disorders [^]	107.4	5.8	5.3-6.3	54.6	6.6	5.8-7.4	52.8	5.1	4.5-5.8									
Ill defined and unspecified sites	172.2	8.9	8.3-9.6	87.6	10.7	9.7-11.7	84.6	7.7	6.9-8.5	224.6	11.4	10.7-12.1	111.6	13.1	12.0-14.3	113.0	10.1	9.3-11.0

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Westchester

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	5,767.4	463.3	457.9-468.9	2,821.6	501.4	493.0-510.0	2,945.8	440.9	433.5-448.4	1,485.4	112.2	109.6-114.8	728.6	131.0	126.7-135.4	756.8	99.8	96.5-103.1
Oral cavity and pharynx	117.8	9.2	8.5-10.0	80.2	13.7	12.3-15.1	37.6	5.5	4.7-6.4	20.4	1.5	1.2-1.9	13.8	2.4	1.8-3.0	6.6	0.9	0.6-1.3
Lip	3.4	0.3	0.1-0.4	2.0	0.3	0.2-0.7	1.4	0.2	0.1-0.4	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Tongue	40.6	3.2	2.7-3.6	30.0	5.0	4.3-5.9	10.6	1.6	1.2-2.1	6.6	0.5	0.3-0.7	5.0	0.9	0.6-1.3	1.6	0.2	0.1-0.5
Salivary gland	13.0	1.0	0.8-1.3	7.0	1.2	0.9-1.8	6.0	0.9	0.6-1.3	3.0	0.2	0.1-0.4	2.4	0.5	0.2-0.8	0.6	0.1	0.0-0.3
Floor of mouth	3.6	0.3	0.1-0.4	1.8	0.3	0.1-0.5	1.8	0.2	0.1-0.5	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Gum & other mouth	19.0	1.5	1.2-1.8	9.8	1.7	1.2-2.3	9.2	1.3	0.9-1.8	3.4	0.2	0.1-0.4	2.0	0.3	0.1-0.6	1.4	0.2	0.1-0.5
Nasopharynx	5.2	0.5	0.3-0.7	3.8	0.8	0.4-1.2	1.4	0.3	0.1-0.5	1.0	0.1	0.0-0.2	0.4	0.1	0.0-0.2	0.6	0.1	0.0-0.3
Tonsil	21.6	1.7	1.4-2.0	17.2	2.9	2.3-3.6	4.4	0.6	0.4-1.0	0.8	0.1	0.0-0.2	0.8	0.1	0.0-0.4	0.0	0.0	0.0-0.2
Oropharynx	4.0	0.3	0.2-0.5	3.2	0.6	0.3-0.9	0.8	0.1	0.0-0.3	1.8	0.1	0.1-0.3	1.2	0.2	0.1-0.4	0.6	0.1	0.0-0.2
Hypopharynx	5.8	0.5	0.3-0.7	4.2	0.7	0.4-1.1	1.6	0.2	0.1-0.5	1.2	0.1	0.0-0.2	0.6	0.1	0.0-0.3	0.6	0.1	0.0-0.3
Other buccal cavity and pharynx	1.6	0.1	0.0-0.2	1.2	0.2	0.1-0.4	0.4	0.1	0.0-0.2	2.6	0.2	0.1-0.4	1.4	0.3	0.1-0.6	1.2	0.2	0.1-0.4
Digestive system	966.0	76.2	74.1-78.5	518.2	93.1	89.5-96.8	447.8	63.2	60.5-66.0	423.8	32.1	30.7-33.5	235.2	41.9	39.5-44.4	188.6	24.5	22.9-26.2
Esophagus	43.6	3.4	3.0-3.9	31.6	5.7	4.8-6.7	12.0	1.6	1.2-2.1	33.8	2.6	2.2-3.1	25.4	4.6	3.8-5.5	8.4	1.1	0.8-1.5
Stomach	100.0	8.1	7.4-8.8	56.8	10.4	9.2-11.7	43.2	6.4	5.5-7.3	40.2	3.1	2.7-3.6	24.8	4.4	3.7-5.3	15.4	2.2	1.7-2.7
Small intestine	34.4	2.8	2.3-3.2	20.2	3.6	2.9-4.4	14.2	2.1	1.6-2.7	6.0	0.4	0.3-0.7	4.8	0.8	0.5-1.3	1.2	0.2	0.1-0.4
Colorectal	409.4	32.8	31.4-34.3	208.4	37.7	35.4-40.2	201.0	29.0	27.1-30.9	128.8	9.6	8.8-10.4	64.8	11.6	10.4-13.0	64.0	8.0	7.1-9.0
Colon excluding rectum	291.2	23.2	22.0-24.5	141.6	25.8	23.9-27.8	149.6	21.2	19.7-22.9	101.2	7.5	6.8-8.2	51.0	9.1	8.0-10.3	50.2	6.3	5.5-7.1
Cecum	54.8	4.2	3.7-4.8	23.2	4.1	3.4-5.0	31.6	4.2	3.6-5.0									
Appendix	20.8	1.9	1.6-2.4	7.4	1.4	1.0-2.0	13.4	2.4	1.8-3.1									
Ascending colon	52.2	4.0	3.5-4.5	24.6	4.5	3.7-5.4	27.6	3.6	3.0-4.3									
Hepatic flexure	12.8	1.0	0.8-1.3	6.8	1.3	0.9-1.8	6.0	0.8	0.5-1.2									
Transverse colon	28.2	2.2	1.8-2.6	15.4	2.8	2.2-3.6	12.8	1.6	1.3-2.1									
Splenic flexure	10.6	0.8	0.6-1.1	4.8	0.9	0.5-1.3	5.8	0.8	0.5-1.1									
Descending colon	18.8	1.6	1.3-1.9	11.6	2.1	1.6-2.7	7.2	1.1	0.8-1.6									
Sigmoid colon	72.8	6.1	5.4-6.7	38.6	7.0	6.1-8.1	34.2	5.3	4.5-6.2									
Large intestine, NOS	20.2	1.5	1.2-1.8	9.2	1.7	1.2-2.3	11.0	1.3	1.0-1.7									
Rectum & rectosigmoid	118.2	9.6	8.8-10.4	66.8	11.9	10.7-13.3	51.4	7.7	6.8-8.8	27.6	2.1	1.8-2.5	13.8	2.5	1.9-3.2	13.8	1.7	1.3-2.2
Rectosigmoid junction	22.8	1.9	1.5-2.2	14.6	2.6	2.0-3.3	8.2	1.3	0.9-1.8									
Rectum	95.4	7.8	7.1-8.5	52.2	9.4	8.2-10.6	43.2	6.5	5.6-7.4									
Anus, anal canal & anorectum	23.6	1.9	1.6-2.3	6.8	1.2	0.8-1.7	16.8	2.5	2.0-3.1	2.8	0.2	0.1-0.4	1.0	0.2	0.1-0.5	1.8	0.2	0.1-0.5
Liver and intrahepatic bile duct	100.0	7.7	7.1-8.5	69.6	12.0	10.8-13.4	30.4	4.3	3.6-5.1	58.2	4.4	3.9-5.0	40.4	7.0	6.0-8.0	17.8	2.5	2.0-3.1

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Westchester

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	78.0	6.0	5.4-6.6	57.2	9.7	8.6-11.0	20.8	2.9	2.4-3.6	39.0	3.0	2.5-3.4	29.4	5.0	4.2-5.9	9.6	1.3	1.0-1.8
Intrahepatic bile duct	22.0	1.8	1.4-2.1	12.4	2.3	1.7-3.0	9.6	1.4	1.0-1.8	19.2	1.5	1.2-1.8	11.0	2.0	1.5-2.6	8.2	1.1	0.8-1.5
Gallbladder	19.4	1.5	1.2-1.8	6.2	1.1	0.8-1.6	13.2	1.8	1.4-2.3	9.2	0.7	0.5-1.0	2.6	0.5	0.3-0.9	6.6	0.9	0.6-1.3
Other biliary	24.0	1.8	1.5-2.2	13.0	2.3	1.7-2.9	11.0	1.5	1.1-2.0	6.2	0.5	0.3-0.7	2.8	0.5	0.3-0.9	3.4	0.5	0.3-0.8
Pancreas	193.2	14.9	13.9-15.9	98.6	17.8	16.2-19.5	94.6	12.5	11.4-13.8	132.0	10.0	9.2-10.8	65.8	11.8	10.6-13.2	66.2	8.5	7.6-9.5
Retroperitoneum	5.6	0.5	0.3-0.7	3.4	0.6	0.4-1.0	2.2	0.4	0.2-0.7	0.4	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.0	0.0	0.0-0.2
Peritoneum, omentum & mesentery	5.2	0.4	0.3-0.6	0.2	0.0	0.0-0.2	5.0	0.7	0.4-1.0	2.8	0.2	0.1-0.4	0.6	0.1	0.0-0.3	2.2	0.4	0.2-0.7
Other digestive organs	7.6	0.6	0.4-0.8	3.4	0.6	0.3-1.0	4.2	0.6	0.4-1.0	3.4	0.3	0.1-0.4	1.8	0.3	0.1-0.6	1.6	0.2	0.1-0.4
Respiratory system	627.6	48.2	46.5-50.0	296.2	52.7	50.0-55.5	331.4	45.1	42.9-47.4	288.4	21.6	20.5-22.8	142.0	25.4	23.6-27.4	146.4	18.8	17.4-20.2
Nasal cavity, middle ear & sinuses	11.2	1.0	0.7-1.3	7.0	1.3	0.9-1.9	4.2	0.6	0.4-1.0	1.0	0.1	0.0-0.2	0.8	0.1	0.0-0.4	0.2	0.0	0.0-0.2
Larynx	30.2	2.3	1.9-2.7	24.4	4.1	3.4-5.0	5.8	0.8	0.5-1.1	8.2	0.6	0.4-0.8	7.2	1.3	0.9-1.8	1.0	0.1	0.0-0.4
Lung and bronchus	583.8	44.8	43.1-46.5	263.0	46.9	44.3-49.6	320.8	43.6	41.4-45.8	277.4	20.8	19.7-21.9	132.8	23.8	22.0-25.7	144.6	18.5	17.2-20.0
Pleura	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.0	0.0	0.0-0.2	1.0	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.4	0.1	0.0-0.2
Trachea, mediastinum, other respiratory	2.2	0.2	0.1-0.4	1.6	0.3	0.1-0.7	0.6	0.1	0.0-0.4	0.8	0.1	0.0-0.2	0.6	0.1	0.0-0.3	0.2	0.0	0.0-0.2
Bones & joints	12.2	1.2	0.9-1.5	7.0	1.4	1.0-2.0	5.2	0.9	0.6-1.4	4.4	0.4	0.2-0.6	2.6	0.5	0.3-0.9	1.8	0.3	0.1-0.6
Soft tissue (including heart)	40.6	3.5	3.1-4.1	21.8	4.1	3.4-5.0	18.8	3.1	2.5-3.8	14.8	1.2	1.0-1.6	7.4	1.5	1.0-2.0	7.4	1.1	0.8-1.6
Skin*	247.4	19.7	18.6-20.9	141.8	25.8	23.9-27.8	105.6	15.4	14.0-16.8	28.6	2.1	1.7-2.4	17.4	3.1	2.5-3.9	11.2	1.3	1.0-1.7
Melanoma of the skin	222.2	17.7	16.6-18.8	127.2	23.0	21.2-24.9	95.0	13.8	12.6-15.2	18.2	1.3	1.1-1.7	11.6	2.1	1.6-2.7	6.6	0.8	0.5-1.1
Breast	922.8	77.6	75.3-80.0	11.2	2.0	1.5-2.6	911.6	142.9	138.6-147.3	123.0	9.7	8.9-10.5	1.8	0.3	0.1-0.6	121.2	17.1	15.7-18.6
Breast (in situ)#	303.6	26.6	25.2-28.0	1.2	0.2	0.1-0.5	302.4	50.1	47.5-52.8									
Female genital system							347.0	52.2	49.7-54.8							96.6	13.1	11.9-14.4
Cervix uteri							34.2	6.3	5.3-7.3							7.8	1.2	0.9-1.7
Corpus uteri and NOS							201.6	29.0	27.2-30.9							39.2	5.2	4.5-6.1
Ovary							80.8	12.6	11.4-14.0							44.0	6.0	5.2-6.8
Vagina							2.4	0.4	0.2-0.7							0.6	0.1	0.0-0.2
Vulva							13.8	1.9	1.4-2.4							3.8	0.4	0.3-0.7
Other female genital organs							14.2	2.1	1.6-2.7							1.2	0.2	0.1-0.4
Male genital system				827.0	140.8	136.4-145.2							82.8	15.1	13.7-16.7			
Prostate				797.0	134.1	129.9-138.4							80.6	14.7	13.3-16.2			
Testis				24.6	5.6	4.7-6.7							1.4	0.3	0.1-0.6			
Penis				4.4	0.8	0.5-1.3							0.8	0.1	0.0-0.4			
Other male genital organs				1.0	0.2	0.1-0.5							0.0	0.0	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Westchester

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	469.2	36.6	35.1-38.2	327.6	58.4	55.6-61.4	141.6	19.9	18.4-21.5	73.0	5.3	4.8-5.9	49.8	9.0	7.9-10.2	23.2	2.8	2.3-3.5
Urinary bladder (including in situ)	270.4	20.7	19.6-21.9	195.2	35.1	32.9-37.4	75.2	10.1	9.1-11.2	45.0	3.2	2.8-3.7	30.4	5.5	4.7-6.5	14.6	1.7	1.3-2.2
Kidney and renal pelvis	188.8	15.2	14.2-16.3	126.0	22.3	20.5-24.1	62.8	9.4	8.3-10.5	25.4	2.0	1.6-2.3	17.8	3.2	2.6-4.0	7.6	1.0	0.7-1.5
Ureter	6.2	0.4	0.3-0.6	3.2	0.6	0.3-0.9	3.0	0.4	0.2-0.7	1.6	0.1	0.0-0.2	0.6	0.1	0.0-0.3	1.0	0.1	0.0-0.3
Other urinary organs	3.8	0.3	0.2-0.4	3.2	0.5	0.3-0.9	0.6	0.1	0.0-0.3	1.0	0.1	0.0-0.2	1.0	0.2	0.1-0.4	0.0	0.0	0.0-0.2
Eye & orbit	14.4	1.1	0.9-1.5	5.8	1.0	0.7-1.5	8.6	1.3	0.9-1.8	0.6	0.0	0.0-0.1	0.4	0.1	0.0-0.3	0.2	0.0	0.0-0.2
Brain / other central nervous system (all behaviors)	285.6	24.2	22.9-25.6	106.4	20.1	18.4-22.0	179.2	27.8	25.9-29.7	55.4	4.5	4.0-5.1	29.2	5.4	4.5-6.4	26.2	3.8	3.2-4.6
Malignant brain / other central nervous system	71.8	6.5	5.8-7.3	39.0	7.7	6.6-8.8	32.8	5.5	4.6-6.5	44.8	3.7	3.2-4.3	26.0	4.8	4.0-5.7	18.8	2.8	2.3-3.5
Malignant brain	65.6	5.9	5.3-6.6	35.6	7.0	6.0-8.1	30.0	5.0	4.2-5.9									
Malignant other central nervous system	6.2	0.6	0.4-0.9	3.4	0.7	0.4-1.1	2.8	0.5	0.3-0.9									
Benign brain / other central nervous system#	213.8	17.7	16.6-18.8	67.4	12.5	11.1-13.9	146.4	22.3	20.6-24.0	10.6	0.8	0.6-1.1	3.2	0.6	0.3-1.0	7.4	1.0	0.7-1.4
Benign brain	15.4	1.5	1.2-1.9	7.8	1.6	1.1-2.1	7.6	1.4	1.0-2.0									
Benign other central nervous system	198.4	16.2	15.2-17.3	59.6	10.9	9.7-12.3	138.8	20.8	19.2-22.5									
Endocrine system	213.2	20.2	19.0-21.5	62.2	12.0	10.7-13.5	151.0	28.1	26.1-30.3	10.4	0.8	0.6-1.0	5.8	1.0	0.7-1.4	4.6	0.6	0.4-0.9
Thyroid	198.8	19.0	17.8-20.2	54.4	10.5	9.3-11.9	144.4	27.1	25.0-29.2	8.2	0.6	0.4-0.8	4.6	0.8	0.5-1.2	3.6	0.4	0.3-0.7
Other endocrine (including thymus)	14.4	1.3	1.0-1.6	7.8	1.5	1.0-2.0	6.6	1.1	0.7-1.5	2.2	0.2	0.1-0.3	1.2	0.2	0.1-0.4	1.0	0.1	0.0-0.3
Lymphomas	309.6	25.6	24.3-26.9	170.0	31.6	29.4-33.8	139.6	20.9	19.3-22.6	57.4	4.2	3.7-4.7	29.8	5.3	4.4-6.2	27.6	3.5	2.9-4.1
Hodgkin lymphoma	31.8	3.2	2.7-3.7	16.4	3.3	2.6-4.1	15.4	3.1	2.4-3.9	3.2	0.2	0.1-0.4	1.4	0.2	0.1-0.5	1.8	0.2	0.1-0.5
Non-Hodgkin lymphomas	277.8	22.4	21.2-23.7	153.6	28.2	26.2-30.4	124.2	17.8	16.4-19.3	54.2	4.0	3.5-4.5	28.4	5.0	4.2-6.0	25.8	3.2	2.7-3.9
Myeloma	111.2	8.7	8.0-9.5	59.8	10.7	9.5-12.0	51.4	7.3	6.4-8.2	37.2	2.8	2.4-3.2	19.0	3.4	2.8-4.2	18.2	2.3	1.8-2.9
Leukemias	225.2	18.4	17.3-19.5	129.4	23.8	22.0-25.8	95.8	14.0	12.8-15.4	68.0	5.1	4.6-5.7	38.8	7.1	6.1-8.1	29.2	3.8	3.2-4.5
Lymphocytic leukemias	127.8	10.4	9.5-11.2	78.0	14.1	12.7-15.6	49.8	7.3	6.4-8.3	16.0	1.2	0.9-1.5	9.8	1.8	1.3-2.4	6.2	0.7	0.5-1.0
Acute lymphocytic leukemia	15.6	1.7	1.3-2.1	10.2	2.2	1.6-2.9	5.4	1.2	0.8-1.8	4.0	0.3	0.2-0.5	2.4	0.4	0.2-0.8	1.6	0.2	0.1-0.5
Chronic lymphocytic leukemia	105.4	8.1	7.4-8.8	62.4	10.9	9.7-12.3	43.0	5.9	5.1-6.7	11.0	0.8	0.6-1.0	6.8	1.3	0.9-1.8	4.2	0.4	0.2-0.7
Other lymphocytic leukemias	6.8	0.6	0.4-0.8	5.4	0.9	0.6-1.4	1.4	0.2	0.1-0.5	1.0	0.1	0.0-0.2	0.6	0.1	0.0-0.3	0.4	0.1	0.0-0.2
Myeloid and monocytic leukemias	86.6	7.1	6.5-7.9	44.6	8.4	7.3-9.6	42.0	6.2	5.4-7.2	40.8	3.1	2.7-3.6	22.4	4.1	3.3-4.9	18.4	2.5	2.0-3.1
Acute myeloid leukemia	54.6	4.5	4.0-5.1	28.8	5.4	4.6-6.4	25.8	3.8	3.1-4.6	34.6	2.7	2.3-3.1	18.6	3.4	2.7-4.2	16.0	2.2	1.7-2.7
Acute monocytic leukemia	2.6	0.2	0.1-0.4	1.2	0.2	0.1-0.5	1.4	0.2	0.1-0.5	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Chronic myeloid leukemia	29.0	2.4	2.0-2.8	14.4	2.7	2.1-3.4	14.6	2.2	1.7-2.8	3.6	0.3	0.1-0.4	1.8	0.3	0.1-0.6	1.8	0.2	0.1-0.5
Other myeloid/monocytic leukemias	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.2	0.0	0.0-0.2	2.6	0.2	0.1-0.4	2.0	0.4	0.2-0.7	0.6	0.1	0.0-0.3
Other leukemias	10.8	0.9	0.7-1.2	6.8	1.3	0.9-1.9	4.0	0.5	0.3-0.8	11.2	0.8	0.6-1.1	6.6	1.2	0.8-1.7	4.6	0.6	0.4-0.9
Other acute leukemias	3.4	0.3	0.2-0.5	2.0	0.4	0.2-0.7	1.4	0.2	0.1-0.4	3.2	0.2	0.1-0.4	1.8	0.3	0.2-0.7	1.4	0.2	0.1-0.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Sex, 2016-2020
Westchester

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	7.4	0.6	0.4-0.8	4.8	0.9	0.6-1.4	2.6	0.3	0.2-0.6	8.0	0.6	0.4-0.8	4.8	0.9	0.5-1.3	3.2	0.4	0.2-0.7
Mesothelioma	8.4	0.6	0.5-0.9	5.2	0.9	0.6-1.4	3.2	0.4	0.2-0.7									
Kaposi sarcoma	3.2	0.3	0.2-0.5	3.0	0.6	0.3-1.0	0.2	0.0	0.0-0.2									
Myelodysplastic syndromes	61.8	4.6	4.1-5.2	33.0	6.2	5.3-7.3	28.8	3.6	3.0-4.3									
Chronic myeloproliferative disorders [^]	71.0	5.7	5.1-6.3	34.4	6.2	5.3-7.3	36.6	5.1	4.4-6.0									
All defined and unspecified sites	100.0	7.4	6.7-8.1	48.8	8.7	7.7-9.9	51.2	6.4	5.6-7.2	111.2	8.2	7.6-9.0	56.0	10.1	8.9-11.4	55.2	6.9	6.1-7.8

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2022

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.